Document:

Exhibit 10.12

 

CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE
HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

 

 

 

 

 

 

 

 

MASTERS
SERVICES AGREEMENT

 

BY AND BETWEEN

 

SUTTER
HEALTH

 

AND

 

AUGMEDIX,
INC.

 

FOR THE PROVISION OF:

 

REMOTE
SCRIBE SERVICES THROUGH USE OF

GOOGLE
GLASS DEVICE AUGMEDIX
SOLUTION

 

Effective Date: April 15,
2015

 

 

 

 

 

 

 

 

 

 

 

 

     

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

Table of Contents

  

	Master Services Agreement	1
	 	 	 
	Recitals	1
	 	 	 
	I. SERVICES COVERED	1
	 	 	 
	A.	Services/Scope of Work	1
	 	 	 
	B.	Independent Contractor Relationship	1
	 	 	 
	C.	Subcontractors	2
	 	 	 
	D.	Payment/Expenses	2
	 	 	 
	E.	Taxes	2
	 	 	 
	II. COMPLIANCE 	3
	 	 	 
	A.	Compliance Laws	3
	 	 	 
	B.	Vendor Credentialing	3
	 	 	 
	C.	Conflict of Interest	3
	 	 	 
	D.	OIG List of Excluded Entities	3
	 	 	 
	E.	Access to Records	3
	 	 	 
	R.	Accessibility	4
	 	 	 
	III. TERMS AND TERMINATION	4
	 	 	 
	A.	Term	4
	 	 	 
	B.	Termination Without Cause	4
	 	 	 
	C.	Termination or Modification in the Event of Government Action	4
	 	 	 
	D.	Effect of Termination	5
	 	 	 
	E.	Termination/Expiration Assistance	5
	 	 	 
	F.	Survival of Provisions	6
	 	 	 
	G.	Grievance Process	6
	 	 	 
	IV. LEGAL 	6
	 	 	 
	A.	Warranties	6
	 	 	 
	B.	Ownership of Proprietary Rights	7
	 	 	 
	C.	Confidentiality	8

 

    i

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

	D.	Indemnification	9
	 	 	 
	E.	Limitation of Liability/Exceptions	11
	 	 	 
	F.	Insurance	11
	 	 	 
	V.  MISCELLANEOUS	13
	 	 	 
	A.	Notices	13
	 	 	 
	B.	Conflict with Sutter Health Agreements	13
	 	 	 
	C.	Publicity	13
	 	 	 
	D.	Use of Marks	14
	 	 	 
	E.	Non-Solicitation	14
	 	 	 
	F.	Force Majeure	14
	 	 	 
	G.	Governing Law	15
	 	 	 
	H.	Dispute Resolution	15
	 	 	 
	I.	Assignment and Delegation	16
	 	 	 
	J.	Entire Agreement/Modification	16
	 	 	 
	K.	Sutter Content	16
	 	 	 
	L.	Survival	16
	 	 	 
	M. 	 Waiver	16
	 	 	 
	N.	Severability	16
	 	 	 
	O.	Headings	16
	 	 	 
	P.	Counterparts	16
	 	 	 
	Q.	No Third Party Beneficiary	17
	 	 	 
	R.	No Referrals/Nonexclusivity	17
	 	 	 
	S.	GPO Agreements	17
	 	 	 
	T.	Attorneys’ Fees	17
	 	 	 
	U.	Integration	17
	 	 	 
	V.	List of Agreement Documents	17
	 	 	 
	W. 	Execution	17
	 	 	 
	Signature Page	18

 

    ii

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

MASTER SERVICES AGREEMENT

 

Remote Scribe Services through
use of Google Glass Device Augmedix Solution

 

This Master Services Agreement
(“Agreement”) effective the date last signed below (“Effective Date”) by and between Sutter Health, a
California nonprofit public benefit corporation (“Sutter”), and Augmedix, Inc., a Delaware corporation (“Augmedix”).
Sutter and Augmedix may be referred to herein individually as a “Party” and collectively as the “Parties.”

 

R E C I T A L S

 

WHEREAS, Augmedix is a provider
of remote scribe services through the use of Google Glass devices and the Augmedix Solution (“Services”);

 

WHEREAS, Sutter is a non-profit
public benefit corporation which owns and operates an integrated healthcare system in Northern California;

 

WHEREAS, Augmedix wishes to
(i) grant to Sutter certain license rights in and to the Augmedix Solution, and (ii) provide Services to Sutter; and

 

WHEREAS, Sutter desires to
obtain Services from Augmedix.

 

NOW, THEREFORE, in consideration
of the premises set forth above and the mutual promises and agreements set forth herein, the Parties, each intending to be legally
bound hereby, agree as follows:

 

	I.	SERVICES COVERED

 

A. Services/Scope
of Work. During the Term of this Agreement, Augmedix agrees to provide to Sutter and Sutter agrees to purchase Services
from Augmedix for the fees and other pricing set forth in the terms and conditions herein. There will be no other charges or fees
without the prior written approval of Sutter and Augmedix. If Sutter purchases any Services through a Purchase Order or Statement
of Work that conflicts with or is inconsistent with this Agreement, this Agreement shall control except unless the Parties mutually
agree in writing, signed by authorized management level representatives of each Party, to the conflict or inconsistency.

 

B. Independent
Contractor Relationship. The Parties agree that Augmedix is an independent contractor, and not an employee, agent, or
partner of, or joint venturer with Sutter. Sutter shall thus not exercise control over the methods by which Augmedix performs
its obligations under this Agreement; notwithstanding the foregoing, Sutter shall retain all professional and administrative responsibility
for the Services rendered under this Agreement to the extent required to comply with Title 22 of the California Code of Regulations.

 

    1

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

C. Subcontractors.
In addition, Augmedix may use such assistants and/or subcontractors as Augmedix deems necessary to carry out Augmedix’s
duties under this Agreement at Augmedix’s sole expense; Augmedix shall assume responsibility for the payment of any compensation
and expenses to such assistants and/or subcontractors, and shall hold Sutter harmless from any failure to provide such compensation
and expenses. Augmedix agrees to impose on its subcontractors performing Services under this Agreement obligations no less strict
than those imposed upon Augmedix under this Agreement with respect to safety, security, confidentiality, PHI and PII. Augmedix
shall be responsible and liable for all acts of its subcontractors, their employees or agents performing Services. The Parties
further agree that Sutter may request Augmedix to replace any of its assistants and/or subcontractors providing Services under
this Agreement if Sutter reasonably determines that such individual is unfit or is providing unsatisfactory Services in performing
Augmedix's obligations. Except as otherwise set forth in Exhibit A, Augmedix shall not use, access, or disclose PHI (as
defined in HIPAA) collected from Sutter’s patients to, nor allow any subcontractors or agents to use, access, or disclose
any PHI outside of the United States of America.

 

D. Payment/Expenses. During
the Term of this Agreement, Augmedix agrees to provide the Services described or listed on the attached Exhibit A, and
Sutter agrees to purchase such Services at the fees indicated in Exhibit A and in accordance with the terms and
conditions set forth herein. Beginning June 1, 2015, Augmedix will directly invoice the respective foundation or subsidiary
of Sutter receiving Services [*] prior to the applicable fees; all invoices will be subject to [*] payment terms after
receipt of accurate invoices from Augmedix. Notwithstanding the foregoing, Augmedix shall invoice Sutter on April 15, 2015,
for all applicable fees incurred by Sutter between May 1, 2015 to September 31, 2015 under the Agreement. Sutter may, at its
discretion, make payment by check or by an electronic payable (E- payables) payment method. Other than as stated in this
Agreement, any Exhibit or as subsequently agreed to in writing between the Parties, Augmedix is solely responsible for
payment of any other expenses incurred in connection with carrying out Augmedix’s duties under this Agreement. Such
expenses include costs of all travel, lodging, food, licenses, bonds, taxes and costs of doing business. In no event will
Sutter be responsible to pay any expenses of Augmedix not contained in this Agreement or as otherwise agreed to in writing
between the Parties, whether or not incurred in connection with Augmedix’s performance under this Agreement.

 

E. Taxes.
Sutter shall be responsible for all sales and use taxes due to any federal, state, or local taxing authority by virtue of
this Agreement. Augmedix shall be responsible for all other taxes, including but not limited to Augmedix’s net income taxes
and excise taxes imposed on Augmedix (e.g., Medical Device Excise Tax). The Parties further agree that Sutter shall be responsible
for applicable taxes due to any purchase of Services, excluding taxes based on Augmedix’s net income. Augmedix agrees that
any Sutter payments to Augmedix under this Agreement will be subject to seven percent (7%) tax withholding unless Augmedix can
establish that either (a) Augmedix has resident status in the State of California and/or (b) a California tax return was filed
in Augmedix’s name for the immediately preceding calendar or fiscal year.

 

    2

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

	II.	COMPLIANCE

 

A. Compliance
with Laws. Augmedix will perform its obligations under this Agreement in strict compliance with all applicable laws. Sutter
will not be responsible for monitoring Augmedix’s nor any subcontractor’s compliance with any applicable laws.

 

B. Vendor
Credentialing. Augmedix agrees to participate in Sutter’s Vendor Credentialing service which requires
Augmedix and its representatives to register and provide requested documentation, as further described at the following
website: http://www.sutterhealth.org/about/vendors.html. Augmedix further agrees to
maintain any licenses or certification necessary for the provision of the Services at Augmedix’s sole expense
throughout the Term of this Agreement.

 

C. Conflict
of Interest. Augmedix acknowledges that Sutter maintains and enforces a Conflict of Interest Policy. Augmedix will use
reasonable efforts to act in a manner that does not encourage, facilitate or cause the violation of the Conflict of Interest Policy
by individuals who are subject to that Policy. Augmedix represents that, to its knowledge, the Augmedix personnel involved in
the negotiation, implementation and performance of this Agreement have no knowledge of any circumstances constituting a conflict
of interest with respect to Augmedix’s transaction of business with Sutter. Augmedix agrees to notify Sutter within thirty
(30) days of any such Augmedix personnel learning of any circumstances constituting a conflict of interest hereunder.

 

D. OIG
List of Excluded Entities. Augmedix certifies that neither it nor its subcontractors performing Services are currently
named as an excluded entity or individual on the “List of Excluded Individuals/Entities” of the Department of Health
and Human Services Office of the Inspector General (“OIG List”). Augmedix shall immediately notify Sutter if at any
point during the Term Augmedix is named as an excluded entity or individual on the OIG List.

 

E. Access
to Records. Augmedix shall make available, for the term of this Agreement and for four (4) years following its expiration,
to Sutter and/or the Secretary, U.S. Department of Health and Human Services, the U.S. Comptroller General and their representatives
this Agreement and all other books, documents, and records as are necessary to certify the nature and extent of the costs incurred
by Sutter in purchasing Services under this Agreement. Augmedix agrees to indemnify Sutter in the event that any amount of reimbursement
is denied or disallowed because of the failure of Augmedix to comply with this obligation. Such indemnity shall be subject to
the terms and conditions of Section IV.D of this Agreement and include the amount of reimbursement denied, plus any interest,
penalties and legal costs. This paragraph is intended to assure compliance with Section 1861 of the Social Security Act.

 

    3

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

F. Accessibility.
If applicable, Augmedix will provide Services under this Agreement such that the net product of such Services, including,
but not limited to: software applications and operating systems, Web-based internet information and applications, information,
documentation and support, desktop and portable computers, video and multimedia products, self-contained, closed products, and
telecommunication products are usable by a person with a disability in accordance with Title III of the Americans with Disabilities
Act, 42 U.S.C. § 12181, et seq., and/or Section 504 of the Rehabilitation Act of 1973, 29 U.S.C. §§ 701,
et seq., and Section 1194.22 (a) – (p) of the Electronic and Information Technology Accessibility Standards, 36 C.F.R.
Part 1194 (implementing Rehabilitation Act Section 508 (29 U.S.C. § 794d)).

 

	III.	TERM AND TERMINATION

 

A. Term.
The initial term of this Agreement shall be for one (1) year, commencing on the Effective Date (“Initial Term”).
The Agreement shall automatically renew on the same terms and pricing for five successive one (1) year terms (each, a “Renewal
Term”), unless Sutter provides written notice to Augmedix of Sutter’s intent to terminate the Agreement at least ninety
(90) days prior to the end of the Initial Term or any Renewal Term. The Initial Term and the Renewal Terms are collectively referred
to herein as the Agreement “Term”.

 

B. Termination
Without Cause. This Agreement may be terminated, in whole or in part, with or without cause, upon ninety (90) days’
advance written notice by Sutter to Augmedix.

 

C. Termination
or Modification in the Event of Government Action.

 

 1. This Agreement shall terminate if both:

 

a) as
a result of the enactment of any new applicable federal or state law or regulation, or any change in any existing applicable federal
or state law or regulation or any new interpretation of any applicable federal or state law or regulation by any court or regulatory
agency, the performance by a Party of any material obligation under this Agreement would be rendered illegal or any material provision
of this Agreement would be rendered invalid or unenforceable, or the arrangement between the Parties set forth in this Agreement
could reasonably be expected to have a material adverse effect on a Party or its Affiliates (for example a potential revocation
of any license or certification), and (ii) the Parties are unable to negotiate a mutually acceptable amendment to this Agreement
pursuant to Section V.J. below. If any immaterial provision of this Agreement is held to be illegal, invalid or unenforceable
for any reason, this Agreement shall be deemed amended to delete such provision, such amendment to apply only with respect to
the operation of this Agreement in the particular jurisdiction in which such provision is held to be illegal, invalid or unenforceable,
and the remainder of this Agreement shall remain in full force and effect and enforceable in accordance with its terms.

 

    4

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

b) The
Parties agree that the Party affected by the new law or regulation or the change in law or regulation or the interpretation of
a law or regulation shall use reasonable efforts to give the other Party at least sixty (60) days prior written notice of the
effective date of such new law, change, or interpretation.

 

c) The
Parties agree that, notwithstanding the foregoing provisions of this Section, either Party may, within ten (10) business days
of giving or receiving notice of the new law, change, or interpretation, notify the other Party of its wish to renegotiate the
applicable terms of this Agreement (“Renegotiation Notice”), in which event the Parties shall negotiate in good faith,
for a period of sixty (60) days from delivery of the Renegotiation Notice, an amendment to this Agreement that addresses the portion
of this Agreement rendered illegal, invalid or unenforceable by the new law, change, or interpretation while preserving to the
greatest extent possible the original intent of this Agreement. If the Parties successfully conclude such negotiations prior to
the effective date of the new law, change, or interpretation, this Agreement shall not terminate and shall be amended to reflect
the negotiated terms. If the Parties are unable to successfully conclude such negotiations prior to the effective date of the
new law, change, or interpretation and such effective date is within the sixty (60) day negotiation period, negotiations shall
continue but this Agreement shall be deemed amended to delete such portion rendered illegal, invalid or unenforceable, such amendment
to apply only with respect to the operation of this Agreement in the particular jurisdiction in which such portion is held to
be illegal, invalid or unenforceable, and the remainder shall remain in full force and effect and enforceable in accordance with
its terms, subject to the subsequent sentence. In the event the Parties are unable to successfully conclude such negotiations
within the sixty (60) day negotiation period, this Agreement shall terminate at the end of the sixty (60) day negotiation period.

 

D. Effect
of Termination. Upon notice of termination by either party, Augmedix shall cease or wind-down performance of the Services
in accordance with Sutter’s requests. For clarification, Sutter shall pay Augmedix in accordance with Section I.D. any
fees earned and expenses incurred by Augmedix for Services performed up to the time of termination. Within 30 days (or such other
period as agreed by the parties) after the termination or expiration of this Agreement, Statement of Work or Exhibit or at the
end of the termination/expiration assistance period described below, whichever occurs later (the “End Date”), (a)
each party shall return or securely destroy Confidential Material of the other party in accordance Section IV.C.; and (b)
if applicable, both Parties shall deliver to the other Party or its designee, any such data feed or other delivery mechanism as
agreed to by the Parties.

 

E. Termination/Expiration
Assistance. Upon termination or expiration of this Agreement, a Statement of Work or Exhibit for any reason, Augmedix
shall for up to 30 days after the date of termination or expiration, at Sutter’ option, (a) continue to provide the Services
in accordance with this Agreement in order to facilitate Sutter’ transition of the Services to Sutter or its designee without
interruption or adverse effect and (b) provide such reasonable assistance as may be requested by Sutter to effectuate such transition.
This Agreement shall continue in full force and effect with respect to the performance of such termination/expiration assistance.
In consideration of such termination/expiration assistance, Sutter shall pay Augmedix at the then-applicable rates in accordance
with the provisions of this Agreement (including the applicable Statement of Work or Exhibit).

 

    5

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

F. Survival
of Provisions. Notwithstanding anything to the contrary herein, in the event of the termination or expiration of this
Agreement, the indemnification, non- solicitation, confidentiality provisions and other obligations of the Parties, or any other
clauses herein, which by their terms or nature are to be performed or complied with subsequent to the expiration or termination
of this Agreement shall survive and continue in full force and effect.

 

G. Grievance
Process. A dispute arising as set forth in Section V.H. above may be resolved by each Party appointing a representative
to meet and attempt to resolve such a dispute. The representatives shall meet as often as the Parties reasonably deem necessary
to discuss the problem in an effort to resolve the dispute without the necessity of any formal proceeding. In the event the representatives
cannot resolve such dispute within ninety (90) days following receipt of notice from the Party requesting the process set forth
in Section V.H., then either Party may pursue its available remedies as set forth in Section V.H.

 

	IV.	LEGAL

 

A.
Warranties. Augmedix warrants that:

 

1. All
Services will be performed by Augmedix in a professional manner, consistent with the standard of skill and care exercised by the
best professionals within Augmedix’s industry on projects of comparable scope and complexity, in a similar location, and
in conformance with the requirements of this Agreement and within the deadlines mutually set by the Parties;

 

2. Augmedix
is sufficiently experienced, properly qualified, registered, licensed, equipped, organized and financed to perform the Services
in compliance with the terms of this Agreement, and will ensure that all employees, subcontractors and agents will have the requisite
experience and qualifications to perform the Services in a lawful and proper manner;

 

3. The
Augmedix Google Glass Devices furnished by Augmedix under this Agreement shall be new;

 

4. To
Augmedix’s knowledge, no services, materials, equipment or other matters furnished by Augmedix to Sutter under this Agreement
will in any way infringe upon or violate any valid third party intellectual property rights;

 

    6

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

5. Augmedix
will not take any action which will void, invalidate, or otherwise adversely affect any manufacturer’s or third party warranty
held by Sutter with respect to any of Sutter’s equipment, systems or property; and

 

B.
Ownership of Proprietary Rights.

 

1. Augmedix
agrees that Sutter shall be the owners of all proprietary rights in and to any documentation, records, text and other works of
authorship, data, metadata, databases, information, ideas, innovations, discoveries, inventions, compositions, know-how, conceptions,
designs, symbols, names, procedures, methods, processes, improvements, products, prototypes, samples, computer programs or routines
(in object code or embedded format, regardless of the medium on which it resides), hardware and/or software configurations, translations,
trade secrets and other property and materials, tangible or intangible, whether or not patentable or registrable under copyright,
patent or similar laws, within the foregoing: (i) furnished to Augmedix, or to which Augmedix is given access by Sutter in connection
with the performance of this Agreement; and/or (ii) expressly set forth in Exhibit
A as specifically created for Sutter and owned by Sutter (collectively “Intellectual Property”). Augmedix shall
not have any interest in such Intellectual Property and may use such Intellectual Property only as necessary to perform under
this Agreement. Accordingly, Augmedix hereby assigns to Sutter all of Augmedix’s right, title and interest in and to the
Intellectual Property. Augmedix further acknowledges its obligation to assist Sutter or its designee, at Sutter’s (or designee’s)
expense, in every proper way to secure Sutter’s or its designee’s, rights in the Intellectual Property and any copyrights,
patents, trademarks, moral rights or other intellectual property rights relating thereto. This obligation includes maintaining
and preserving accurate and complete records of all pertinent information and data with respect thereto (“Records”),
disclosing to Sutter or its designee all Intellectual Property and Records, and executing all applications, specifications, oaths,
assignments, recordations and instruments necessary to obtain, maintain and transfer such rights to Sutter or its designee (or,
if not transferable, to waive such rights). The Parties further agree that nothing in this paragraph or in this Agreement shall
limit Sutter’s sole and exclusive intellectual property rights in and to its own data (including metadata) provided to or
accessed by Augmedix, or developed or generated by Augmedix for Sutter in accordance with Section IV(B)(ii) above during the course
of this Agreement. Except as expressly authorized by Sutter or as permitted herein, Augmedix may not use, aggregate or otherwise
modify such data or metadata for Augmedix’s own use or for use with or by third parties.

 

2. Notwithstanding
the foregoing:

 

a) Sutter
agrees that Augmedix shall be the owner of all proprietary rights in and to the Augmedix Solution (as defined in Exhibit B),
and improvements thereof, and all associated intellectual or other proprietary rights. In addition, to the extent Sutter provides
any suggestions, recommendation or other feedback to Augmedix with respect to the Augmedix Solution, Sutter hereby grants to Augmedix
a non-exclusive, perpetual, non-terminable, non-revocable, royalty-free, sublicenseable license to use any such feedback in connection
with the development or commercialization of Augmedix Solution.

 

    7

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

b) Augmedix
and/or its vendors may collect, use and store data regarding the quality or performance of the Augmedix Solution or the applicable
vendor’s component. Data to be collected are: bitrate, network quality, latency, packet loss, software stability, signaling
attributes, frame rate, protocol used, picture quality, delay, jitter, hardware performance, A/V offset and processor use for
aggregate assessment purposes. For clarity, Augmedix and/or its vendors are not precluded from using PHI for quality and control
purposes in accordance with the terms of this Agreement or any Exhibit.

 

C.
Confidentiality.

 

1. Each
Party shall hold the following “Confidential Information” in strict confidence and not disclose the same to
any other person or entity except as provided herein: each other’s proprietary and confidential records and information,
including but not limited to all information, pricing and terms relating to or contained in this Agreement; the content of all
negotiations and other discussions regarding contract terms, conditions and pricing; all service and product data, trade secrets,
financial data, pricing, business plans and any other information or technology received from the other Party in implementing
this Agreement; the confidential information of vendors and other third parties disclosed to the receiving Party as part of the
provision of Services under this Agreement; all personally identifiable information of a Party’s employees, agents, and
patients; and all information derived from the foregoing.

 

2. Notwithstanding
the above:

 

a) A
Party may disclose Confidential Information to the personnel within its organization, its physicians who may use the Services
or products (or other services, products or technology of Augmedix) and its legal and accounting advisors who require the Confidential
Information in connection with the Party’s internal business processes and its rights and obligations under this Agreement,
provided that such disclosing Party uses commercially reasonable efforts to require any such recipient to use the information
solely for these purposes and to keep it strictly confidential, except as required by law and subject to the requirements of 2.b)
below.

 

b) A
Party may disclose Confidential Information as required by law, provided that such disclosing Party provides reasonable prior
notice to the other Party to enable such other Party to attempt to prevent or limit the disclosure and the disclosing Party assists
the other Party upon request in seeking relief from or limiting the disclosure.

 

    8

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

c) In
addition, Sutter shall have the right to disclose contract terms, conditions and pricing terms, as well as other Confidential
Information, including vendor and other third party confidential information, to those parties and/or consultants not already
mentioned above that Sutter has or will contract with or retain in the course of managing its business, provided those parties/consultants
agree in writing that they shall not use or divulge such Confidential Information to any third party except as necessary for the
discharge of their obligations to Sutter or as required by law. Furthermore, Augmedix shall have the right to disclose the contract
terms to its legal and financial advisors, and to its current and prospective investors, lenders and acquirers and their respective
legal and financial advisors.

 

d) A
Party may disclose Confidential Information with the prior written consent of the other Party.

 

3. Both
Parties further agree to comply, and to ensure that their employees and agents comply, with all applicable federal and California
privacy laws relating to personally identifiable information, including but not limited to the Health Insurance Portability and
Accountability Act of 1996 and its attendant regulations, as amended from time to time (“HIPAA”), the Health Information
Technology for Economic and Clinical Health Act (“HITECH”), the California Medical Information Act (CMIA), the Fair
Credit Reporting Act (FCRA), and regulations promulgated under these laws. Augmedix also agrees to execute a separate HIPAA/HITECH
Business Associate Agreement attached hereto as Exhibit C.

 

4. Neither
Party shall be obligated to hold the following information in confidence (and such information shall not be deemed to be Confidential
Information): information that is or becomes publicly available through no fault of the recipient, information developed by a
Party without using any Confidential Information, information lawfully possessed by a Party before receipt from the disclosing
Party, and information lawfully disclosed to a Party on a non- confidential basis from a person or entity that is not bound by
a duty of confidentiality.

 

D.
Indemnification.

 

1. General
Indemnification. Each Party (the “Indemnifying Party”) agrees to indemnify, defend and hold the other Party
(the “Indemnified Party”), and its respective affiliates, and its and their officers, directors, employees,
representatives, agents, other authorized users, successors and assigns harmless from and against any and all claims, losses,
judgments, liens, demands, damages, liabilities, penalties, fines, expenses, obligations, causes of action, suits, or costs,
including reasonable attorneys’ fees (collectively, the “Claims”) to the extent that such Claims are
caused by, arise out of, or are connected in any way with:

 

a) any
negligence, unlawful conduct or willful misconduct of the Indemnifying Party or its employees, subcontractors or agents, to the
maximum extent permitted by law;

 

    9

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

b) the
breach of this Agreement by the Indemnifying Party or its employees, subcontractors or agents of any of its contractual obligations,
covenants, undertakings or promises under this Agreement;

 

c) property
loss, damage, personal injury or death, caused by the Indemnifying Party or by any of its employees, subcontractors or agents;

 

d) in
the case of Augmedix as the Indemnifying Party, defects in design or manufacture of a product or malfunctioning of a product when
used in accordance with its written instructions, specifications or other product documentation;

 

but not to the extent
resulting from the negligence, unlawful conduct or willful misconduct of the Indemnified Party or its respective employees, representatives,
servants, subcontractors and agent.

 

2. Intellectual
Property Indemnification. Augmedix will defend, indemnify, protect and hold harmless Sutter and its Representatives from and
against any and all Claims to the extent the Claim is based on an allegation that use of the Services and all related materials,
software, equipment and other deliverables provided in connection therewith, in accordance with this Agreement infringes any patent
or any copyright, trademark, trade secret or other proprietary right Augmedix will have no liability for third party equipment
or components, or to the extent such Claim: (a) involves infringement that is attributable to any Sutter-supplied designs or specifications;
(b) is based on modification or combination of any deliverables provided by Augmedix with any non-Augmedix hardware or software,
to the extent such Claim results from such modification or combination; or (c) to the extent it results from failure of Sutter
to use updated or modified versions of any deliverables provided by Augmedix for avoiding such Claim.

 

3. Procedure.
The Indemnified Party shall provide prompt written notice to the Indemnifying Party of any claim for which the Indemnified Party
is seeking indemnification. The Indemnifying Party shall have the sole right to control the defense. The Indemnified Party may
participate in the defense of the claim at its own expense. Further, upon the request of the Indemnifying Party, at the Indemnifying
Party’s sole expense, the Indemnified Party shall cooperate as is reasonable in the defense. The Indemnifying Party shall
not settle any claim that includes an admission of wrongdoing by the Indemnified Party or otherwise adversely affects the Indemnified
Party’s interests without its prior written consent.

 

    10

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

E. Limitation
of Liability/Exceptions. Other than as set forth below, (1) in no other event shall either Party be liable for any
special, incidental, or consequential damages, lost profits, or any other indirect damages even if it has been informed of
the possibility thereof, (2) except for Sutter’s payment obligations under Exhibit A, each Party’s aggregate
liability for any other damages will in no event exceed the greater of (A) total amounts due to Augmedix pursuant to
this Agreement in the twenty-four (24) months preceding the initial claim, and (B) the amount of recoverable insurance with
respect to the applicable claim.

 

NOTWITHSTANDING
ANY OTHER PROVISION OF THIS AGREEMENT, ANY PURPORTED LIMITATION ON A PARTY’S LIABILITY, (EACH, A “PARTY”
FOR PURPOSES OF THIS PARAGRAPH), EITHER AS TO TYPE OR AMOUNT OF DAMAGES, SHALL NOT APPLY TO ANY CLAIM ARISING FROM
(A) ANY OUT OF POCKET COSTS REASONABLY INCURRED BY A PARTY AS A RESULT OF THE OTHER PARTY’S BREACH OF ITS
OBLIGATIONS WITH RESPECT TO CONFIDENTIAL INFORMATION OR INDIVIDUALLY IDENTIFIABLE INFORMATION (INCLUDING, BUT NOT LIMITED TO,
PROTECTED HEALTH INFORMATION), B) DAMAGES TO THE EXTENT PROXIMATELY CAUSED BY THE PARTY’S OR ITS REPRESENTATIVE’S
(I.E., ITS EMPLOYEE’S, DIRECTOR’S, OFFICER’S, SUBCONTRACTOR’S OR OTHER AGENT’S) GROSS
NEGLIGENCE OR WILLFUL MISCONDUCT, OR (B) DAMAGES AWARDED TO THIRD PARTIES THAT ARE COVERED BY A PARTY’S DEFENSE
AND INDEMNITY OBLIGATIONS SET FORTH IN SECTION IV.D.

 

F.
Insurance.

 

1. Requirements.
Augmedix shall obtain and maintain all proper and necessary insurance to guard against all applicable risk at its sole cost and
expense, including, but not limited to, the following:

 

a) Commercial
General Liability Insurance in an amount not less than [*] per occurrence and [*] annual aggregate covering any and all damage
to property or injury to persons which arise from services performed under the Agreement. Coverage shall include Premises and
Operations, Independent Contractors, Products and Completed Operations including but not limited to any professional services
performed under the Agreement, Contractual Liability and Broad Form Property damage coverage;

 

b) Excess
or Umbrella Liability Insurance extending over the required Commercial General Liability, Automobile Liability and Employer’s
Liability in an amount not less than [*] per occurrence and [*] annual aggregate;

 

    11

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

c)  Workers’
Compensation Insurance in compliance with statutory requirements in the jurisdiction in which the work will be performed
and Employers Liability insurance with limits of [*] each accident, [*] disease policy limit, and [*] each disease employee
limit. Where permitted by law, such insurance shall contain waivers of the insurer’s right of subrogation against
Sutter, its Officers, Directors and Employees.

 

d) Automobile
Liability Insurance in an amount not less than [*] per accident coverage for all owned, non-owned and hired automobiles.

 

e) Professional
Liability Insurance (Errors and Omissions) covering negligent acts, errors or omissions arising out of the rendering of or
failure to render professional services as contracted under this Agreement, whether committed or alleged to have been committed
by Augmedix or by its employees, contractors or others for whom the Augmedix is legally responsible with minimum limits of [*]
each claim, [*] aggregate.

 

f) Information
Security & Privacy Insurance in the amount of [*] per claim, including coverage for unauthorized access, failure of security,
breach of privacy perils, wrongful disclosure of information, as well as notification costs and regulatory defense.

 

2. Extended
Coverage. If any such insurance is written on a claims-made policy form, the policy shall have a retroactive date prior to
or coinciding with the effective date of this Agreement and shall continue for five (5) years following termination of this Agreement.
In the event that a claims-made policy is canceled, terminated or non-renewed, Augmedix shall obtain an extended reporting period
endorsement for the remainder of the five (5) year period.

 

3. Certificate
of Insurance. Augmedix shall furnish Certificates of Insurance acceptable to Sutter prior to commencement of Services, and
thereafter, not less than ten (10) days prior to any expiration or renewal date. The Certificate of Insurance shall provide that
there will be no cancellation or reduction of coverage without thirty (30) days prior written notice to Sutter. All insurance
policies will be written by a company authorized to do business in the state of California and with an A.M. Best Rating of A VII
or better. In no event will the coverage or limits of any insurance maintained by Augmedix under this Section F., or the lack
or unavailability of any other insurance, limit or diminish in any way Augmedix's obligations or liability to Sutter under this
Agreement. Any acceptance of insurance certificates by Sutter shall not limit or relieve Augmedix of the duties and responsibilities
assumed by it under this Agreement.

 

4. Additional
Insureds. The Commercial General Liability and Automobile Liability Insurance maintained by Augmedix pursuant to this Agreement
shall be endorsed to name Sutter, its officers, directors, and employees as Additional Insureds. It is agreed that the insurance
afforded such Additional Insureds shall apply as primary insurance and that any other insurance carried by Sutter shall be excess
only and shall not contribute with this insurance.

 

    12

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

	V.	MISCELLANEOUS

 

A. Notices.
All communications and notices between the Parties hereto, whether or not required or permitted under this Agreement, shall
be in writing and either delivered personally, or by courier services, or sent by first class, certified United States mail, return
receipt requested, postage prepaid, to the Party’s address appearing below. Either Party may from time to time change its
address for purpose of receipt of notice by a notice delivered in compliance with this subsection.

 

Sutter Health

Attn: Chief Operating Officer,

2200 River Plaza
Drive

Sacramento, CA 95833

 

A copy is to be sent to:

Sutter Health Office of the General Counsel

Attn:
Senior Vice President & General Counsel

2200 River Plaza Drive

Sacramento, CA 95833

 

Augmedix, Inc.

Attn: CEO

1161 Mission Street, Suite 210

San Francisco, CA
94103

 

A copy is to be sent to:

Fenwick & West, LLP

Attn:
Stefano Quintini

801 California Street

Mountain View, CA 94041

 

B. Conflict
with Sutter Health Agreement. If Augmedix has an agreement with Sutter or a Sutter affiliate (“Sutter Affiliate
Contract”) on the same subject matter as this Agreement, this Agreement shall supersede the Sutter Affiliate Contract.

 

C. Publicity.
The Parties agree that all publicity and public announcements concerning the existence of this Agreement and of the subject
matter set forth herein shall be jointly planned and coordinated by and among the Parties. Neither Party shall disclose any of
the specific terms of this Agreement to any third party, except its subcontractors and agents with a need to know, without the
prior written consent of the other Party, which consent shall not be withheld unreasonably. Notwithstanding the foregoing, any
Party may disclose information concerning this Agreement as required by the rules, orders, regulations, subpoenas or directives
of a court, government or governmental agency, and shall provide notice to the other Party of having so disclosed unless not reasonably
practicable to do so.

 

    13

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

D. Use
of Marks. Other than as stated in this Agreement or an applicable Statement of Work, neither Party shall use the name,
logo, or likeness of the other Party, in any electronic medium, signage, advertising, or promotional material, without the prior
written consent of the other Party. Such consent may be granted or withheld in the sole discretion of the Party whose consent
is required; however, such consent shall not be unreasonably withheld.

 

E. Non-Solicitation. During
the Term of this Agreement and for a period of one (1) year after the termination of this Agreement (the “Restricted
Period”), neither Augmedix nor Sutter will, purposely (on either Party’s own behalf or on behalf of any other
person or entity) contact, recruit, solicit or otherwise seek to induce any employee or affiliated provider of the other
Party to terminate his/her employment or engagement with the other Party. This covenant applies to any employee or Provider
who, at the time of such attempted recruitment/hire by either Party, is currently employed or engaged with the other Party or
was previously employed or engaged with the other Party within the one (1) year period immediately preceding their
termination from Augmedix or Sutter.

 

F. Force
Majeure. Neither Party shall be liable nor deemed to be in default for any delay or failure in performance of any of its
obligations under this Agreement to the extent and for such periods of time as such delay or failure to perform results directly
or indirectly from any act of God, war (declared or undeclared), action of any governmental authority, terrorism, riot, revolution,
explosion, sabotage, nuclear incident, natural disaster, inclement weather, lightning, earthquake, fire, flood, storm, sinkhole,
epidemics, pandemic, vandalism, strike or other work interruption or any similar or dissimilar cause beyond the reasonable control
of either Party (“Excusable Delay”). The Party so affected will give prompt notice to the other Party of an Excusable
Delay, in each case specifying to the extent practicable the estimated duration of such Excusable Delay, and shall take whatever
reasonable steps are necessary to relieve the effect of such Excusable Delay as rapidly as possible. If Augmedix remains unable
to provide Service to Sutter for a period of thirty (30) days or more, Sutter has the right to obtain Service, partially or completely,
from competitors without penalty and without further payment to Augmedix. In the event of a disaster (e.g. act of God,
earthquake, fire, flood, natural disaster, inclement weather, epidemic, pandemic, act of terrorism, explosion, sabotage, nuclear
incident) and the Sutter requires the Services of the Augmedix, Augmedix agrees that it will use all commercially reasonable and
good faith efforts to provide such Services within twenty- four (24) hours’ notice from Sutter, or as soon thereafter as
possible, and to provide such Services as quickly as possible. This provision shall apply equally to a disaster event that has
already occurred (e.g. an earthquake) and to an event that is imminent (e.g. a flood), upon the sole discretion of the Sutter.

 

    14

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

G. Governing
Law. This Agreement and all transactions contemplated by this Agreement shall be governed by, and construed and enforced
in accordance with the laws of the State of California.

 

H. Dispute
Resolution. The Parties agree to meet and confer in good faith to resolve any problems or disputes that may arise under
this Agreement. If such good faith meet and confer does not result in resolution within thirty (30) days, unless mutually extended
in writing, either Party may proceed to arbitration. Meet and confer shall be a condition precedent to the filing of any arbitration
demand by any Party. In addition, should the Parties, prior to submitting a dispute to arbitration, desire to utilize other impartial
dispute settlement techniques such as mediation or fact-finding, a joint request for such services may be made to the Judicial
Arbitration and Mediation Services (“JAMS”), or the Parties may initiate such other procedures as they may mutually
agree upon at such time. The Parties further agree that all disputes arising between the Parties based on or related to this Agreement,
whether involving a claim in tort, contract, or otherwise, shall be settled by final and binding arbitration, upon a written demand
given by any Party to the other Parties. The arbitration shall be conducted in San Francisco, California by a single, neutral
arbitrator who is licensed to practice law and who is agreed to by the Parties to the dispute. The written demand shall contain
a detailed statement of the matter and facts and include copies of all related documents supporting the demand. All such arbitration
proceedings shall be administered by JAMS, however, the arbitrator shall be bound by applicable state and federal law, and shall
issue a written opinion setting forth findings of fact and conclusions of law. The Parties agree that the decision of the arbitrator
shall be final and binding as to each of them. Judgment upon the award rendered by the arbitrator may be entered in any court
having jurisdiction. The arbitrator shall have no authority to award punitive damages or to add to, modify, or refuse to enforce
any agreements between the Parties. The arbitrator shall have no authority to make any award that could not have been made by
a court of law. The Party against whom the award is rendered shall pay any monetary award and/or comply with any other order of
the arbitrator within sixty (60) days of the entry of judgment on the award, or take an appeal pursuant to the provisions of the
California Civil Code. The Parties waive their right to a jury or court trial. In all cases submitted to arbitration, the Parties
agree to share equally the administrative fee as well as the arbitrator’s fee, if any, unless otherwise assessed by the
arbitrator. The administrative fees shall be advanced by the initiating Party subject to final apportionment by the arbitrator
in this award. Each Party shall be solely responsible for its own legal fees and expenses and other costs of any arbitration.

 

    15

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

I. Assignment
and Delegation. Neither Party may, directly or indirectly, in whole or in part, either by operation of law or
otherwise, assign or transfer this Agreement or delegate any of its obligations under this Agreement without the other
Party’s written consent, except that either Party may assign this Agreement, without the other Party’s consent,
to an affiliate or to a successor or acquirer, in connection with a merger or acquisition, or the sale of all or
substantially all of such Party’s assets or the sale of that portion of such Party’s business to which this
Agreement relates. Any attempted assignment, transfer or delegation otherwise without such prior written consent will be void
and unenforceable. Any assignment permitted hereunder of either Party's rights to a purchaser of all or substantially all of
said Party's assets or stock or to any successor by way of merger, consolidation or similar transaction shall require that
such successor assumes all of the assigning Party’s obligations hereunder. Notwithstanding the foregoing, Sutter, or
its permitted successive assignees or transferees, may assign or transfer this Agreement or delegate any rights or
obligations hereunder without consent: (1) to any entity controlled by, or under common control with, Sutter, or its
permitted successive assignees or transferees; or (2) in connection with a merger, reorganization, transfer, sale of assets
or product lines, or change of control or ownership of Sutter, or its permitted successive assignees or transferees.

 

J. Entire
Agreement/Modification. This Agreement, including the Recitals (which are incorporated herein by this reference) constitutes
the Parties’ complete understanding with regard to the subject matter of this Agreement, and supersedes all prior written
or oral agreements or understandings with respect thereto. This Agreement may be modified only in writing signed and dated by
each Party’s management level representative who has actual signature authority to legally bind the Party on whose behalf
the signature is made.

 

K. Sutter
Content. Customer Data (as defined in Exhibit D) will not be stored outside of the U.S. Borders.

 

L. Survival.
Termination or expiration of this Agreement for any reason shall not relieve either Party of any obligation or liability incurred
prior to the expiration or termination of this Agreement. The following provisions shall survive termination or expiration of
this Agreement, in addition to those that by their nature are intended to survive termination: PAYMENT/EXPENSES; WARRANTIES; OWNERSHIP
OF PROPRIETARY RIGHTS; CONFIDENTIALITY; INDEMNIFICATION; LIMITATION OF LIABILITY/EXCEPTIONS; INSURANCE and DISPUTE RESOLUTION.

 

M. Waiver.
Any failure of a Party to insist upon strict compliance with any term or condition of this Agreement shall not be deemed to
be a waiver of such term or condition. To be effective, a waiver must be in writing, signed and dated by the Parties.

 

N. Severability.
In the event any portion of this Agreement is declared void by a court or arbitrator, such portion shall be severed from this
Agreement, and the remaining provisions shall remain in effect, unless the effect of such severance would be to alter substantially
this Agreement or the obligations of the Parties, in which case this Agreement may be immediately terminated.

 

O. Headings.
The headings are inserted into this Agreement for reference and convenience only, and will not affect the meaning or interpretation
of any provision hereof.

 

P. Counterparts.
This Agreement may be executed in counterparts, each of which will be an original and which together will constitute one and
the same instrument. A photocopy of the executed Agreement may be used as if it were the original Agreement.

 

    16

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

Q. No
Third Party Beneficiary. Nothing contained in this Agreement is intended nor shall it be construed to create rights running
to the benefit of third parties, unless otherwise expressly provided in this Agreement.

 

R. No
Referrals/Nonexclusivity. Nothing in this Agreement is intended to obligate and shall not obligate any Party to the Agreement
to refer clients to any other Party. Further, this Agreement is not exclusive, and the Parties may enter into similar agreements
with other Parties.

 

S. GPO
Agreements. If Augmedix is under contract with Novation for this Service category, the Augmedix agrees to report sales
under this Agreement and to pay administrative fees to Novation per terms of the Novation Agreement. If and when Services are
added to the Agreement, Augmedix will pay applicable administration fees with respect to such Services at that time and on a go
forward basis during the term of the Agreement.

 

T. 
Attorneys’ Fees. If any legal action or other proceeding is commenced to enforce or interpret any provision of,
or otherwise relating to, this Agreement, the prevailing Party shall be entitled to an award of attorneys’ fees and costs.
For this purpose “expenses” include, without limitation, court or other proceeding costs, and experts’ and attorneys’
fees and their expenses.

 

U. Integration.
This Agreement, including all Exhibits hereto, as set forth in Section V.V., constitutes the entire understanding of
the Parties, and revokes and supersedes all prior agreements between the Parties regarding the subject matter hereof and is intended
as a final expression of their Agreement. It shall not be modified or amended except in writing signed by the Parties hereto and
specifically referring to this Agreement. This Agreement shall take precedence over any other documents which may conflict with
this Agreement.

 

V. List of
Agreement Documents.

 

Master Services Agreement

 

Exhibit A: Description of Services

 

Exhibit A-1: Authorized Users

Exhibit A-2: Google Joint Publicity
Opportunity

Exhibit A-3: Publicity Support

Exhibit A-4: Assistance with
Grants and Studies

Exhibit A-5: Participation in
Product Roundtables

Exhibit A-6: Augmedix Epicenter
Program

Exhibit A-7: Foreign Remote Scribing
Locations

 

Exhibit B: Definitions

Exhibit C: Business Associate
Agreement

Exhibit D: Security of Data Systems

 

W. Execution.
By their signatures below, each of the signatories to this Agreement represent that they have the authority to execute this Agreement
and to bind the Party on whose behalf their execution is made.

 

SIGNATURE PAGE TO
FOLLOW

 

    17

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

SIGNATURE PAGE

 

	SUTTER HEALTH	 	AUGMEDIX, INC.
	 	 	 	 	             
	By:	/s/ Sarah Krevans	 	By:	/s/ Ian Shakil
	Name:	Sarah Krevans	 	Name:	Ian Shakil
	Title:	Chief Operating Officer	 	Title:	CEO
	Date;	April 15, 2015	 	Date;	April 15, 2015

 

    18

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

 EXHIBIT A

 

DESCRIPTION
OF SERVICES

 

		1.	OVERVIEW AND DEFINITIONS

 

		1.1.	Project Overview. Augmedix will provide Service,
powered by Google Glass, to facilitate coordination of Scribing into the Sutter electronic health record, in pending status, awaiting
the provider’s review, finalization and approval.

 

		1.2.	Definitions. As used in this Exhibit, all terms
not otherwise defined in the Agreement shall have the meanings indicated in Exhibit B: Definitions.

 

		1.3.	Authorized Users.

 

		1.3.1.	Meaningful Growth Phase [*]: Sutter agrees to be invoiced and pay for additional
                                                                                    Authorized Users as specified by Schedule A-1A, for a total of [*] additional Authorized Users by [*]. Sutter agrees and
                                                                                    understands that its addition of said Authorized Users according to Schedule A-1A, and Sutter’s use of Steady State OUS
                                                                                    Services by [*], is essential to the commercial success of the Parties, and if such goals are not met, Augmedix may choose to
                                                                                    1) cease allowing additional Authorized Users; and 2) withdraw its support or not include Sutter from the activities listed
                                                                                    in Exhibit A-3, A-4 and A-5. See Schedule A-1B for a listing of current Authorized Users.

 

		1	Maximum Growth
in [*]: The maximum number of additional Authorized Users for calendar year 2015 shall be [*] (this number includes the additional
Authorized Users as anticipated in Section 1.3.1 above), with the designation of additional Authorized Users above [*] by mutual
written consent of the Parties.

 

		1.3.3.	Sutter may
remove any Authorized User upon [*] prior written notice to Augmedix.

 

		2.	PARTIES RESPONSIBILITIES

 

		2.1.	Augmedix Responsibilities. Commencing on the
Effective Date, Augmedix will perform the following Services:

 

		2.1.1.	Implementation and Training. Augmedix will coordinate
and manage an implementation period including evaluating site IT infrastructure, collecting physician and site preferences, and
sending staff on-site at the Sutter Facility in order to facilitate the on boarding of Sutter employees, Sutter physicians and
providers, and Augmedix Scribes. Augmedix will provide 1) appropriate employee and provider training, and 2) patient education
materials within the first three months of the Effective Date. Augmedix will be responsible for training Sutter employees, physicians
and providers on relevant procedures.

 

    19

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

		2.1.2.	Remote Scribing. Following completion of the
implementation period, Scribing is to be performed by Augmedix Scribes at a Customer pre-approved centralized third party HIPAA
compliant facility and/or on-site for quality and training purposes. The Parties agree that Sutter can designate whether or not
such Remote Scribing is performed within the United States or permitted to be performed outside of the United States. The pricing
for Steady-State Inside United States Services and Steady-State Outside United States Services is provided in Section 3.1 of this
Exhibit. Any agreed upon Outside United States locations for Remote Scribing Services shall be listed in Exhibit A-7. Augmedix
will facilitate coordination of Scribing into the EHR, in pending status, awaiting the provider’s review, finalization and
approval. Audio and video content generated during a patient session using the Augmedix Google Glass Device will at all times
be encrypted and streamed in real time through the Sutter Wi-Fi network, with an exception for temporary caching on the Augmedix
Google Glass Device to ensure continuity of the data stream. Notwithstanding the foregoing, for purposes of this Agreement, “streamed
in real time” means streaming without any caching, storage or retention of the content; provided, however, that buffering
for the purpose of transmitting the content is permitted.

 

		2.1.3.	Technology
Maintenance. Augmedix shall be responsible for ensuring the availability and functionality of sufficient Augmedix Google Glass
Devices to provide the Services. The Augmedix Google Glass Devices and other hardware or materials provided for the purpose of
this Agreement are owned by Augmedix and will be provided and supported entirely by Augmedix to Sutter. Augmedix will guarantee
[*] uptime with exceptions for disruptions to Wi-Fi, power, EHR and facilities. Augmedix will respond to all requests for support
within [*] of request during scheduled clinic hours.

 

		2.2.	Sutter Responsibilities.Commencing on the
Effective Date, Sutter will have the following responsibilities:

 

		2.2.1.	Infrastructure. Sutter will provide the required
infrastructure, including logins, software licenses, remote permissions, and necessary bandwidth and reliability, to connect with
EHR and for the Augmedix Google Glass Device stream, subject to Augmedix’s compliance with all applicable policies and procedures
of Sutter.

 

		2.2.2.	Patient Education. Sutter will work together
with Augmedix to develop patient education materials, including an FAQ within the first three months of execution of the underlying
Agreement.

 

		2.2.3.	Training. Sutter will provide training to Scribes
pertaining to the use of certain software applications installed on the Hardware, including EHR software.

 

    20

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

		2.2.4.	Access. Sutter will arrange for appropriate
access and related credentials for use of certain software applications on the Hardware by Scribes.

 

		2.2.5.	Compliance. Sutter shall ensure that patients
(a) are informed, prior to the use of the Augmedix Solution, of the function, extent, and purpose of the Augmedix Solution and
utilization of audiovisual equipment by means of the Glass device, and (b) are afforded the option to opt-out of such use, each
of (a) and (b) in compliance with all applicable privacy laws and regulations.

 

		2.2.6.	Scheduling.
Sutter staff will update patient status in the EHR or scheduling software available to the Scribe. Sutter will provide an estimate
of Augmedix Scribe availability requirements no less than [*] in advance of each month’s requirement on a day by day basis
for each Authorized User. This estimate will be used by Augmedix to staff the Augmedix solution. [*] prior to the first of the
month and each month thereafter, Sutter shall provide a daily schedule for each Authorized User for each day of the following
month (“Daily Schedule”).

 

		2.3.	Software and Equipment.

 

		2.3.1.	Software.

 

		2.3.1.1.	License. Subject to the terms and conditions
of this Agreement, Augmedix hereby grants Sutter a non-exclusive, non-transferable license for Sutter and its Authorized Users
to use the Augmedix Solution and Documentation at the Sutter Facility for the sole purpose of receiving the Services in accordance
with this Agreement. The Software may be used on a concurrent user basis.

 

		2.3.1.2.	Restrictions. Without the prior written consent
of Augmedix, Sutter agrees not to (nor assist or encourage third parties to): (a) sell, rent, lease, lend, license, sublicense,
distribute or otherwise transfer the Software or Documentation to any third party; (b) decompile, disassemble or reverse engineer
the Software, in whole or in part; (c) write or develop any derivative software or any other software program based upon the Software,
the Documentation or any Augmedix Confidential Information; (d) use the Software to provide processing or other services to third
parties, or otherwise use the Software on a “service bureau” basis; or (e) provide, disclose, divulge or make available
to, or permit use of the Software or Documentation by any third party without Augmedix’s prior written consent. The Software
contains Embedded Software and Sutter will comply with any applicable license terms and conditions as set forth in subsection
(c) below.

 

    21

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

		2.3.2.	Augmedix Google Glass Devices.

 

		2.3.2.1.	The acquisition (including with respect to all applicable
software licenses), installation, configuration, and maintenance of all such Augmedix Google Glass Devices will be solely the
responsibility of Augmedix.

 

		2.3.2.2.	Sutter shall ensure that Authorized Users (i) maintain
the Augmedix Google Glass Devices in good repair, condition and working order, (ii) use the Augmedix Google Glass Devices in accordance
with the applicable user manual(s) and the guidelines provided from time to time by Augmedix, and (iii) without limiting the foregoing,
do not use the Augmedix Google Glass Devices outside of the approved site or for purposes not contemplated under this Agreement,
or disable any protective safeguards.

 

		3.	FEES.

 

		3.1.	Service Pricing:

 

		3.1.1.	Steady-State
Inside United States (“IUS”) Services. The IUS Services shall be provided to Sutter for a fee of $[*] / FTE provider
/ month (“IUS Services Fee”).

 

		3.1.2.	Steady-State
Outside United States (“OUS”) Services. The OUS Services shall be provided to Sutter for a fee of $[*] / FTE provider
/ month (“OUS Services Fee”).

 

		3.2.	Prepayment:
Sutter shall provide Augmedix an initial prepayment for each Authorized User scheduled to utilize the Services after April 1,
2015 (“Prepayment”). The Prepayment is equal to [*] of the full-time FTE IUS or OUS Services Fee associated
with that specific Authorized User. The Prepayment shall be credited back to Sutter only if Sutter decides to timely terminate
an Authorized User in accordance with the notice requirements of this Agreement, in which case the Prepayment amount shall be
reduced beginning in the final [*] of Service for that specific Authorized User by the amount of the IUS or OUS Service Fees invoiced
under this Agreement for that specific Authorized User, with any remaining amount of the Prepayment being refunded to Sutter.
By way of example, if an additional Authorized User was scheduled to begin utilizing Service on April 1, 2015 at an OUS Service
Fee schedule, the Prepayment for such an Authorized User would be [*] and Augmedix would invoice Sutter for the full applicable
OUS Service Fee beginning and continuing from April 1, 2015; if Sutter gave notice to terminate that Authorized User on January
1, 2016, then the Prepayment would be reduced to $[*] by March 31, 2016.

 

Pricing is turn-key per provider to include
implementation, training, one (1) Google Glass unit per physician, battery packs as needed and remote scribing.

 

    22

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

SCHEDULE A-1A

 

MEANINGFUL GROWTH PHASE - ADDITIONAL
AUTHORIZED USERS

 

	Deadline	 	Additional Authorized Users
	[*]	 	[*]
	[*]	 	[*]
	[*]	 	[*]
	[*]	 	[*]
	[*]	 	[*]
	[*]	 	[*]

 

    23

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

SCHEDULE A-1B

 

INITIAL
AUTHORIZED USERS

 

Name: [*]

Customer Facility: [*]

Daily Schedule: Patient time all day Monday,
Wednesday and Friday

FTE: [*]

Hours: [*] per month

 

Name: [*]

Customer Facility: [*]

Daily Schedule: Patient time all day Monday,
Wednesday AM, Thursday PM and Friday AM

FTE: [*]

Hours: [*] per month

 

Name: [*]

Customer Facility: [*]

Daily Schedule: Patient time Tuesday AM, potential
patient time Tuesday PM, Thursday AM, potential patient time Thursday PM, all day Friday

FTE: [*]

Hours: [*] per month

 

Name: [*]

Customer Facility: [*]

Daily Schedule: Patient time all day Monday, Tuesday
AM, potential patient time Tuesday PM, Wednesday AM, potential patient time Wednesday PM, all day Thursday and Friday AM

FTE: [*]

Hours: [*] per month

 

Name: [*]

Customer Facility: [*]

Daily Schedule: Patient time all day Monday,
Tuesday Thursday and Friday

FTE: [*]

Hours: [*] per month

 

Name: [*]

Customer Facility: [*]

Daily Schedule: Patient time Monday PM, potential patient
time Monday AM, all day Tuesday, Thursday and Friday

FTE: [*]

Hours: [*] per month

 

    24

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

Name: [*]

Customer Facility: [*]

Daily Schedule: Patient time Monday PM, Wednesday
AM, Thursday PM and Friday AM

FTE: [*]

Hours: [*] per month

 

Name: [*]

Customer Facility:[*]

Daily Schedule: Patient time Monday all day,
Wednesday AM and Friday AM

FTE: [*]

Hours: [*] per month

 

Name: [*]

Customer Facility:[*]

Daily Schedule: Patient time Tuesday all day,
Wednesday AM, potential patient time Wednesday PM, Thursday and Friday all day

FTE: [*]

Hours: [*] per month

 

Name: [*]

Customer Facility: [*]

Daily Schedule: Patient time 1st, 3rd,
4th, 5th week Tuesday AM, potential patient time 2nd week Wednesday AM, 2nd week Wednesday PM,
Friday AM

FTE: [*]

Hours: [*] per month

 

This list is subject to modification
upon consent of both Parties.

  

    25

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

EXHIBIT A-2

 

GOOGLE JOINT PUBLICITY OPPORTUNITY

 

Sutter may participate in
a publicity and branding initiative with Google and Augmedix. The initiative’s purpose will be to publicly highlight the
Sutter Health experience with Google Glass and the Augmedix Solution. Both Parties acknowledge that Google and its selected advertising
agency (mssngpeces.com) have successfully collaborated with Augmedix, Sutter Health, and Palo Alto Medical Foundation stakeholders
to produce a two-minute concept video in furtherance of this initiative. This video has been provided to all parties and is authorized
for internal use only by all parties. Google, Sutter Health, and Augmedix will work together in good faith to plan a public unveiling
of the Augmedix-Sutter relationship, alongside a video release. Google will provide final content edits and timelines approvals
to ensure alignment with the overall Google Glass PR and branding timeline.

 

    26

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

EXHIBIT
A-3

 

PUBLICITY SUPPORT

 

1. General
Description: During the term of this Agreement, Augmedix will make its executives available for videos, statements, and photo
opportunities in order to support any Sutter press initiatives associated with the Services. It is also agreed to and understood
that Augmedix will provide speakership opportunities for Sutter business leaders and physicians.

 

2. Each
Party Costs: Augmedix and Sutter are responsible for their respective external costs of marketing associated with the above
and shall share equally in any costs associated with co- developed marketing materials.

 

3.
Term and Termination.

 

		3.1.	Term: The term of the Publicity Support as provided
in this Exhibit A-3 shall commence on execution of this Agreement and shall continue and be in effect for the Term of the
Agreement.

 

		3.2.	Renewal: This Exhibit A-3 shall automatically
renew for renewal periods of one (1) year unless Sutter provides Augmedix with at least fifteen (15) days written notice of Sutter’s
intent not to renew prior to expiration of the then current term.

 

		3.3.	Termination: Sutter may terminate its Publicity
Support as defined in Exhibit A-3 with ninety (90) days notice to Augmedix. The termination of the Publicity Support by
Sutter does not terminate either parties other obligations and deliverables as provided in this Agreement or in its attached exhibits.

 

    27

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

EXHIBIT A-4

 

ASSISTANCE WITH GRANTS AND
STUDIES

 

1. General
Description: During the term of this Agreement, Augmedix will provide reasonable support in any identified research and publication
efforts, whether privately or publicly funded, conducted by Sutter in collaboration with Augmedix. To the extent possible, Augmedix
will assist in the collection of data metrics and assist in the workflow to accommodations required to complete the identified
research study and publication effort.

 

2.
Term and Termination.

 

		2.1.	Term: The term of this Exhibit A-4 shall
commence on execution of this Agreement and shall continue and be in effect for the Term of the Agreement.

 

		2.2.	Renewal: This Exhibit A-4 shall automatically
renew for renewal periods of one (1) year unless Sutter provides Augmedix with at least fifteen (15) days written notice of Sutter’s
intent not to renew prior to expiration of the then current term.

 

		2.3.	Termination: Sutter may terminate Exhibit
A-4 with ninety (90) days notice to Augmedix. The termination of Exhibit A-4 by Sutter does not terminate either parties
other obligations and deliverables as provided in this Agreement or in its attached exhibits.

 

    28

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

EXHIBIT A-5

 

PARTICIPATION
IN PRODUCT ROUNDTABLES

 

1.General Description:Sutter shall
be given a seat at the Augmedix Product Roundtable which will confer to Sutter the opportunity to guide future platform partnerships
and features.

 

2.
Term and Termination.

 

		2.1.	Term: The term of Exhibit A-5 shall
commence on execution of this Agreement and shall continue and be in effect for the Term of the Agreement.

 

		2.2.	Renewal: This Exhibit A-5 shall automatically
renew for renewal periods of one (1) year unless Sutter provides Augmedix with at least fifteen (15) days written notice of Sutter’s
intent not to renew prior to expiration of the then current term.

 

		2.3.	Termination: Sutter may terminate Exhibit
A-5 with ninety (90) days notice to Augmedix. The termination of Exhibit A-5 by Sutter does not terminate either parties
other obligations and deliverables as provided in this Agreement or in its attached exhibits.

 

    29

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

EXHIBIT A-6

 

AUGMEDIX
EPICENTER PROGRAM

 

As an early adopting of the
Augmedix Solution, Sutter may serve as a reference customer on behalf of Augmedix for non Sutter Health physicians and business
leaders who desire to see and discuss the Augmedix’s Solution.

 

    30

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

Exhibit A-7

 

FOREIGN REMOTE SCRIBING LOCATIONS

 

[*]

 

Location #1:

 

[*]

 

Location #2:

 

[*]

 

    31

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

EXHIBIT
B

 

DEFINITIONS

 

“Augmedix Google Glass
Device(s)” means the Google Glass device (or similar devices such as the Looxcie, Vuzix M100, Golden-I, etc.) that has
been deployed by Augmedix for use as part of the Augmedix Solution.

 

“Augmedix Solution”
means the Scribing solution provided by Augmedix to the Sutter, including the Augmedix Google Glass Device and associated software.

 

“Authorized User(s)”
means an employee or contractor who are designated by Sutter as an Authorized User.

 

“Documentation”
means all materials and documentation provided by Augmedix to Sutter, whether in hard copy, magnetic media or machine-readable
form, pertaining to the capabilities, operation, software and/or services of the Augmedix Solution, as amended and updated by Augmedix
from time to time.

 

“Full-Time Employee (FTE)”
equates to 140 hours of service per month (4 week period).

 

“Hardware”
means the minimum recommended hardware required to operate the Software, as described herein.

 

“Scribe(s)” means
an individual who performs Scribing on behalf of a Sutter provider.

 

“Scribing” means
the act of EHR data entry and lookup from the perspective of, and on behalf of the provider based on the interaction between a
patient and provider. Scribing activities will be reviewed, finalized and approved by provider before any Scribe-created data becomes
part of the subject patient’s medical record.

 

“Software” means
the software required to operate the Augmedix Google Glass Device. Software includes any embedded software.

 

    32

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

EXHIBIT C

 

BUSINESS ASSOCIATE AGREEMENT

 

This Business Associate
Agreement (“Agreement”) is by and between Sutter Health, a California nonprofit public benefit corporation (“Covered
Entity”), and Augmedix, Inc., a Delaware corporation (“Business Associate”), and is effective as of the
date last signed below (the “Effective Date”).

 

R E C I T A L S

 

A. The
parties desire to comply with federal and California laws regarding the Use and Disclosure of individually identifiable health
information, in particular with the provisions of the federal Health Insurance Portability and Accountability Act (HIPAA), and
the Health Information Technology for Economic and Clinical Health Act (HITECH), and regulations promulgated under these laws.

 

B.
The parties have accordingly agreed to enter into the following terms and conditions.

 

A G R E E M E N T

 

Now therefore, in consideration
of the promises set forth herein, the parties agree as follows:

 

1. Definitions.
The parties agree that any capitalized terms shall have the same definition as given to them under HIPAA and HITECH and
regulations promulgated under these laws.

 

2. Protected
Health Information. Business Associate agrees that it shall keep confidential all Individually Identifiable Health Information
protected under California and federal law, including, but not limited to, Protected Health Information that Business Associate
receives from Covered Entity, or creates or receives on behalf of Covered Entity (hereafter “PHI”). Such PHI shall
be and remain the property of Covered Entity.

 

3. Obligations
of Business Associate. Business Associate shall limit its Use and Disclosure of PHI only as necessary and appropriate
to fulfill its specific obligations to Covered Entity, and agrees to the following, without limiting the foregoing:

 

(a) Use of Protected Health Information (“PHI”): Business Associate agrees that it, and its agents, employees and
Subcontractors, shall not Access, Use or Disclose PHI other than as permitted or required by the Agreement or as required by law.

 

    33

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

(b) Safeguards:
Business Associate shall comply with Subpart C of 45 CFR Part 164 (“Security Rule”) with respect to electronic PHI,
to prevent Use or Disclosure of PHI other than as provided for by the Agreement. Additionally, Business Associate will comply with
the following specific requirements relevant to Subpart C of 45 CFR Part 164 (“Security Rule”):

 

		i.	Covered Entity’s PHI that is transmitted, transacted
or stored must be encrypted with FIPS 140-2 compliant encryption, such as the Advanced Encryption Standard (AES). Business Associate
acknowledges and understands that Covered Entity’s standard is AES 256 encryption for transmitting PII and/or PHI. While
currently some of Business Associate’s transmissions of Covered Entity’s PHI uses AES 128 encryption, Business Associate
will implement AES 256 encryption for Covered Entity’s PHI no later than 12/31/2015. In addition, Business Associate, when
transmitting Covered Entity’s PHI outside of the United Sates (and within the United States when applicable and as requested
by Covered Entity), will only access Covered Entity’s EHR to/from specific IP addresses and locations approved by Covered
Entity.

 

		ii.	Covered Entity’s PHI remains solely on servers located within the
United States.

 

		iii.	Business Associate will apply all applicable security patches, service
packs and hot fixes on applications and information systems that transmit, transact or store Covered Entity’s PHI within
thirty (30) days of release.

 

		iv.	Business Associate will perform a thorough background check that will include,
at a minimum, criminal check, employment verification, drug testing, and name/address verification for all employees requiring
access to information systems that transmit, transact or store Covered Entity’s PHI. Background checks will include married
name and maiden name where appropriate.

 

		v.	Business Associate will employ multifactor authentication (e.g., tokens,
one (1) time passwords, etc.) for remote access to applications and information systems that transmit, transact or store Covered
Entity’s PHI.

 

		vi.	Business Associate will securely sanitize all media containing Covered Entity’s
PHI (i.e., make the PHI unreadable or unusable through encryption or physical destruction) prior to disposal or re-use.

 

    34

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

(c) Reporting:
Business Associate shall report to the Privacy Officer of Covered Entity any Use or Disclosure of protected health
information not provided for by the Agreement of which it becomes aware, including Breaches of Unsecured PHI as required at
45 CFR § 164.410 within forty-eight (48) hours of Discovery. Reports shall include, information available at the time of
such reporting to the extent possible: A description of what happened, including the date of the discovery; the types of PHI
that were involved; any steps individuals should take to protect themselves from potential harm; and what Business Associate
is doing to investigate, mitigate, and protect against further unauthorized Disclosures or Breaches. Initial reports shall be
supplemented as more information becomes available to Business Associate. Business Associate shall also promptly report in
electronic form to the Security Officer of Covered Entity any Security Incident relating to Electronic PHI of which Business
Associate becomes aware, except that no report shall be required for unsuccessful attempts at unauthorized Access, Use,
Disclosure, modification, or destruction of PHI or unsuccessful attempts at interference with systems operations in an
information system, such as “pings” on a firewall. Reports required under section shall be made to the following
individuals, as applicable:

 

Sutter Health, Chief Privacy Officer

[*]

[*]

Ph: [*]

 

Sutter Health, Chief Information Security
Officer

[*]

[*]

Ph: [*]

 

(d) Workforce,
Agents and Subcontractors: Business Associate shall not disclose PHI to any member of its Workforce, or to any of its
agents or Subcontractors, unless such Disclosure is necessary for Business Associate to fulfill the terms of the Agreement.
Business Associate shall also ensure that any Subcontractors that create, receive, maintain, or transmit protected health
information on behalf of the Business Associate agree to the same restrictions, conditions, and requirements that apply to
the Business Associate with respect to such information in accordance with 45 CFR § 164.502(e)(1)(ii) and 164.308(b)(1).
Business Associate shall not disclose PHI, nor allow an agent or Subcontractor to disclose PHI, outside of the United States
of America without the express written consent of Covered Entity. The foregoing does not preclude Business Associate from
utilizing its subcontractors or agents residing outside of the United States to provide supporting services and functions so
long as:

 

		i.	Business Associate’s subcontractors and agents
only have foreign remote access to Covered Entity’s PHI from workstations located in a secured facility approved by Covered
Entity. Addresses of such facilities must be included in Exhibit A-7 of this Agreement and Business Associate will inform Covered
Entity of any additions or deletions of facilities listed in Exhibit A-7.

 

		ii.	Business Associate contractors and agents fully comply
with the provisions of HIPAA and this Agreement in the same manner as the Business Associate when handling PHI of Covered Entity.

 

		iii.	Covered Entity’s PHI remains solely on servers
located within the United States.

 

		iv.	The subcontractors and agents conduct such services
within a secured facility that has badge access with logging and cameras located solely at exit and entry points,

 

    35

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

		v.	Workstations utilized by Business Associate’s subcontractors or agents
have technical controls to protect against unauthorized dissemination of PHI (i.e. Data Leak Prevention system (DLP), removable
media restrictions, and restricted Internet Access).

 

(e) Access
to PHI: Upon the request by Covered Entity, Business Associate shall promptly provide PHI to Covered Entity within five (5)
days to permit any individual whose PHI is maintained by Business Associate to have Access to and to copy his/her PHI in accordance
with 45 CFR § 164.524, and applicable California law. Such PHI shall be produced in the format requested by Covered Entity,
unless it is not readily producible in such format, in which case it shall be produced in hard copy format. If an individual contacts
Business Associate directly for such Access, Business Associate shall direct the individual to contact the Covered Entity. This
requirement to provide Access to the PHI shall only apply if the PHI in Business Associate’s possession is part of the Covered
Entity’s Designated Record Set.

 

(f) Amendment
of PHI: Upon the request of Covered Entity, Business Associate shall amend PHI and/or make PHI available to Covered
Entity within five (5) business days for amendment, in such manner as Covered Entity may from time to time request, in
accordance with 45 CFR § 164.526 and applicable California law. If an individual contacts Business Associate directly to
amend PHI, Business Associate shall direct the individual to contact the Covered Entity. This requirement to amend the PHI
shall only apply if the PHI in Business Associate’s possession is part of the Covered Entity’s Designated Record
Set.

 

(g) Accounting
of Disclosures of PHI: Upon the request of Covered Entity, Business Associate shall provide to Covered Entity within five
(5) business days an accounting of all Disclosures of PHI in order for Covered Entity to comply with 45 CFR § 164.528
Business Associate shall provide the date of the Disclosure, the name and, if known, the address of the recipient of the PHI,
a brief description of the PHI disclosed, and the purpose of the Disclosure. If an individual contacts Business Associate
directly for such an accounting, Business Associate shall direct the individual to contact the Covered Entity.

 

(h) Minimum
Necessary: Business Associate and its agents or Subcontractors shall request from Covered Entity and so Use and disclose only
the Minimum Necessary PHI necessary to accomplish the purpose of the request, Use, or Disclosure. In all cases, Business Associate
agrees to comply with guidance issued from time to time by the Secretary of Health and Human Services regarding Minimum Necessary.

 

(i) Prohibition
on Sale of PHI: Business Associate shall not directly or indirectly receive remuneration in exchange for any PHI.

 

(j) Other
Obligations: To the extent that Business Associate is responsible for carrying out an obligation of Covered Entity under
Subpart E of 45 CFR Part 164, Business Associate shall comply with the requirements of Subpart E that apply to Covered Entity
in the performance of that obligation.

 

    36

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

(k) Audits,
Investigations Inspections: Business Associate shall make its internal practices, books, and records relating to the Use and
Disclosure of PHI received from, or created by the Business Associate on behalf of, the Covered Entity available to the Secretary
of the United States Department of Health and Human Services (“Secretary”), or the Secretary’s designee, for
purposes of determining the Covered Entity’s and/or Business Associate’s compliance with the applicable laws and regulations.
Business Associate shall cooperate with Covered Entity related to government or regulatory investigations, including making Business
Associate’s information relating to the Use and Disclosure of PHI available to Covered Entity.

 

(l) Identity
Theft Red Flags: To the extent Business Associate performs a service or activity on behalf of Covered Entity in
connection with a covered account (as defined by 16 CFR Part 681.1(b)(3)), Business Associate will perform the service or
activity in accordance with reasonable policies and procedures designed to detect, prevent, and mitigate the risk of identity
theft (as defined in 16 CFR 603.2(a)).

 

(m) Mitigation
Procedures: Business Associate agrees to mitigate, to the extent practicable, any harmful effect that is known to
Business Associate of a Use or Disclosure of PHI in violation of this Agreement.

 

(n) Indemnification:
Subject to the terms and conditions of Section IV(D) and IV(E) of the Agreement, each party agrees to indemnify and defend,
and hold harmless the other party, its affiliates, and any of its or their officers, directors, attorneys, agents or
employees, from all claims, costs, settlement fees, attorneys’ fees, losses, damages, liabilities and penalties arising
from or connected with the breach by the indemnifying party or any of its officers, directors, agents, Subcontractors or
employees, of its obligations under this Agreement with respect to PHI. This provision shall survive the termination or
expiration of this Agreement.

 

(o) Insurance:
Business Associate shall obtain and maintain all proper and necessary insurance to cover liabilities related to Business
Associate’s obligations concerning the PHI received from, or created by Business Associate on behalf of, Covered Entity
pursuant to this Agreement in the minimum amounts of $[*] per claim. Business Associate shall notify Covered Entity
promptly of any changes or termination of coverage that affects such insurance coverage during the term of this
Agreement.

 

(p) Legal
Process: In the event that Business Associate is served with legal process (e.g., a subpoena) or request from a government
agency (e.g., the Secretary) that potentially could require the Disclosure of PHI, Business Associate shall provide prompt notice
of such legal process to the Privacy Officer of Covered Entity. In addition, Business Associate shall not disclose the PHI without
the express written consent of Covered Entity unless pursuant to a valid and specific court order or to comply with a request by
a governmental regulatory agency under its statutory or regulatory authority.

 

    37

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

4.
Permitted Uses and Disclosures by Business Associate.

 

(a) Management
and Administration. Business Associate and its respective agents, employees and Subcontractors are authorized to Use or
disclose PHI for Business Associate’s own proper management and administration, and to fulfill any of Business
Associate’s legal responsibilities; provided, however, that the Disclosures are required by law or Business Associate
has received from any third-party recipient of PHI written assurances that (i) the PHI will be held confidentially and Used
or further disclosed only as required by law or for the purposes for which it was disclosed to the third-party, and (ii) the
third-party will notify Business Associate of any instances of which the third- party becomes aware that the confidentiality
of the PHI has been breached.

 

5.
Obligations of Covered Entity.

 

(a) Authorizations:
Covered Entity shall obtain from individuals any applicable consents, authorizations and other permissions necessary or
required by law for Covered Entity and Business Associate to fulfill their obligations under this Agreement.

 

(b) Restrictions:
Covered Entity shall notify Business Associate in writing of any unique restrictions in the Use or Disclosure of an individual’s
PHI that Covered Entity has agreed to that may affect Business Associate’s performance of its obligations under this Agreement.
Covered Entity must agree to the request of an individual to restrict Disclosure of PHI about the individual to a Health Plan if
the Disclosure is for the purpose of carrying out Payment or Health Care Operations and is not otherwise required by law; and the
PHI pertains solely to a health care item or service for which the individual, or person other than the Health Plan on behalf of
the individual, has paid Covered Entity in full.

 

(c) Revocations:
Covered Entity shall notify Business Associate in writing of any changes in, or revocation of, permission by an individual relating
to the Use or Disclosure of PHI, if such changes or revocation may affect Business Associate’s performance obligations under
this Agreement.

 

6.
Termination.

 

(a) Breach:
Without limiting the rights of the parties under this Agreement, if either party breaches its obligations under this Agreement,
the non-breaching party may terminate this Agreement and may, but is not required to, provide the breaching party an opportunity
to cure the breach within thirty (30) days prior to the effectiveness of such termination (or such shorter time period as determined
by the non-breaching party in its sole discretion).

 

(b) Automatic
Termination: This Agreement shall automatically terminate upon the mutual agreement of the parties.

 

    38

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

(c) Procedure
upon Termination: Upon termination of this Agreement, Business Associate shall return or destroy, at Covered Entity’s
option, all PHI that it maintains in any form, and shall retain no copies of PHI, if feasible. Business Associate shall certify
to Covered Entity that Business Associate has destroyed and/or returned all PHI, in accordance with Covered Entity’s request.
If the parties agree that the return or destruction of PHI is not feasible, Business Associate shall continue to extend the protections
of this Agreement to the PHI, and limit further Use of the PHI to those purposes that make the return or destruction of the PHI
infeasible. Business Associate shall notify Covered Entity what PHI Business Associate shall retain. This obligation on Business
Associate shall survive any termination of this Agreement.

 

7. Amendment.
The parties agree to take such action as is necessary to amend this Agreement for Covered Entity to comply with HIPAA or other
applicable law. The parties agree that this Agreement may only be modified by mutual written amendment, signed by both parties,
effective on the date set forth in the amendment.

 

8. No
Third-Party Beneficiaries. Unless otherwise set forth herein, nothing contained herein is intended nor shall be construed
to create rights running to the benefit of third-parties.

 

9. Independent
Contractor. The parties agree that Business Associate is an independent contractor, and not an employee, agent, or partner
of, or joint venturer with, Covered Entity.

 

10. Entire
Agreement. This Agreement (together with any recitals and exhibits, which are hereby incorporated by this reference) constitutes
the entire understanding and agreement between the parties relating to PHI, and it supersedes any and all prior or contemporaneous
agreements, representations and understandings of the parties.

 

11. Waiver.
Any failure of a party to insist upon strict compliance with any term, undertaking or condition of this Agreement shall not
be deemed to be a waiver of such term, undertaking or condition. To be effective, a waiver must be in writing, signed and
dated by the parties to this Agreement.

 

12. Counterparts.
This Agreement may be executed in multiple counterparts, each of which shall be deemed an original and all of which together
shall be deemed one and the same instrument. Any photocopy of this executed Agreement may be used as if it were the
original.

 

13. Governing
Law. Notwithstanding any other provision to the contrary, this Agreement shall be governed and construed in accordance
with the laws of the State of California.

 

14. Interpretation.
Any ambiguities shall be resolved to permit Covered Entity and Business Associate to comply with HIPAA and HITECH, and regulations
promulgated under these laws.

 

15. Execution.
By their respective signatures and execution dates, below, each of the following represents that he or she is duly authorized to
execute this Agreement and to bind the party on whose behalf such execution is made.

 

    39

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

	SUTTER HEALTH	 	AUGMEDIX, INC.
	 	 	 
	By: 	/s/ Sarah
    Krevans	 	By:	/s/ Ian
    Shakil            
	Name: 	Sarah Krevans	 	Name: 	Ian Shakil
	Title:	Chief Operating Officer	 	Title:   	CEO
	Date:	April 15, 2015	 	Date:  	April 15, 2015

 

    40

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

Exhibit D

 

SECURITY OF DATA AND SYSTEMS

 

		1.	Objective. The purpose of this Exhibit D
(“Exhibit”) is to ensure the confidentiality, integrity, and availability of all Customer Data and Systems
transmitted, accessed, developed, used or provided under this Agreement. In the event any term or condition in this Exhibit conflicts
with a term or condition of the Agreement or the Business Associate Agreement, if any, the term or condition of the Agreement
or the Business Associate Agreement shall control. Capitalized terms used in this Exhibit and not defined herein shall have the
meanings set forth in the Agreement. Nothing in this Exhibit shall relieve Augmedix, Inc. (“Supplier”) of any obligations
under the Agreement, or the Business Associate Agreement, if any, nor be deemed a waiver by Sutter Health (“Customer”)
of any rights or remedies therein. For purposes of this Exhibit and for the product or use of the product as specified in this
Agreement, “Customer Data” means Protected Health Information (“PHI”) and Personally Identifiable
Information (“PII”) collected by or made available to Supplier under the Agreement, or “Metadata”, which
means proprietary structural, technical and administrative data regarding the design and specification of such PHI or PII. Supplier
and Customer acknowledge and agree that as the product or use of the product evolves, they will from time to time engage in discussions
to revisit these definitions as appropriate. For clarity, 1) Customer Data is subject to the confidentiality provisions of the
Agreement and this Exhibit, and 2) Supplier shall not use Metadata for the purpose of re-identifying PHI or PII. For purposes
of this Exhibit, “Systems” means without limitation all computers, computer systems, networks, databases, servers,
communication systems, Intranet(s) and means of access to such systems, including but not limited to, passwords, tokens, keys,
logon scripts or other authentication information.

 

		2.	Obligations of Supplier. Supplier shall limit its
use and disclosure of Customer Data only as necessary and appropriate to fulfill its specific obligations to Customer and, without
limiting the foregoing, agrees to the following:

 

		a.	Customer Data. Customer Data will not be stored
outside of the U.S.

 

		b.	Policies and Standards. Supplier shall maintain
and strictly adhere to its Security Policies and Standards as required and necessary to protect the confidentiality, integrity
and availability of Customer Data. Such Supplier Security Policies and Standards will be provided by Supplier to Customer immediately
upon written request.

 

		c.	Breach. Supplier shall report to the Customer
Chief Information Security officer, and any additional Customer personnel or agents designated by Customer, any Breach of security
by Supplier, its agents or subcontractors within forty-eight (48) hours of discovery. The term “Breach” as used in
this Exhibit shall mean the unauthorized acquisition, access, use, or disclosure of protected health information or personally
identifiable information which compromises the security or privacy of such information, except where an unauthorized person to
whom such information is disclosed would not reasonably have been able to retain such information, except that no report shall
be required for unsuccessful attempts at unauthorized access, use, disclosure, modification, or destruction of protected health
information or personally identifiable information or unsuccessful attempts at interference with systems operations in an information
system, such as “pings” on a firewall. The reports required by this Section shall include, to the extent possible:

 

		(i)	A description of what happened, including the date
of the Breach and the date of the discovery of the Breach, if known;

 

    41

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

		(ii)	A description of the types of Customer Data, including Unsecured PHI, that
were involved in the Breach where “Unsecured PHI” means PHI that does not have adequate controls in place to prevent
disclosure to unauthorized individuals;

 

		(iii)	Any steps individuals should take to protect themselves from potential harm
resulting from the Breach; and

 

		(iv)	A description of what Supplier is doing to investigate the Breach, to mitigate
harm to individuals, and to protect against any further Breaches.

 

		(v)	Supplier shall also promptly report in electronic form to the Customer
Data Security Office any Security Incident relating to ePHI of which Supplier becomes aware. For the purposes of this Exhibit,
“Security Incident” means any adverse event or occurrence where some aspect of data security could be threatened, e.g.,
loss of data confidentiality, disruption of data systems integrity, or disruption or denial of data or system availability.

 

		d.	Maintenance. Maintain all software accessing Customer Data so as
to remain within one generation of the then current maintenance releases and remain on a supported release unless otherwise agreed
to by Customer, with the exception of the Augmedix Google Glass Device. This shall include, but not be limited to, the obligation
to promptly implement any security-related Enhancement1 or Fix2 made available by the supplier of such software.

 

		e.	Updates. Maintain all server and client systems on supported versions
of operating system software and provide, at a minimum, quarterly updates to maintain all applicable operating system updates to
current recommended levels. Operating system critical security updates will be applied to client systems as soon as possible and
in no case longer than thirty (30) days after release. Operating system critical security updates will be applied by Supplier to
server systems as soon as possible, and in no case longer than sixty (60) days after release.

 

		f.	Data Capture. Capture relevant system and application
activity data for audit purposes, e.g. periodic account review, privileged user activity review, etc., as required by HIPAA and
HITECH if Customer ePHI is involved and make such data available as requested by Customer in support of potential privacy Breach
investigations, accounting of disclosures, or other activities as required by regulation.

 

		g.	Minimum Necessary Data. Supplier and its agents or subcontractors
shall request from Customer and so use and disclose only the Minimum Necessary Data necessary to accomplish the purpose of the
applicable request, use, or disclosure.

 

 

 

1 “Enhancements” means
improvements which add features to, or otherwise improve functionality or performance of, a software product.

 

2
“Fix” means
an upgrade, update, workaround or other modifications to a software product, other than an Enhancement, which is made by or on
behalf of the licensor in order to correct defects or errors in the software product.

 

    42

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

		h.	Identity Theft Red Flags. To the extent Supplier
performs a service or activity on behalf of Customer in connection with a covered account (as defined by 16 C.F.R. Part 681.1(b)(3)),
Supplier will perform the service or activity in accordance with reasonable policies and procedures designed to detect, prevent,
and mitigate the risk of identity theft (as defined in 16 C.F.R. 603.2(a)).

 

		i.	Payment Card Industry Data Security Standards (PCI
DSS) Compliance. To the extent that Supplier has access to Customer’s credit cardholder data or sensitive authentication
data as defined by the Payment Card Industry Data Security Standard (PCI DSS), Supplier is currently certified to be in compliance
with the Payment Card Industry Data Security Standard, including PCI DSS Version 1.1 Requirement 12.10 for processors and service
providers, and Appendix A for Hosting Providers, by a qualified security assessor (QSA) and approved scanning vendor (ASV), as
applicable. Any changes in Supplier’s certification require prompt written notification to Customer. Supplier agrees to
continue to meet all PCI DSS requirements and to validate that compliance annually according to the credit card industry rules,
which include but are not limited to the PCI Security Standards Council’s PCI Data Security Standard. Supplier will also
provide written evidence of this compliance to Customer annually. If applicable, Supplier agrees that their electronic check processing
functionality will comply with the appropriate NACHA- The Electronic Payment Association provisions. Applications purchased from
a third party that will be used by a Merchant to store, process or transmit sensitive cardholder data must be Payment Application
Best Practices (PABP) certified (This certification ensures that the application is compatible with PCI requirements). The term
“Merchant” as used in this Section means authorized acceptors of credit cards for the payment of goods and services.

 

		j.	Permissions. When provided with an authorized
request for new, changed or deleted access permissions, Supplier will comply with such request, if appropriate, within fortyeight
(48) hours during regular business hours.

 

		3.	Upon termination of this agreement Supplier must return
and/or expunge Customer Data per Customer’s direction.

 

		4.	Subcontractors. Supplier’s execution of any subcontracts,
including subcontracts approved by Customer, will not relieve, waive or diminish any obligation Supplier may have to Customer under
this Exhibit.

 

		5.	Access to Information Systems. Access, if any, to Customer’s
Systems (“Customer’s Information Systems”) is granted solely to perform the Services under this Agreement, and
is limited to those specific Customer Information Systems, time periods and personnel as are separately agreed to by Customer and
Supplier from time to time. Customer may require Supplier’s employees, Subcontractors or agents to sign individual agreements
prior to access to Customer’s Information Systems. Use of Customer Information Systems during other time periods or by individuals
not authorized by Customer is expressly prohibited. Access is subject to Customer business control and information protection policies,
standards and guidelines as may be modified from time to time. Use of any other Customer Information Systems is expressly prohibited.
This prohibition applies even when a Customer Information System that Supplier is authorized to access serves as a gateway to other
Information Systems outside Supplier’s scope of authorization. Supplier agrees to access Information Systems only from specific
locations approved for access by Customer. For access outside of Customer premises, Customer will designate the specific network
connections to be used to access Information Systems.

 

    43

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

		6.	Storage and Security. Supplier shall operate and maintain the servers
in good working order with access restricted to qualified employees of Supplier and persons specifically designated by Customer.
Supplier shall undertake and perform the measures set forth in this Exhibit to ensure the confidentiality, integrity, and availability
of all Customer Data and other proprietary information transmitted through or stored on the servers. If applicable, Supplier shall
also maintain independent archival and backup copies of the Customer Data in accordance with the same security standards provided
to original, on-line copies. Supplier shall provide a detailed description of Supplier’s service environment, including facility
locations and applicable security requirements, restrictions and considerations regarding the regulatory environment of the location
where Customer Data is stored. Supplier must specify if the storage environment for Customer Data is a multi-tenant environment
and identify any storage locations that are co-location data center environments. The detailed description of Supplier’s
service environment shall be incorporated in this Exhibit as Appendix B.

 

		7.	Business Continuity Plan.

 

		(i)	Plan. Supplier will develop and keep current a formal business continuity
plan which details strategies for response to and recovery from a broad spectrum of potential disasters that could disrupt operations
and timely delivery of materials and services required pursuant to this Agreement. (“Disaster” means a serious disruption
of the functioning of an organization, causing widespread human, business interruption, material or environmental losses that exceed
the ability of the organization to cope using only its own resources).

 

		(ii)	Material Hazard Analysis. This plan will include a baseline material
Hazard analysis, a written recovery plan and documented emergency and incident response procedures, a mitigation plan to prevent
losses or minimize effects of unavoidable ones, and a crisis communication plan. “Hazard” means an existing or unusual
occurrence in the natural or human-made environment that may adversely affect human life, property, or activity to the extent of
a disaster. Industrial/Technological Hazards include destruction of data storage, retrieval, and processing facilities, hazardous
materials release, loss of data systems integrity from breaches of security, power failures, structural failures, telecommunications
failures, and transportation failures. Natural Hazards include earthquake, flood, hurricane, landslide, tornado, tsunami, volcano,
wild or forest fire, and windstorm and winter storm.

 

		(iii)	Annual Test. Supplier will conduct an annual test and evaluation
of its business continuity plan, which upon request by Customer may be witnessed by Customer, to ensure expected systemic and process
responsiveness from Supplier.

 

		(iv)	Availability. Upon request, Supplier will make its business continuity
plan and the annual evaluation available to Customer or its designated representative for review.

 

		8.	Training. Supplier shall ensure Supplier’s workforce, including
subcontractors, receive all security awareness training on policies and procedures applicable to their job duties prior to receiving
access to Customer Information Systems and Customer Data and periodically thereafter.

 

    44

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

		9.	Termination for Security Violations. Customer and
Supplier agree that the prevention of security violations is an essential purpose of this Exhibit. The failure of Supplier to
perform any obligation existing pursuant to this Exhibit shall be handled according to the termination and dispute resolution
provisions of the Agreement. In the event of an actual or threatened breach of Supplier’s obligations under this Exhibit,
Customer reserves the right to suspend use of Services upon notice to Supplier (which notice shall contain a description of customer’s
reasonable concerns) until such time as such concerns have been addressed, with Supplier reserving the right to terminate the
Agreement if such suspension lasts longer than 30 days .

 

		10.	Audit. Notwithstanding any other audit provisions
in the Agreement, and with regard to security, Customer reserves the right to audit, inspect, and make copies or extracts of Supplier’s
records and processes associated with Supplier’s performance under this Exhibit at any time with seven (7) days prior notice
to Supplier through an independent auditor reasonably acceptable to Supplier and subject to customary confidentiality obligations.
Any audit or inspection will occur during Supplier’s normal business hours. Customer’s right to audit, inspect, and
make copies or extracts of Supplier’s records and processes shall continue for a period of two (2) years following the termination
or expiration of the Agreement. Supplier shall cooperate in all audits and inspections conducted by Customer’s auditor and
shall remedy any discrepancies identified pursuant to such audits and inspections within a mutually agreeable timeframe. Any audits
or inspections conducted by Customer’s auditor pursuant to this Section shall in no way be deemed to relieve Supplier of
any of its obligations, responsibilities or liabilities under this Exhibit or the Agreement or under any applicable laws. Any
election by Customer to conduct, or any failure by Customer to conduct, any such audit or inspection shall in no event be deemed
to constitute Customer’s approval of any activity undertaken by Supplier or of any method, system or procedure used by Supplier
in performance of this Exhibit or the Agreement.

 

    45

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

SCHEDULE 1

 

SUPPLIER’S SECURITY ARCHITECTURE, POLICIES
AND STANDARDS

 

	Administrative Safeguards
	 
	Specifications	 	Minimum Requirements
	 	 	 
	Security Management	 	 
	 	 	 
	 	Risk Analysis	 	Supplier will conduct an accurate and thorough assessment of the potential risks and vulnerabilities to the confidentiality, integrity and availability of PII and/ or PHI.
	 	 	 	Supplier will perform quarterly vulnerability scans on information systems storing, transmitting or transacting Customer’s PII and/or PHI.
	 	 	 	 
	 	Risk Management	 	Supplier will develop and implement a risk management plan.
	 	 	 	Supplier will apply all applicable security patches, service packs and hot fixes on information systems that contain or process Customer’s PII and/or PHI within thirty (30) days of release.
	 	 	 	Supplier will evaluate, implement and maintain security measures based on an analysis of the risks.
	 	 	 	Supplier, using commercially reasonable and appropriate measures, will protect Customer’s PII and/or PHI against unauthorized (malicious or accidental) disclosure, modification, or destruction of information, unintentional errors and omissions, IT disruptions due to natural or man-made disasters, failure to exercise due care and diligence in the implementation and operation of Suppliers IT system.
	 	 	 	Supplier will ensure that database transaction journaling is enabled for databases that contain Customer’s PII and/or PHI
	 	 	 	 
	 	Sanction Policy	 	Supplier will apply appropriate sanctions against workforce members who fail to comply with the security policies and procedures of the Customer and the Supplier.
	 	 	 	 
	 	Information System Activity Review	 	Supplier will regularly review records of information system activity, such as audit logs, access reports, and security incident tracking reports.
	 	 	 	Supplier will employ Security Event and Incident Monitoring (SEIM) technology such as intrusion detection and prevention systems on IT systems that transmit, transact, or store Customer’s PII and/or PHI and will review/analyze activity records for indications of inappropriate or unusual activities daily.
	 	 	 	 
	Workforce Security	 	 
	 	 	 
	 	Workforce Screening	 	Supplier will perform a thorough background check that will include, at a minimum, criminal check, credit report, employment verification, drug testing, workers compensation report, name/address verification for all employees requiring access to information systems that transmit, transact or store Customer’s PII and/or PHI. Background checks will include married name and maiden name where appropriate.
	 	 	 	 
	 	Termination Procedure	 	Supplier will terminate access to information systems that transmit, transact or store Customer’s PII and/or PHI immediately upon termination of individual employment.
	 	 	 	 
	 	Authorization and Supervision	 	Supplier will: (i) ensure that workforce members have appropriate access to PII and/or PHI following the principles of Minimum Necessary and Least Privilege and (ii) prevent workforce members who do not have access to PII and/or PHI from obtaining access to PII and/or PHI.

 

    46

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

	Information Access Management	 	 
	 	 	 
	 	Access Authorization	 	Supplier must implement policies and procedures for granting access to Customer’s PII and/or PHI.
	 	 	 	Supplier will provide secure role-based account management granting privileges utilizing the principle of least privilege.
	 	 	 	Supplier will monitor all user accounts with administrative level access to Operating Systems and databases transmitting, transacting or storing Customer’s PII and/or PHI.
	 	 	 	Supplier will restrict the ability to install software to only authorized technical support personnel.
	 	 	 	 
	 	Access Establishment and Modification	 	Supplier will implement policies and procedures to establish, document, review, and modify a user’s right to access systems that transmit, transact or store Customer’s PII and/or PHI.
	 	 	 	 
	Security Awareness and Training	 	 
	 	 	 
	 	Security Reminders	 	Supplier will provide periodic security reminders and updates to all personnel with access to Customer’s PII and/or PHI.
	 	 	 	Supplier will maintain effective controls and procedures guarding against, detecting, and reporting malicious software.
	 	 	 	 
	 	Log-in monitoring	 	Supplier will maintain controls and procedures for monitoring log-in attempts and reporting discrepancies. Additionally, Supplier will ensure information systems that transmit, transact or store Customer’s PII and/or PHI produce activity logs that contain sufficient information to establish what events occurred, the sources of the events, and the outcome of the events (e.g., user authentication, access to data, modification of data). Supplier will retain the activity logs for a minimum of one (1) year.
	 	 	 	 
	 	Password Management	 	Supplier will maintain procedures for creating, changing, and safeguarding passwords. Specifically, Supplier will employ authentication for system access that is NIST Special Publication 800-63 compliant for an organization level of 2 or higher.
	 	 	 	 
	Security Incident Procedures	 	 
	 	 	 	Supplier will maintain policies and procedures to address security incidents. Supplier will review and update as appropriate security procedures annually.
	 	Response and Reporting	 	Supplier shall maintain controls and procedures to identify and respond to suspected or known security incidents; mitigate, to the extent practicable, harmful effects of security incidents that are known to the Supplier and document security incidents and their outcomes.

    47

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

	Contingency Plan	 	 
	 	 	 
	 	Data Backup Plan	 	Supplier will establish and maintain defined and documented procedures to create and maintain retrievable exact copies of Customer’s PII and/or PHI.
	 	 	 	 
	 	Disaster Recovery Plan	 	Supplier will establish and maintain defined and documented procedures to restore any loss of Customer’s data.
	 	 	 	 
	 	Emergency Mode Operation Plan	 	Supplier will establish and maintain defined and documented procedures to enable continuation of critical business processes for protection of the security of Customer’s PII and/or PHI while operating in emergency mode.
	 	 	 	 
	 	Testing and Revision Procedure	 	Supplier will ensure the contingency plans are reviewed and tested annually.
	 	 	 	 
	Physical Safeguards
	 
	 	Facility Access Controls	 	Supplier shall maintain controls and procedures to limit physical access to information systems that transmit, transact or store Customer’s PII and/or PHI and the facility or facilities in which they are housed while ensuring that properly authorized access is allowed.
	 	 	 	Supplier shall maintain controls and procedures to validate personnel access to facilities based on their role, including visitor controls.
	 	 	 	 
	 	Workstation Use	 	Supplier shall maintain controls and procedures specifying the secure configuration of workstations having access to information systems that transmit, transact or store Customer’s PII and/or PHI.
	 	 	 	 
	 	Workstation Security	 	Supplier will implement physical safeguards for all workstations that access PII and/or PHI to restrict access to authorized users.
	 	 	 	 
	 	Device and Media Controls	 	Supplier shall implement controls and procedures that govern the receipt and removal of hardware and electronic media that contain Customer’s PII and/or PHI into and out of a facility, and the movement of these items within the facility.
	 	 	 	 
	 	Disposal and Media Re- use	 	Supplier shall implement policies and procedures to address the final disposition of Customer’s PII and/or PHI and/or the hardware or electronic media on which it is stored. Supplier will sanitize all media containing Customer’s PII and/or PHI in compliance with NIST Special Publication 800-88 Guidelines prior to disposal or re-use.
	 	 	 	 
	Technical Safeguards
	 
	 	Access Control	 	Supplier shall implement controls and procedures for information systems that transmit, transact, or store Customer’s PII and/or PHI to allow access only to those persons or software programs that have been granted access rights.
	 	 	 	 
	 	Unique User Identification	 	Supplier will assign a unique user ID and password for identifying and tracking user identity and will not allow the use of shared accounts.
	 	 	 	 
	 	Encryption	 	Supplier will encrypt all Customer’s PII and/or PHI that is transmitted, transacted or stored with FIPS 140-2 compliant encryption, such as the Advanced Encryption Standard (AES). Supplier acknowledges and understands that Customer’s standard is AES 256 encryption for transmitting PII and/or PHI. While currently some of Business Associate’s transmissions of Covered Entity’s PHI use AES 128 encryption, Business Associate will implement AES 256 encryption for Covered Entity’s PHI no later than 12/31/2015.
	 	 	 	 
	 	Automatic Log-off	 	Supplier will ensure that information systems that transmit, transact, or store Customer’s PII and/or PHI automatically terminate or lock remote sessions in less than fifteen (15) minutes of inactivity requiring user re-authentication.
	 	 	 	 
	 	Integrity	 	Supplier shall implement controls procedures to protect Customer’s PII and/or PHI from improper alteration or destruction.
	 	 	 	 
	 	Person or Entity Authentication	 	Supplier will maintain controls and procedures to verify that a person or entity seeking access to information systems that transmit, transact, or store Customer’s PII and/or PHI the one claimed.
	 	 	 	Supplier will employ a 2-factor authentication for remote user access to information systems that transmit, transact, or store Customer’s PII and/or PHI.

    48

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

	Transmission Security
	 
	 	Encryption	 	Supplier shall ensure that information systems that transmit Customer’s PII and/or PHI employ encryption compliant with FIPS 140-2 encryption standards to prevent unauthorized disclosure of information during transmission.
	 	 	 	 
	 	Boundary Protection	 	The supplier’s information system monitors and controls communications at the external boundary of the information system and at key internal boundaries within the system. (e.g., firewall between internet facing servers and the internal network)

 

    49

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

FIRST AMENDMENT TO THE MASTER SERVICES
AGREEMENT

 

This Amendment to the Master Services Agreement
(“Amendment”), effective as of July 22, 2016 (“First Amendment Effective Date”) amends that certain Master
Services Agreement, effective April 15, 2015 (“Agreement”) by and between Sutter Health, a California nonprofit public
benefit corporation (“Sutter”), and Augmedix, Inc., a Delaware corporation (“Augmedix”). Sutter and Augmedix
may be referred to herein individually as a “Party” and collectively as the “Parties.”

 

R E C I T A L S

 

WHEREAS, the Parties have agreed to revise
the rollout of the additional Authorized Users, set forth in Schedule A-1A of Exhibit A; and

 

WHEREAS, the Parties have agreed to revise
the list of authorized foreign Remote Scribing locations, set forth in Exhibit A-7.

 

NOW, THEREFORE, in consideration of the
premises set forth above and the mutual promises and agreements set forth herein, the Parties, each intending to be legally bound
hereby, agree as follows:

 

		1.	Schedule A-1A of Exhibit A (Meaningful Growth Phase – Additional Authorized Users), is hereby
deleted in its entirety and replaced with the Schedule A-1A, attached hereto and incorporated herein.

 

		2.	Exhibit A-7 (Foreign Remote Scribing Locations), is hereby deleted in its entirety and replaced
with the Exhibit A-7, attached hereto and incorporated herein.

 

		3.	The following language is hereby added as the new Section 11 “Physical Security Audit”
of Exhibit D (Security of Data and Systems).

 

Sutter
reserves the right to audit and inspect the foreign remote scribing locations identified on Exhibit A-7, as well as new scribing
locations Augmedix subsequently desires to engage (in advance of commencing services at any new scribing location), at Sutter’s
sole expense, upon thirty (30) days advance written notice, for compliance with the physical security standards set forth in Schedule
1 attached hereto, and upon good faith consultation with Augmedix, any other physical security standards that may be customary,
reasonably necessary, or required by law at the time of the audit. Sutter shall advise Augmedix, in writing, of any discrepancies
identified by the audit. Augmedix shall remediate discrepancies identified in the audit, within thirty (30) days after notification
from Sutter, unless otherwise mutually agreed in writing between the parties. For avoidance of doubt, Section IV.C of the Agreement
(Confidentiality) shall apply to this Section 11.

 

		4.	All other Terms and Conditions of the Agreement remain unchanged. All capitalized terms used in
this Amendment and not otherwise defined shall have the meanings given to them in the Agreement.

 

    1

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

		5.	By
their respective signatures, below, each of the following represents that he or she is duly authorized to execute this Amendment
and to bind the Party on whose behalf such execution is made.

 

	SUTTER HEALTH	 	AUGMEDIX, INC.
	 	 	 	 	 
	By:	/s/ Don Wreden	 	By:	/s/ Ian Shakil
	Name: 	Don Wreden, MD	 	Name:	Ian Shakil
	Title:	SR. VP, Patient Experience	 	Title:	CEO & Co-Founder
	Date:	8/1/16	 	Date:	7/25/2016

 

    2

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

SCHEDULE A-1A

 

MEANINFUL GROWTH PHASE – ADDITIONAL
AUTHORIZED USERS

 

	Deadline	 	Additional Authorized
    Users
	[*]	 	[*]

 

    3

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

EXHIBIT A-7

 

FOREIGN REMOTE SCRIBING LOCATIONS

 

[*]

 

Location #1:

[*]

 

Location #2:

[*]

 

[*]

 

Location #1:

[*]

 

    4

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

SCHEDULE 1

 

PHYSICAL SECURITY AUDIT STANDARDS

 

	 	Control
	 	 
	1	
        The security personnel are deployed round the clock
at the entry and exit points of the premises, to monitor the movement of people in and out of the premises.

	 	 
	2	Closed Circuit Television (CCTV) Cameras are installed at the entry and exit points of the premises.
	 	 
	3	CCTV cameras are installed within the premises to monitor the exterior areas of the property.
	 	 
	4	The premises are monitored round the clock through CCTV cameras by the security personnel to provide real time detection of unauthorized entry.
	 	 
	5	Personnel (other than personnel from the IT Department) are deployed to monitor the video surveillance.
	 	 
	6	CCTV cameras recordings are retained for a specified period and are available for review in the event of a data breach.
	 	 
	7	Employees are required to display their photo ID cards while within the premises to prevent unauthorized access to secured areas.
	 	 
	8	The security personnel are responsible for verifying that employees use their photo ID cards.
	 	 
	9	
        Access to the Scribe facility/ secured area is restricted
to authorized personnel by means of an EACS/ Biometric Access Control device.

	 	 
	10	
        The security personnel are responsible for ensuring
that details of visitors/ vendors (including delivery drivers and courier delivery personnel), such as name, contact person, signatures,
entry and exit time are recorded in the ‘Visitor Register’ or ‘Vendor Register’ maintained. These registers
are retained for a specified period and are available for review in the event of a data breach.

	 	 
	11	Visitors are allowed access to the premises, only under the supervision of an authorized employee/ security personnel and are escorted during their visit.
	 	 
	12	The security personnel are deployed to monitor the movement within the premises.
	 	 
	13	Access granted to delivery drivers and courier delivery personnel is restricted to a loading dock or authorized drop off area of the premises only.
	 	 
	14	
        The premise is surrounded by thick
        bushes/ hedges or fencing at the property perimeter in order to prevent entry to the premises except through designated entry
        points.

	 	 

    5

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

SECOND AMENDMENT TO THE MASTER SERVICES
AGREEMENT

 

This Amendment to the Master Services Agreement
(“Amendment”), effective as of August 22, 2017 (“Second Amendment Effective Date”) amends that certain Master
Services Agreement, effective April 15, 2015, as amended (“Agreement”) by and between Sutter Health, a California nonprofit
public benefit corporation (“Sutter”), and Augmedix, Inc., a Delaware corporation (“Augmedix”). Sutter and
Augmedix may be referred to herein individually as a  “Party” and collectively as the “Parties.”

 

RECITALS

 

WHEREAS, the Parties have agreed to update
and expand the list of authorized Foreign Remote Scribing Locations, set forth in Exhibit A-7.

 

NOW, THEREFORE, in consideration of the
premises set forth above and the mutual promises and agreements set forth herein, the Parties, each intending to be legally bound
hereby, agree as follows:

 

		l.	Exhibit A-7 (Foreign Remote Scribing Locations), is hereby deleted in its entirety and replaced
with the amended Exhibit A-7, attached hereto and incorporated herein.

 

		2.	All other Terms and Conditions of the Agreement remain unchanged. All capitalized terms used in
this Amendment and not otherwise defined shall have the meanings given to them in the Agreement.

 

		3.	By their respective signatures, below, each of the following represents that he or she is duly
authorized to execute this Amendment and to bind the Party on whose behalf such execution is made.

 

	SUTTER HEALTH	 	AUGMEDIX, INC.
	 	 	 	 	 
	By:	/s/ Albert S. Chan	 	By:	/s/ Ian Shakil
	Name: 	Albert S. Chan, MD	 	Name: 	Ian Shakil
	Title:	VP, Chief of Digital Patient Exp	 	Title:	CEO 
	Date:	8/23/17	 	Date:	8/22/2017

 

    1

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

EXHIBIT A-7

 

FOREIGN REMOTE SCRIBING LOCATIONS

 

[*]

 

Location #1:

[*]

 

Location #2:

[*]

 

[*]

 

Location #1:

[*]

 

[*]

 

Location # l:

[*]

 

Location #2:

[*]

 

[*]

 

Location # 1:

[*]

 

[*]

 

Location #1:

[*]

 

    2

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

THIRD AMENDMENT TO THE MASTER SERVICES
AGREEMENT

 

This Third Amendment to the Master Services
Agreement (“Amendment”), effective as of April 5, 2018 (“Third Amendment Effective Date”) amends that certain
Master Services Agreement, effective April 15, 2015, as amended (“Agreement”) by and between Sutter Health, a California
nonprofit public benefit corporation (“Sutter”), and Augmedix, Inc., a Delaware corporation (“Augmedix”).
Sutter and Augmedix may be referred to herein individually as a “Party” and collectively as the “Parties.”

 

R E C I T A L S

 

WHEREAS, the Parties have agreed to update
and expand the list of authorized Foreign Remote Scribing Locations, set forth in Exhibit A-7.

 

NOW,
THEREFORE, in consideration of the premises set forth above and the mutual promises and agreements set forth herein, the Parties,
each intending to be legally bound hereby, agree as follows:

 

		1.	Exhibit A-7 (Foreign Remote Scribing Locations), is hereby deleted in its entirety and replaced
with the amended Exhibit A-7, attached hereto and incorporated herein.

 

		2.	All other Terms and Conditions of the Agreement remain unchanged. All capitalized terms used in
this Amendment and not otherwise defined shall have the meanings given to them in the Agreement.

 

		3.	By their respective signatures, below, each of the following represents that he or she is duly
authorized to execute this Amendment and to bind the Party on whose behalf such execution is made.

 

	SUTTER HEALTH	 	AUGMEDIX, INC.
	 	 	 	 	 
	By:	/s/ Albert Chan	 	By:	/s/ Ian Shakil
	Name: 	Albert Chan	 	Name: 	Ian Shakil
	Title:	Chief of Digital Pt Experience	 	Title:	CEO & Co-Founder
	Date:	4/7/2018	 	Date:	4/4/2018

 

    1

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

EXHIBIT A-7

 

FOREIGN REMOTE SCRIBING LOCATIONS

 

[*]

 

Location #1:

[*]

 

Location #2:

[*]

 

[*]

 

Location #1:

[*]

 

[*]

 

Location #1:

[*]

 

Location #2:

[*]

 

[*]

 

Location #1:

[*]

 

[*]

 

Location #1:

[*]

 

[*]

 

Location #1:

[*]

[*]

 

    2

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

[*]

 

Location #1:

[*]

[*]

 

[*]

 

Location #1:

[*]

[*]

 

    3

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

FOURTH AMENDMENT TO THE MASTER SERVICES
AGREEMENT

 

This Fourth Amendment to the Master Services
Agreement (“Fourth Amendment”), effective as of September 14, 2018 (“Fourth Amendment Effective Date”), amends
that certain Master Services Agreement, effective April 5, 2015, as amended (“Agreement”), by and between Sutter Health,
a California nonprofit public benefit corporation (“Sutter”), and Augmedix, Inc., a Delaware corporation (“Augmedix”).
Capitalized terms used but not otherwise defined herein shall have the same meaning as in the Agreement. Sutter and Augmedix may
be referred to herein individually as a “Party” and collectively as the “Parties.”

 

RECITALS

 

WHEREAS, the Parties have agreed to amend the Agreement to change
the applicable Fees for the Services and related terms and to reflect certain additional understandings between the Parties.

 

NOW, THEREFORE, in consideration of the
premises set forth above and the mutual promises and agreements set forth herein, the Parties, each intending to be legally bound
hereby, agree as follows:

 

1. Section
1.D (Payment/Expenses). Section 1.D (Payment/Expenses) of the Agreement is hereby deleted and replaced with the following provision:

 

D. Payment/Expenses.
During the Term of this Agreement, Augmedix agrees to provide the Services described or listed on the attached Exhibit
A, and Sutter agrees to purchase such Services at the fees indicated in Exhibit A and in accordance with the terms
and conditions set forth herein. As of the Fourth Amendment Effective Date, Augmedix will directly invoice the respective foundation
or subsidiary of Sutter for Implementation Fees for each New Authorized User upon Service Order execution, and for monthly service
fees [*] prior to the applicable month of service. All invoices will be subject to [*] payment terms after receipt of accurate
invoices from Augmedix. Sutter may, at its discretion, make payment by check or by an electronic payable (E-payables) payment
method. Other than as stated in this Agreement, any Exhibit, or as subsequently agreed to in writing between the Parties, Augmedix
is solely responsible for payment of any other expenses incurred in connection with carrying out Augmedix’s duties under
this Agreement. Such expenses include costs of all travel, lodging, food, licenses, bonds, taxes and costs of doing business.
In no event will Sutter be responsible to pay any expenses of Augmedix not contained in this Agreement or as otherwise agreed
to in writing between the Parties, whether or not incurred in connection with Augmedix’s performance under this Agreement.

 

To the extent that billing category
changes result in an overpayment or underpayment of Fees for the applicable invoice period, Augmedix will reconcile any credits
owed to, or additional amounts owed by, Sutter against any prepaid amounts on a quarterly basis. The parties shall agree to any
amounts owed to, or by, Sutter, in writing, prior to making such billing adjustment. In the event that Service for a particular
Authorized User has not been prepaid, Augmedix shall apply any credits owed to, or additional amounts owned by, Sutter against
the earliest subsequent invoice. Additionally, in the event that Sutter prepaid for any Service and the Service is cancelled in
accordance with Section 1.1.3 of Exhibit A of the Agreement, any remaining prepayment balance will be credited towards payment
for another Authorized User within [*] of the effective date of termination.

 

    1

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

2. Exhibit
B (Definitions). The following terms shall be added to the definitions set forth in Exhibit B:

 

“Dedicated Seat” means an Augmedix
Solution service package that is dedicated to one Authorized User.

 

“Full-Time Scribe (FT Scribe)” equates
to 160 scribe hours per month.

 

“Shared Seat” means an Augmedix
Solution service package that is shared between two Authorized Users, subject to certain terms and conditions.

 

3. Section
3 (Fees) of Exhibit A (Description of Services). Section 3 of Exhibit A of the Agreement is hereby deleted in its entirety
and replaced with the following provision:

 

3. FEES

 

3.1.
Implementation and Swap Fees. In consideration
for Services rendered in connection with the implementation of New Authorized Users, Customer shall pay a non-refundable implementation
fee in the amount of $[*] (non-refundable) per New Authorized User, as defined in Section 3.2.3, below (“Implementation
Fee”). Customer may swap one New Authorized User for another New Authorized User without incurring an Implementation
Fee for the other New Authorized User, provided that both New Authorized Users practice within the same department and specialty.
Notwithstanding the foregoing, if Customer swaps one New Authorized User for another less than [*] prior to the on-site implementation
start date, or anytime thereafter, Customer shall (i) pay
a swap fee in the amount of $[*] (each a “Swap Fee”), and (ii) if the existing New Authorized User is in production,
continue to pay applicable monthly service fees during the transition to the other New Authorized User.

 

3.2.
Service Fees.

 

3.2.1. Initial
Authorized Users. Notwithstanding anything to the contrary herein, during the Term of the Agreement, Augmedix will provide
the Services to the initial Authorized Users identified on Schedule A-1B for the Fees set forth below:

 

3.2.1.1. Steady-State
Inside United States (“IUS”) Services. The IUS Services shall be provided to Sutter for a fee of $[*] / FT Scribe
(equivalent to 160 scribe hours) / month.

 

    2

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

3.2.1.2. Steady-State
Outside United States (“OUS”) Services. The OUS Services shall be provided to Sutter for a fee of $[*] / FT Scribe
(equivalent to 160 scribe hours) / month.

 

3.2.2. Other Current Authorized Users.
Subject to the applicable discounts, Augmedix will provide the Services to other current Authorized Users for the monthly fees
set forth below based upon the billing category each Authorized User falls into, as determined by the Authorized User’s Daily Schedule
and average monthly usage:

 

Monthly OUS Service Fees for Current
Authorized Users*

 

	Billing Category - Scribe Service Hours/Mo.	 	Price
                                         List:
 November
                                         1, 

                                         2018 –

                                         February 28, 

                                         2019
 Fees include

             [*]
 discount
                                         

                                         unless
 otherwise 

               noted
	 	 	Price
                                         List:

                                         March 1,

                                         2019 – 

                                         December 31, 

                                         2019
 Fees include 

             [*] discount

             unless
 otherwise

                noted
	 	 	Price
                                         List: 

                                         2020
 Fees include

             [*] discount
	 	 	Price
                                         List: 

                                         2021
 Fees include

             [*] discount
	 
	Up to [*] hours	 	 	$[*]
 (includes
                                         [*] discount)
	 	 	$	$[*]
 (Includes
                                         [*] discount)
	 	 	$	[*]	 	 	$	[*]	 
	Up to [*] hours	 	$	[*]	 	 	$	[*]	 	 	$	[*]	 	 	$	[*]	 
	Up to [*] hours	 	$	[*]	 	 	$	[*]	 	 	$	[*]	 	 	$	[*]	 
	Up to [*] hours	 	$	[*]	 	 	$	[*]	 	 	$	[*]	 	 	$	[*]	 
	Up to [*] hours	 	$	[*]	 	 	$	[*]	 	 	$	[*]	 	 	$	[*]	 
	Up to [*] hours	 	$	[*]	 	 	$	[*]	 	 	$	[*]	 	 	$	[*]	 
	Hours over [*]	 		$[*] per hour	 	 		$[*] per
                                      hour	 	 		$[*] per
                                      hour	 	 		$[*]
                                      per hour	 

 

		*	Fees will be discounted
an additional [*] if Customer prepays the fees on an annual basis.

 

    3

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

3.2.3. New
Authorized Users. A “New Authorized User” is an Authorized User who is provided access to the Services on or after
the Fourth Amendment Effective Date. Subject to the applicable discounts, Augmedix will provide the Services to New Authorized
Users for the monthly fees (“Service Fees”) set forth below based upon the billing category each New Authorized User
falls into, as determined by (i) the New Authorized User’s Daily Schedule and average monthly usage, and (ii) whether the
New Authorized User has a Dedicated Seat or a Shared Seat:

 

Monthly OUS Service Fees for
New Authorized Users*

 

	Billing
    Category - Scribe Service Hours/Mo.	 	Price
                                         List:

                                         Forth

                                         Amendment

                                         Effective

                                         Date –

                                         December 31,

                                         2018 Fees

                                         include [*] 

                                         discount
	 	 	Price
    list:

    2019 Fees

    include [*] 

    discount	 	 	Price
    List:

    2020 Fees 

    include [*]

    discount	 	 	Price
    List: 

    2021 Fees 

    include [*]

    discount	 
	Dedicated
    Seat: Up to [*] hrs	 	$	[*]	 	 	$	[*]	 	 	$	[*]	 	 	$	[*]	 
	Dedicated
    Seat: Up to [*] hrs	 	$	[*]	 	 	$	[*]	 	 	$	[*]	 	 	$	[*]	 
	Dedicated
    Seat: Up to [*] hrs:	 	$	[*]	 	 	$	[*]	 	 	$	[*]	 	 	$	[*]	 
	Dedicated
    Seat: Up to [*] hrs	 	$	[*]	 	 	$	[*]	 	 	$	[*]	 	 	$	[*]	 
	Dedicated
    Seat: Up to [*] hrs	 	$	[*]	 	 	$	[*]	 	 	$	[*]	 	 	$	[*]	 
	Shared
    Seat: Up to [*] hrs	 	$	[*]	 	 	$	[*]	 	 	$	[*]	 	 	$	[*]	 
	Hours
    over [*]	 		$[*]
                                      per hour	 	 		$[*]
                                      per hour	 	 		$[*]
                                      per hour	 	 		$[*]
                                      per hour	 

 

		*	Fees will be discounted
an additional [*] if Customer prepays the fees on an annual basis.

 

Notwithstanding anything to the contrary herein, Shared
Seat pricing is subject to the following terms and conditions:

 

		●	Authorized Users must use the Augmedix Solution at the same designated Customer Facility.

		●	In the event Authorized Users are specialists, both Authorized Users must have the same practice specialty.

		●	Authorized Users must use the same standardized note style and templates and workflow.

		●	Scribing services will only be available to one Authorized User at any given time. It shall be the obligation of Sutter to
manage Authorized Users’ Daily Schedules to ensure that schedules do not overlap.

		●	The Authorized Users shall be limited to nine (9) consecutive Scribe Service hours in any given clinic day.

		●	Authorized Users will share the same Google Glass kit (or smartphone).

 

3.3. Augmedix
reserves the right to reclassify an Authorized User into a different Billing Category on a going-forward basis based upon the
Authorized User’s historical monthly usage, upon thirty (30) days’ written notice and detailed documentation of Authorized User’s usage. Sutter may request reclassification of an Authorized User into a different Billing Category based on anticipated monthly
usage by providing thirty (30) days’ written notice to Augmedix.

 

    4

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

3.4. Prepayment:
Sutter shall provide Augmedix an initial prepayment for each Authorized User scheduled to utilize the Services after April 1,
2015 (“Prepayment”). The Prepayment is equal to [*] of the full-time FTE IUS or OUS Services Fee
associated with that specific Authorized User. The Prepayment shall be credited back to Sutter only if Sutter decides to
timely terminate an Authorized User in accordance with the notice requirements of this Agreement, in which case the
Prepayment amount shall be reduced beginning in the final [*] of Service for that specific Authorized User by the amount of
the IUS or OUS Service Fees invoiced under this Agreement for that specific Authorized User, with any remaining amount of the
Prepayment being refunded to Sutter. By way of example, if an additional Authorized User was scheduled to begin utilizing
Service on April 1, 2015 at an OUS Service Fee schedule, the Prepayment for such an Authorized User would be $[*] and
Augmedix would invoice Sutter for the full applicable OUS Service Fee beginning and continuing from April 1, 2015; if Sutter
gave notice to terminate that Authorized User on January 1, 2016, then the Prepayment would be reduced to $[*] by March 31,
2016. For avoidance of doubt, this provision does not apply to New Authorized Users.

 

3.5. Vacations/Leave
of Absence. Sutter shall continue to pay an Authorized User’s monthly fees in the event of a vacation and/or leave of
absence of two (2) consecutive calendar weeks or less. In the event Sutter desires to suspend Services for an Authorized User
for more than two (2) consecutive calendar weeks, Augmedix will hold the Scribe assigned to such Authorized User during his/her
absence, provided that Sutter pays a monthly minimum fee of $[*] (“Suspension Fee”).

 

4. Service
Commitment.

 

a. Service
Credits. Subject to subsection (c) below, in the event an Authorized User experiences a Scribe coverage gap of two (2) consecutive
hours or more during any month of service, Augmedix will provide a service credit equal to [*] the hourly rate of such
Authorized User for the period during which the Scribe was unavailable per Authorized User per incident (each a “Service
Credit”). By way of example, if Augmedix fails to provide a Scribe to an Authorized User for [*] consecutive hours, Augmedix
will provide a Service Credit equal to the cost of [*] hours of Service during such month per Authorized User per incident. Augmedix
will provide a Service Credit for Scribe cover gaps of less than [*] only if Augmedix is unable to provide [*] of the affected
Authorized User’s patient notes for the period during which the Scribe was unavailable within [*] of the coverage gap.

 

b. Service
Credit Payment. If Augmedix confirms that it failed to meet the service commitments set forth in this section, then Augmedix
will issue the service credit to Sutter’s account and apply such amount to the next scheduled payment for Services. Augmedix will
apply all Service Credits only against future payment otherwise due from Sutter.

 

    5

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

c. Service
Commitment Exclusions. The Service Commitment in this section does not apply to any performance/service issues: (i) caused
by factors outside of Augmedix’s reasonable control, including any force majeure event, a patient declining use of the Augmedix
service, loss of Internet access due to internet service provider error outside of Augmedix’s control; (ii) that result from any
actions or inactions of Sutter or any third party, including failure to issue EHR credentials or failure to notify Augmedix of
a schedule change at least ten (10) business days prior to the applicable clinic day; or (iii) that result from Sutter’s equipment,
software or other technology and/or third party equipment, software or other technology (other than third party equipment within
Augmedix’s direct control).

 

5. Service
Order. Sutter may secure Authorized Users, and New Authorized Users, provided that the applicable foundation or affiliate
signs and submits to Augmedix for countersignature, a service order in the format of the template attached hereto as Attachment
A (each a “Service Order”), which is incorporated herein by reference. Such Sutter foundation or
subsidiary shall be responsible for the fees and charges billed by Augmedix according to the applicable Authorized
User’s billing category designated in such Service Order. The Service Order shall state the estimated number of service
hours used per month by each Authorized User. The billing rates per Authorized User shall be in accordance with the amounts
set forth in Section 3 of Exhibit A of the Agreement.

 

6. Meaningful Growth: Augmedix
will apply further discounts for New Authorized Users (as described below) provided that Sutter meets certain growth metrics, as
set forth in the table below for the applicable calendar year. New Authorized Users will be considered activated upon execution
of a Service Order and payment of the Implementation Fee:

 

Meaningful Growth Discounts

 

	Calendar
    Year	 	Net
    Number of New Authorized

    Users at End of Calendar Year	 	Discount
    for the Additional New Authorized Users
	 	 	 	 	 
	2018	 	[*]	 	[*]
	2019	 	[*]	 	[*]
	 	 	[*]	 	[*]
	 	 	[*]	 	[*]
	2020	 	[*]	 	[*]
	 	 	[*]	 	[*]
	 	 	[*]	 	[*]

 

7. General.
Except as expressly amended herein, all other terms of the Agreement are hereby confirmed and remain in full force and effect.
All capitalized terms used in this Amendment and not otherwise defined shall have the meanings given to them in the Agreement.
This Fourth Amendment may be executed in counterparts, all of which taken together shall constitute one single agreement between
the parties and any full and complete copy thereof shall constitute an original.

 

    6

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

8. By
their respective signatures, below, each of the following represents that he or she is duly authorized to execute this Amendment
and to bind the Party on whose behalf such execution is made.

 

	Sutter Health	 	Augmedix, Inc.
	 	 	 	 	 
	By:	/s/ Don Wreden	 	By:	/s/ Manny Krakaris
	Name: 	Don Wreden, MD	 	Name: 	Manny Krakaris
	Title:	SVP Patient Experience	 	Title:	CEO
	Date:	9/19/18	 	Date:	9/16/2018

 

    7

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

Attachment A

 

Service Order

 

This Service Order,
effective as of the date of the last signature below, is made pursuant to the Master Services Agreement, including amendments thereto,
by and between Sutter Health, Inc. (“Client”) and Augmedix, Inc. (“Augmedix”), dated April 15,
2015, for the benefit of Client’s service facility site below. Capitalized terms used but not otherwise defined herein shall have
the same meaning as in the Agreement.

 

Service Facility:___________________

 

	QTY	 	DESCRIPTION	 	PRICE	 	TOTAL	 
	 	 	 	 	 	 	 	 
	—	 	Augmedix Google Glass Kit	 	 	[*]	 	 	 
	—	 	Implementation and Training	 	$	[*]	 	 	 
	—	 	Monthly Service Fees for all Authorized Users
    (see detailed calculation below)	 	 	Per Agreement	 	 	 
	 	 		 	 	TOTAL	 	 	 

 

		●	Google Glass Kit includes secured Google Glass devices with installed Augmedix applications. All hardware and software owned,
supported, and serviced by Augmedix.

 

		●	Please return a signed copy of this Service Order with a Finance/Accounts Receivable contact to use for invoicing purposes.

 

		●	Send all correspondence related to this order form to:

David Cote

Enterprise Manager

[*]

[*]

 

	SUTTER HEALTH	 	AUGMEDIX, INC.
	 	 	 	 	 
	By:	/s/ Don Wreden	 	By:	            

	Print Name:	Don Wreden, MD	 	Print Name	             

	Title:	SVP Patient Experience	 	Title:	      
	Date:	9/19/18	 	Date:	 

 

    8

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

AUTHORIZED USERS

 

	NAME	 	FACILITY	 	PROJECTED TIER	 	HOURS	 	MONTHLY COST
	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 
	 	 	TOTAL	 	 	 	 	 	 

 

    9

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

FIFTH AMENDMENT TO THE MASTER SERVICES
AGREEMENT

 

This Fifth Amendment to the Master Services
Agreement (“Amendment”), effective as of September 9, 2019 (“Fifth Amendment Effective Date”) amends that
certain Master Services Agreement, effective April 15, 2015, as amended (“Agreement”) by and between Sutter Health,
a California nonprofit public benefit corporation (“Sutter”), and Augmedix, Inc., a Delaware corporation (“Augmedix”).
Sutter and Augmedix may be referred to herein individually as a “Party” and collectively as the “Parties.”

 

R E C I T A L S

 

WHEREAS, the Parties have agreed to update
and expand the list of authorized Foreign Remote Scribing Locations, set forth in Exhibit A-7.

 

NOW, THEREFORE, in consideration of the
premises set forth above and the mutual promises and agreements set forth herein, the Parties, each intending to be legally bound
hereby, agree as follows:

 

		1.	Exhibit A-7 (Foreign Remote Scribing Locations), is hereby deleted in its entirety and replaced
with the amended Exhibit A-7, attached hereto and incorporated herein.

 

		2.	All other Terms and Conditions of the Agreement remain unchanged. All capitalized terms used in
this Amendment and not otherwise defined shall have the meanings given to them in the Agreement.

 

		3.	By their respective signatures, below, each of the following represents that he or she is duly
authorized to execute this Amendment and to bind the Party on whose behalf such execution is made.

 

	SUTTER HEALTH	 	AUGMEDIX, INC.
	 	 	 	 	 
	By:	/s/ Albert Chan	 	By:	/s/ Manny Krakaris
	Name: 	Albert Chan	 	Name:	Manny Krakaris
	Title:	Chief of Digital Patient Experience	 	Title:	CEO
	Date:	9/25/2019	 	Date:	9/19/2019

 

    1

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

EXHIBIT A-7

 

FOREIGN REMOTE SCRIBING LOCATIONS

 

1. [*]

 

Location #1:

[*]

 

Location #2:

[*]

 

2. [*]

 

Location #1:

[*]

 

3. [*]

 

Location #1:

[*]

 

Location #2:

[*]

 

4. [*]

 

Location #1:

[*]

 

5. [*]

 

Location #1:

[*]

 

6. [*]

 

Location #1:

[*]

[*]

 

    2

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

7. [*]

 

Location #1:

[*]

[*]

 

8. [*]

 

Location #1:

[*]

[*]

 

9. [*]

 

Location#1:

[*]

[*]

[*]

 

 

3Exhibit 10.13

 

CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY
CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

 

SERVICES AGREEMENT

 

This SERVICES AGREEMENT (“Agreement”)
is made and entered into as of September 1, 2015 (the “Effective Date”) by and between Dignity Health,
a California nonprofit, public benefit corporation, with its business office at 185 Berry Street, Suite 300, San Francisco, CA
94107 (hereinafter referred to as “Dignity Health”), for itself and on behalf of its affiliates, and Augmedix,
Inc., a Delaware corporation with its principal offices at 1161 Mission Street, Suite 210, San Francisco, CA 94103 (hereinafter
referred to as “Augmedix”).

 

RECITALS

 

This Agreement is made in contemplation of the following facts
and circumstances:

 

A. Augmedix
desires to provide certain services, deliverables, software, and hardware in relation to the Augmedix Google Glass Scribe Project,
which is further defined in Section I of this Agreement, in accordance with the terms and conditions of this Agreement.

 

B. Dignity
Health desires that Augmedix provide such services, deliverables, hardware, and software in accordance with the terms and conditions
of this Agreement.

 

AGREEMENT

 

In consideration of the mutual promises
herein, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto
agree as follows:

 

1. Services, Deliverables,
and Augmedix Credentialing Requirements.

 

(a) Capitalized
terms defined on Schedule 1 will have the meanings given on Schedule I when used in this Agreement (including in any SOW).

 

(b) Augmedix
agrees to provide Services and related deliverables, hardware and software, as further described in this Agreement and the Statement
of Work attached hereto as Exhibit A. The Statement of Work attached as Exhibit A and each subsequent Statement of Work entered
into under this Agreement is referred to herein as a “SOW”. Each SOW will be entered into by Augmedix and Dignity
Health or (at Dignity Health’s election, one of Dignity Health’s Affiliates). Each subsequent SOW will be in substantially
the same form as Exhibit A unless Dignity Health otherwise requests. As used herein, “Affiliate” means, with
respect to a specified party, any person, firm, corporation, partnership, or other entity that is controlling, controlled by,
or is under common control with that specified party. With respect to Dignity Health, “Affiliate” also includes any
person, firm. corporation, partnership, joint venture or other entity that: (a) is managed or operated by Dignity Health or another
Dignity Health Affiliate; or (b) is a medical group, clinic, satellite office, or entity associated with Dignity Health or another
Dignity Health Affiliate to which Dignity Health now or in the future provides or is provided on its behalf electronic health
record technology. For purposes of this definition “control” means ownership or control of fifty percent (50%) or
more of the voting rights of the entity in question or the power to otherwise direct the affairs of the entity in question. Dignity
Health and each Dignity Health Affiliate designated by Dignity Health to receive Services or Deliverables under this Agreement
from time to time will constitute a “Client” hereunder. Augmedix shall offer and provide all the Services,
related deliverables, hardware, and software, as further described in this Agreement and Exhibit A, on the terms, conditions.
and prices set forth in this Agreement and Exhibit A, to Dignity Health and each other Client. Upon request by Dignity Health,
Augmedix shall enter into one or more SOWs substantially in the form of Exhibit A with adjustments as necessary for time schedule
and volumes. As used herein, “Services” means the services, tasks, and responsibilities set forth in this Agreement
or an SOW or otherwise provided by Augmedix under this Agreement.

 

Contract
Number: DH-IT-1186

 

    	SFO-154607	1

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

(c) This
Agreement does not grant to Augmedix any exclusive right or privilege to sell to Dignity Health or its affiliates any or all Services
or Deliverables that they may require, and there are no minimum volume commitments under this Agreement or any SOW. Dignity Health
and its affiliates may contract with other vendors for the procurement of any products or services.

 

(d) For
purposes of this Agreement “Deliverable” means any technology, materials or other work product made, created,
developed, written or conceived by Augmedix pursuant to a SOW or otherwise during the period of Augmedix’s work for Client
(whether before or after the date of this Agreement), either solely or jointly with another, but expressly excluding the Augmedix
Solution. For purposes of this Agreement “Customer Owned Deliverable” means any Deliverable that is either
(i) submitted (including but not limited to the written note created by a Scribe of a patient’s history and present illness)
into Client’s electronic health record (or required to be submitted) or otherwise collected (or required to be collected)
in the course of a Scribe documenting a patient visit or (ii) expressly identified as a Customer Owned Deliverable in a SOW. Augmedix
shall provide at its own expense, all equipment, supplies and materials necessary to perform the agreed Services and Client shall
provide no supplies and equipment, unless expressly agreed and stated otherwise in the SOW.

 

(e) As
part of the Services, Augmedix shall provide an Augmedix Google Glass Device for each Authorized User. Augmedix will retain title
for each Augmedix Google Glass Device, and Augmedix shall bear risk of loss each Augmedix Google Glass Device except to the extent
such loss is caused by the negligence of Dignity Health. Augmedix shall promptly repair or replace each Augmedix Google Glass Device
that fails to operate as necessary to support the Services, or otherwise fails to operate in accordance with its specifications
or the requirements of this Agreement, for any reason.

 

(f) Augmedix is hereby notified that
Client has established certain vendor credentialing policy and procedures and that by visiting Client’s facilities,
Augmedix and any agents working on its behalf, are subject to the applicable policies of such facility. Augmedix and its
personnel or agents working on its behalf shall comply with all “vendor credentialing” requirements including
appropriate authentication at the specific location’s visitor’s desk and electronic sign-in via an internet-based
third party service retained by Client.

 

    	SFO-154607	2

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

2. Place of Performance and Subcontracting.

 

(a) Unless otherwise
provided in the SOW, the Services shall be performed only at (i) Client’s place of business, (ii) at a Designated Augmedix
Facility that is either (A) the Augmedix facility in San Francisco, California or (B) a facility of Augmedix or its subcontractor
approved by Dignity Health (each a “Subcontractor”) in the Offshore Due Diligence form approved by Dignity
Health on or after the Effective Date (the “Offshore Diligence Document”), or (iii) such other place as may
be mutually agreed in writing by the parties. If not completed prior to the Effective Date, Augmedix shall complete the Offshore
Due Diligence Document and obtain Dignity Health’s written approval thereof the earlier of (i) within thirty (30) days after
the Effective Date or (ii) by the date on which offshore scribes are being trained on Client’s EHR.

 

(b) In performing its Services, Augmedix shall not (and
shall cause its the Subcontractors not to), remove any property of Client from Client’s premises, and shall (and shall cause
its Subcontractors to) only access such personal information or patient data as minimally necessary to perform the Services.

 

(c) Augmedix
may engage Subcontractors to assist in performance of the Services, subject to the following conditions: (i) each Subcontractor
must be approved by Dignity Health in the Offshore Diligence Document or otherwise in writing, (ii) Augmedix must enter into a
written agreement with each Subcontractor that is at least as protective of Client and Client’s data and other Confidential
Information as this Agreement, and (iii) Augmedix remains solely responsible for the acts and omissions of its Subcontractors in
connection with the Services, Deliverables, Augmedix Solution, and this Agreement.

 

3. Effective Date: Term. This
Agreement shall be effective as of the Effective Date and shall continue in full force and effect unless and until terminated
in accordance with Section 15 hereof.

 

4. Fees, Payment Terms and Warrants

 

(a) Fees
for Services and any associated Deliverables, software or hardware shall be set forth in the SOW. In no event will fees exceed
the fees set forth in the SOW. In no event will the fees exceed the fees set forth in Exhibit B (Pricing).

 

(b) All invoices
shall have a description of all services performed and billed and the name of each physician for whom Services were provided.
Invoices shall be emailed to Client’s accounts payable department at [*] and/or sent to the address specified by Client
from time to time, if different. In addition, Augmedix shall send a copy of each invoice to the Client office manager of each
physician listed in the invoice for his or her written approval. All invoices shall have a description of all services performed
and billed and name of clinic or facility and name of each physician for whom services were provided. Approved invoiced amounts
are payable by mail within thirty (30) days to Augmedix at the address set forth in Section 28.

 

    	SFO-154607	3

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

(c) Client operates in California,
Arizona, and Nevada and may be subject to state tax withholding requirements in these states. As a condition precedent to any
payment made under this Agreement, Augmedix shall complete, sign, and return to Client any certification or statement requested
by Client in order to assist Client’s compliance with any state tax withholding requirements. Withholding of tax at the
source is generally required from any payment derived from a California source, except when certain exceptions are met. Without
limiting the generality of the foregoing, all payments for services performed in California by non-residents or performed by residents
and payable in California shall be deemed subject to tax withholding requirements and shall be calculated based on information
available to Client. To the extent applicable, Augmedix shall specifically complete, sign and return to Client one of the following
two forms: (i) California Franchise Tax Board Form 587 (Nonresident Withholding Allocation Worksheet) or (ii) California Franchise
Tax Board Form 590 (Withholding Exemption Certificate). Augmedix acknowledges that it is solely responsible for the filing of
any tax returns and the satisfaction of any tax due with respect to the payments received under this Agreement. Augmedix also
acknowledges that Client is entitled to rely on the tax certifications or other information or evidence of exemption provided
by Augmedix to Client and hereby releases Client from any liability with respect to any tax withholdings paid to the California
Franchise Tax Board or counterpart state tax agencies in Arizona or Nevada, as applicable; except to the extent any of such withholdings
are refunded to Client. Augmedix shall promptly notify Client upon the change of any reported facts or conditions that are part
of Form 587 or Form 590, and shall provide Client with an updated Form 587 or Form 590.

 

5. Resources
to be Provided by Client. In addition to any resources that may be cited in the SOW, Client shall provide and make available
to Augmedix the following resources in (a) below and such other additional necessary resources as the parties may from time to
time reasonably agree in connection with Augmedix’s performance of the Services:

 

(a) Qualified
Client personnel or representatives who will be designated by Client to consult with Augmedix on a regular basis in connection
with the Services or Deliverable, and certain Client information necessary to enable Augmedix to perform the Services or provide
the Deliverable.

 

(b) Augmedix
shall not modify any of Client’s software, data files or web content that is not specifically identified and authorized by
Client in the SOW or subsequent writing.

 

6. Confidentiality.

 

(a) The parties
may provide or learn information that is confidential (“Confidential Information”) to each other. The Confidential
Information of a party shall include, but not be limited to, sales, financial, contractual and special marketing information,
patient-related data, personal information, discoveries, concepts, ideas, research, engineering methods, systems, source code,
equipment and product usage, program design, customer lists, business and engineering projects, ideas, technical data and concepts
and improvements and development thereof originated by or for the disclosing party, and which were not previously published or
otherwise disclosed to the general public, not previously available without restrictions to the receiving party, nor normally
furnished to others without compensation, and which said party desires to protect against unrestricted disclosure or competitive
use. Confidential Information of Dignity Health also includes derivatives of any patient-related data.

 

    	SFO-154607	4

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

(b) Other
than patient-related data and personal information, Confidential Information shall not include information which: (i) is or becomes
part of the public domain through no act or omission of the receiving party; (ii) was in the receiving party’s lawful possession
prior to the disclosure and had not been obtained by the receiving party either directly or indirectly from the disclosing party;
(iii) is lawfully disclosed to the receiving party by a third party without restriction on disclosure; (iv) is independently developed
by the receiving party; or (v) is disclosed by operation of law. In addition, the receiving party shall be entitled to disclose
Confidential Information to the extent required by law or judicial order, provided that prior written notice of such required disclosure
is furnished to the disclosing party as soon as practicable in order to afford the disclosing party an opportunity to seek a protective
order.

 

(c) If
either party receives Confidential Information from the other party, except as expressly specified in this Agreement, the party
receiving such Confidential Information shall: (i) maintain in strictest confidence such Confidential Information; (ii) not disclose
any such Confidential Information to any person outside that party’s business organization and only disclose or permit the
use of the other party’s Confidential Information to/by its employees, contractors, subcontractors, agents and professional
advisors who need to know it to perform the receiving party’s obligations and exercise the receiving party’s rights
under this Agreement, and who have agreed in writing (or in the case of professional advisors are otherwise bound) to keep it confidential
with a degree of care no less than such parties use to protect their own Confidential Information, but in any case no less than
reasonable care; and (iii) return such Confidential Information to the disclosing party upon the expiration or termination of this
Agreement, or destroy the same.

 

(d) A
party in receipt of the Confidential Information of the other who becomes aware of its unauthorized use or disclosure shall promptly
and fully notify the disclosing party of all facts known to it concerning such unauthorized use or disclosure. In addition to damages,
said party shall be entitled to equitable remedies, including injunctive relief. in the event of breach of this confidentiality
section by the other party. The terms of this Section 6, Confidentiality shall survive the expiration or termination of this Agreement
and will continue in full force and effect for a period of seven (7) years, except the obligation of confidentiality with respect
to patient-identifiable data and personal information shall be perpetual.

 

(e) Without
limiting the foregoing, Augmedix shall comply with all data security and confidentiality provisions set forth in an SOW, including
provisions regarding restricted access to content and data and to encryption.

 

(f) Without limiting the foregoing,
Augmedix shall (and shall cause its Subcontractors to) retain all data (including patient-related data) collected in
connection with the Services as set out in the SOP for this Agreement as agreed upon by the parties. The parties will develop
such SOP promptly after the Effective Date, which process will include requirements for retention of data as required by
applicable law and by Dignity Health. Upon consultation with Augmedix, Dignity Health will have the right to update such SOP
from time to time, as required by law and as reasonably necessary.

 

    	SFO-154607	5

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

(g) Usage Data. The parties acknowledge and agree
that Augmedix may monitor, collect, use and store anonymous and aggregate statistics regarding (i) user activity on the Augmedix
Solution (for clarity, excluding all PHI and other patient-related data other than statistics on patient acceptance of the solution)
for its business purposes, including, but not limited to, enhancing the Augmedix Solution and creating new features thereof and
(ii) to benchmark both by Client facility and by other of Augmedix’s customers data on acceptance or rejection by patients
of Client’s use the Augmedix Solution or part thereof. This sub-section 6(g) is conditioned on Augmedix de-identifying the
data so that neither Dignity Health, Client or any of its facilities or caregivers can be identified when reports based on such
data are shared with third parties. No other license with respect to patient or user related data is granted hereunder and is
reserved solely unto Client.

 

7. Ownership.

 

(a) As between
the parties, Augmedix owns all right, title and interest in and to the Augmedix Solution and any modifications or improvements
made by or on behalf of Augmedix to the Augmedix Solution provided under this Agreement. Notwithstanding the foregoing. Client
and Augmedix shall each retain ownership of, and all right, title and interest in and to, their respective intellectual property
(“IP”), and no license therein, whether express or implied, is granted by this Agreement or as a result of
the work performed hereunder, except to the extent expressly provided in an SOW or this Agreement. Augmedix shall clearly and
explicitly identify in the applicable SOW portions of any Customer Owned Deliverable that Augmedix deems to be solely proprietary
to Augmedix. Any such portion of any Customer Owned Deliverable so identified shall not be subject to the limitations of Section
7(b) below, and shall be solely and exclusively owned by Augmedix. With respect to each portion of a Customer Owned Deliverable
that is subject to Section 7(b) below and with respect to each Deliverable that is not a Customer Owned Deliverable, Augmedix
hereby grants to Client and its affiliates a non-exclusive, royalty-free, paid up, worldwide, perpetual license to use, reproduce,
modify, create derivative works of, distribute, and sub-license such Deliverable.

 

(b) Other
than portions of any Customer Owned Deliverable identified by Augmedix as proprietary pursuant to Section 7(a) above. Client shall
have title to and sole and exclusive ownership of all Customer Owned Deliverables under the applicable SOW. However, upon the express
written consent of Client’s senior vice-president, which consent Client may withhold in its absolute discretion, Augmedix
may obtain from Client for such Customer Owned Deliverable a non-exclusive, royalty-free, paid up, worldwide, perpetual license
(with right to sublicense), for any and all purposes, provided that, to the extent such Customer Owned Deliverable item incorporates
the Confidential Information or proprietary information of Client, Augmedix, in the use of such Customer Owned Deliverable, shall
be bound by the confidentiality obligations under Section 6, Confidentiality.

 

(c) Other than
portions of any Customer Owned Deliverable identified by Augmedix as proprietary pursuant to Section 7(a) above, the Customer
Owned Deliverables shall be deemed a “work made for hire” as that term is defined under Section 101 of the U.S. Copyright
Act and Client shall be considered the person for whom the work was prepared for the purpose of determining authorship of any
copyright in the Customer Owned Deliverables. All such Customer Owned Deliverables shall be the sole property of Client and, to
the extent any such of right or title has been retained by Augmedix, Augmedix shall execute the instruments necessary to complete
the transfer to Client of such ownership and title. If and to the extent, for any reason, the Customer Owned Deliverables are
not, or are determined not to be, a “work made for hire” under U.S. law or be law of any other jurisdiction, Augmedix
hereby assigns to Client all of Augmedix’s right title and interest in and to all copyrights and other rights in the Customer
Owned Deliverables.

 

    	SFO-154607	6

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

8. Remote Access
to Client’s Network. Should it be necessary for Augmedix to access and/or use Client’s computer or network, either
by remote means or in-person, it may do so provided that: (i) such need is specifically stated in the applicable SOW, (ii) access
is only by Augmedix’s personnel or Subcontractors approved in accordance with Section 2, and (iii) each of such personnel
will be issued and always uses a unique User ID and password. Access to the Dignity Health Network by Subcontractor shall only
be upon the express written permission (or as described in the SOW) of Dignity Health’s Chief Privacy and Data Security
Administrator. Furthermore, Augmedix agrees to (i) cause each such personnel to first sign Dignity Health’s Network Usage
Policy; (ii) ensure their compliance with appropriate policies and procedures of Client; and (iii) promptly report to Client any
privacy or security incidents. A copy of the Network Usage Policy and other applicable policies shall be made available upon request.

 

9. Publishing of Web Content.
Should Augmedix be granted access to Client’s network, it shall use such access solely to meet its obligations under this
Agreement, including the applicable SOW. Should a SOW require Augmedix to create or modify software, data or content to be used
on or to support Client’s network or website, Augmedix shall make every reasonable effort to comply with Client’s
applicable policies, procedures and standards; and, if it cannot do so, it shall promptly notify Client.

 

10. Personnel. Personnel provided
by either party to perform the Services or provide a Deliverable hereunder will at all times be considered employees or agents
of the party providing such personnel and will not for any purpose be considered employees or agents of the other party. Each
party shall assume full responsibility for the actions or inactions of the personnel it provides, and shall be solely responsible
for the supervision, direction and control, salaries, workers’ compensation coverage, disability and other insurance, benefits,
as well as all other legal obligations required by law relating to its personnel. Augmedix shall at all times during the term
of this Agreement carry general, professional and other liability insurance coverage in the form and amounts described on Exhibit
C, attached hereto and incorporated by reference.

 

11. Personnel to Provide the Services.

 

(a) Client shall
have the right to review the qualifications of all personnel Augmedix designates to perform the Services, including the Scribes
provided by Augmedix. For the avoidance of doubt, the parties acknowledge and agree that any and all personnel designated by Augmedix
to perform Scribing activities under this Agreement must meet the qualifications of and act in accordance with the duties and
obligations of a Scribe, as set forth both in Dignity Health’s Scribe Services Policy (100.2.001) and in the SOW.

 

(b) In the event
Client determines in good faith that the continued assignment of a particular Augmedix supplied person is not in the best interest
of Client or the project, whether because such person does not have the necessary experience and/or qualifications and/or is otherwise
objectionable to Client. in the exercise of its reasonable discretion, then Client shall give Augmedix written notice requesting
that such person be replaced. Augmedix shall then promptly investigate the matter stated in the request and discuss its findings
with Client. If Client still in good faith requests replacement of the person, Augmedix shall replace the person.

 

    	SFO-154607	7

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

(c) Augmedix
shall ensure that each of its employees and contractors providing Services at any Client facility has met the requirements set
forth on Exhibit E-1 before providing the Services. Augmedix shall perform all screening required by this Section at Augmedix’s
own expense, and Augmedix shall provide certification of completion of all screening upon request. Augmedix represents and warrants
that it has conducted and successfully completed a criminal background check for each of its employees and any contractor providing
services under this Agreement, in accordance with the Client’s standards set forth in Exhibit E-2 (Background Screening
Standards) which include a state and county criminal history investigation and a state sex offender search where the Augmedix
employee or subcontractor resides and where the Client they are servicing is located. Any criminal history identified shall be
reported to Client prior to the Augmedix’s employee or subcontractor providing services under this Agreement and in accordance
with Exhibit F (Background Screening Scoring Guidelines). Augmedix represents and warrants that it has checked the OIG
List of Excluded Providers and the General Services Administration list of parties excluded from participation in federal health
care programs (collectively the “List”) no more than thirty (30) days prior to the Effective Date, and Augmedix
covenants that Augmedix shall check the List every month after the Effective Date, and shall provide proof to Dignity Health that
neither Augmedix, nor any of the Augrnedix Personnel appear on said List. Further, Augmedix represents and warrants that neither
Augmedix, nor any Augmedix Personnel is subject to sanction or exclusion from participation under any Federal or State health
care program. In the event that Augmedix becomes so sanctioned or excluded. Dignity Health may immediately terminate this Agreement.
In addition, any Augmedix Personnel who become so sanctioned or excluded during the term of this Agreement will be immediately
removed by Augmedix upon Augmedix’s becoming aware of such sanction or exclusion and will be thereafter excluded from the
provision of Services under this Agreement. Augmedix shall provide written documentation of its compliance with its obligations
under this provision upon Client’s request. Augmedix may request that Client waive this requirement in the event that Client
has independently conducted the background check for any Augmedix employee or subcontractor providing services under this Agreement.

 

12. Solicitation or Hiring Other Party’s Employees.

 

(a) Neither party,
without the prior written consent of the other party (the “Original Employer”), shall solicit, induce or attempt
to solicit or induce any employee of the Original Employer to become an employee or contractor of the soliciting or inducing party
during the term of this Agreement.

 

(b) Nothing in
this Section 12, Solicitation or Hiring Other Party’s Employees, is intended or shall be construed to prevent, provided
that there is prior notice to the other party, (i) either party from hiring those employees of the other party that have not been
solicited, or (ii) either party from soliciting or hiring any of those employees of the other party in the event of the other
party’s insolvency, bankruptcy, receivership, or any other cessation of business.

 

    	SFO-154607	8

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

13. Relationship of Parties.
Augmedix is an independent contractor in all respects with regard to this Agreement. Nothing contained in this Agreement shall
authorize, empower, or deem any party as partner or agent of any other party in any manner; authorize, or empower or deem one
party to assume or create any obligation or responsibility whatsoever, express or implied, on behalf of or in the name of any
other party; or authorize, empower or deem a party to bind any other party in any manner or make any representation, warranty,
covenant, agreement, or commitment on behalf of any other party.

 

14. No Offshoring. Except
as otherwise approved by Dignity Health under Section 2, Augmedix warrants and represents that: (a) any and all Services and Deliverables
hereunder shall only be provided by its personnel or Client-approved consultants residing within the United States of America
when such Services and Deliverables include the use of or access to PHI by such personnel or consultants, and (b) Augmedix shall
ensure that any patient-related information, and/or Client or Dignity Health Confidential Information, learned by it as a result
of entering into this agreement shall never he transferred outside the jurisdiction of the United States of America and shall
never be transferred to, or accessed by, anyone from outside the United States of America, or with respect to PHI by anyone who
is not personnel or Client-approved Subcontractor of Augmedix. Any modification to the foregoing limitation shall require the
express written consent signed in ink by Client’s President, Chief Operating Officer or Executive Vice President, or if
this Agreement is with Dignity Health, then its Senior Vice President. Any breach of the foregoing shall constitute a material
breach of this Agreement. Notwithstanding the foregoing or anything to the contrary in this Agreement or any SOW, Augmedix shall
not store or permit to be stored any PHI or personally identifiable information related to Client outside the jurisdiction of
the United States of America.

 

15. Termination.

 

(a) Dignity
Health may terminate this Agreement or any one or more SOWs, with or without cause at any time upon providing ninety (90) days’
written notice to Augmedix; provided that, if the termination is for a breach of obligations under HIPAA as defined in Exhibit
D, then the termination provisions in Exhibit D shall apply.

 

(b) Augmedix
may terminate this Agreement or any one or more SOWs, with or without cause upon providing one hundred eighty (180) days’
written notice to Dignity Health; provided that, (i) no such termination notice may be given before the date twelve (12) months
following the Effective Date and (ii) if the termination is for a breach of obligations under HIPAA as defined in Exhibit D, then
the termination provisions in Exhibit 13 shall apply.

 

(c) Either party
may, without prejudice to any other remedies available to it at law or in equity, terminate an SOW in the event that the other
party commits a material breach of its obligations under that SOW (or under this Agreement with respect to that SOW) and fails
to cure that breach within thirty (30) days after notice from the non-breaching party. Termination of one SOW under this clause
(c) will not affect any other SOW.

 

    	SFO-154607	9

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

16. Effect of Termination.
Upon termination of this Agreement, each party shall promptly return to the other any and all personal property and Confidential
Information of the other held by such party, other than as provided in Section I. Services and Deliverables, and Section 7, Ownership,
and shall be subject further to the requirements of Paragraph 5 of Exhibit D (Business Associate Exhibit). If the termination
is initiated by Augmedix or by Client due to Augmedix’s failure to perform or deliver, Augmedix shall promptly refund to
Client any fees or payments it received for Services not performed and Deliverables not completed or done correctly. Notwithstanding
anything to the contrary in this Agreement, the following provisions shall survive any termination or expiration of this Agreement
in accordance with their respective terms: Sections 1(d), 6, 7, 16, 17, 18, 19, 20, and 21 through 37.

 

17. Federal Reporting Requirements.
To comply with Federal Reporting Requirements, Augmedix shall, until the expiration of four (4) years after the furnishing of
any service pursuant to this Agreement, make available upon the written request of the Secretary of Health and Human Services
or the Comptroller General of the United States. or any of their duly authorized representatives, copies of this Agreement and
any books, documents, records and other data of Augrnedix that are necessary to certify the nature and extent of costs incurred
by Client or its affiliates under a particular SOW. If Augmedix carries out any of its duties under this Agreement through a subcontract
with a related organization involving a value or cost of $10,000 or more over a twelve-month period, Augmedix shall cause such
subcontract to contain a clause to the effect that, until the expiration of four (4) years after the furnishing of any service
pursuant to said subcontract, the related organization will make available upon the written request of the Secretary of Health
and Human Services or the Comptroller General of the United States, or any of their duly authorized representatives, copies of
records of said related organization that are necessary to certify the nature and extent of cost incurred by Augmedix for such
service.

 

18. General Warranties.

 

(a) Augmedix warrants and represents
that the Services provided under this Agreement shall be promptly performed and any Deliverable shall be provided with the skill,
judgment and attention to detail and diligence, which are normally exercised by recognized professional firms performing services
of a similar nature. Augmedix represents and warrants that all software and hardware furnished by Augmedix under this Agreement
shall operate in accordance with its applicable specifications and documentation and the requirements of this Agreement and without
material error. Should Augmedix breach any of the foregoing warranties: (i) Augmedix shall promptly re-perform the Services, re-provide
the Deliverables, or repair or replace the affected hardware or software, at its own expense; and (ii) Client will have the right
to terminate the Services for one or more specified Authorized Users at any time without advance notice, except that if Client
desires to terminate Services for more than ten percent (10%) of the Authorized Users under this Agreement at a given time, Client
will provide Augmedix with 90 days’ written notice of such termination. In addition, Client will have the right to suspend
Services for one or more specified Authorized Users without advance notice in cases of unforeseen circumstances outside of the
specific Authorized User’s control; and in all other cases with seven (7) days advance written notice, and such suspension
will continue until Client informs Augmedix that the suspension is lifted. If Client suspends Services for an Authorized User,
then the fees for that Authorized User will not be payable during the suspension and the term of Services for that Authorized
User will be extended for a period of time equal to the duration of the suspension, unless earlier terminated as provided herein.

 

    	SFO-154607	10

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

(b) Augmedix
acknowledges that it is a “Business Associate” as that term is defined under the Health Insurance Portability
and Accountability Act of 1996 and regulations promulgated thereunder by the Department of Health and Human Services (“HIPAA”)
and hereby warrants that it shall comply with the obligations of a Business Associate, commencing on the date of the access to
or receipt of PHI or the date Augmedix’s personnel arrive on Client’s premises, as required by the HIPAA and embodied
in the Business Associate Exhibit (“Exhibit D”), which is attached and incorporated herein by this reference.
Any breach of the terms and conditions of the Business Associate Exhibit shall constitute a material breach of this Agreement.

 

(c) Augmedix
warrants, represents. and covenants that any and all PHI created or accessed in relation to the Services hereunder will (i) be
transmitted only to the Designated Augmedix Facility in connection with a secure Scribing session and (ii) will be cached or stored
only in accordance with the SOP. Any PHI that is cached on the Augmedix Google Glass Device will be cached only in encrypted form,
will be cached only when necessary because the wifi connection to the Designated Augmedix Facility is unavailable, and, except
as specifically provided in the applicable SOP referenced herein, will be erased from the Augmedix Google Glass Device within seventy-two
(72) hours of the time that it is cached.

 

(d) Augmedix
warrants and represents that, at all times during the term of this Agreement, it shall maintain the necessary business license,
current with the requirements of the state, city, and other local authority regulating the business or performance of Services
under this Agreement. Augmedix shall provide Client with a copy of such current business license.

 

(e) Augmedix
warrants, represents, and covenants that the responses and statements made by Augmedix and Augmedix personnel regarding the Services
and Deliverables in conection with (i) Dignity Health’s online security assessment (“RSAM”), approved
by Dignity Health on or after the Effecitve Date and (ii) the Offshore Due Diligence Document, are and will remain true and accurate.
Augmedix shall cooperate and work together with Dignity Health in the process of obtaining any variances or achieving any other
deliverables that are required as a result of the security assessment process described above. If not completed prior to the Effective
Date, Augmedix shall complete the RSAM and obtain Dignity Health’s written approval thereof on the earlier of (i) within
thirty (30) days after the Effective Date or (ii) the date on which offshore scribes are trained on Client’s EHR.

 

19. Limitation of Liability.
Except for liability arising under Section 6, Confidentiality; the Insurance requirements of Exhibit C; out-of-pocket costs
reasonably incurred by Client as a result of a breach by Augmedix of the HIPAA Business Associate provisions in Exhibit D or
otherwise payable pursuant to Exhibit D; fraud; or the willful misconduct of a party: (a) neither Augmedix nor Client shall
be liable to the other for any special, indirect, incidental, or consequential damages regardless of legal theory under which
such damages are sought, and (b) neither Augmedix’s nor Client’s aggregate liability under this Agreement will exceed
(i) [*] or (ii) the total amounts clue to Augmedix pursuant to this Agreement in the twenty-four (24) months preceding the initial
claim, whichever is greater. The foregoing limitations shall not apply to damages awarded to third parties or settlement amounts
incurred with respect to third party claims covered by Augmedix’s indemnity obligations under Section 20(a) or 20(b) or
Section 11 of Exhibit D.

 

    	SFO-154607	11

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

20. Indemnity and Infringement.

 

(a) General
Indemnity. Augmedix shall promptly and fully defend, hold harmless, indemnify, compensate, and reimburse Client and its affiliates
and their respective officers, directors, agents and employees (the “Indemnified Parties”) from and against
all third party claims, demands, liabilities, losses, fines, penalties, assessments, costs, awards, attorneys’ fees costs
of notification or remediation relating to notification required by law, and judgments made or recovered against them for damages
to or loss of personal property, including Client’s Confidential Information, data files. web content, software applications
or for bodily injury or death to any person arising out of, or in connection with this Agreement (collectively “Claims”),
to the extent that any of the foregoing is caused by any breach of this Agreement or any negligence, unlawful conduct or willful
misconduct of Augmedix, its subcontractor or its employees or agents. The Claims covered by this section shall include Claims
made or recovered against Indemnified Parties and Claims issued in favor of a third party. Client shall notify Augmedix of any
such written claim or demand received by Client, and give Augmedix reasonable control of the defense of any action or such claim
or demand provided that any settlement or compromise which requires contribution from the Indemnified Parties must be approved
by the Indemnified Parties and the Indemnified Parties shall, at Augmedix’s expense, cooperate with the indemnifying party
in a reasonable way to facilitate the settlement or defense of such claim or demand. The Indemnified Parties may, at their expense
and option, use counsel of their choosing to observe the defense of any such claim, and will have reasonable access to all defense
documents during the defense. The indemnity and obligations of Augmedix under this section shall survive the expiration or termination
of this Agreement and shall not be limited by reason of any insurance required under this Agreement.

 

(b) Intellectual
Property Indemnification. Augmedix shall promptly and fully defend, hold harmless, and indemnify, compensate, and reimburse
the Indemnified Parties from and against any and all Claims to the extent the Claim is based on an allegation that use of the
Services, Augmedix Solution, or any related materials, software, equipment or other Deliverables (the “Items”)
provided under this Agreement infringes any patent or any copyright, trademark, trade secret or other proprietary right. If any
Item or any part thereof, or Client’s use thereof, is held or likely to be held to infringe the intellectual property right
of another, including any trade secret, copyright, patent or trademark or trade dress, is enjoined or interfered with in any manner.
Augmedix shall. at its sole expense promptly: (1) procure for Client the right to continue using the Items free of any liability
for infringement; or (2) replace or modify the Items at Augmedix’s sole expense with non-infringing services, deliverables,
hardware, or software of equivalent or better functionality which is satisfactory to Client. Any such replacement, substitute,
or modified services, deliverables, hardware, or software shall conform to the applicable SOW. If neither of the foregoing alternatives
is reasonably and promptly available, Augmedix shall, upon request from Client promptly remove the Deliverable or terminate the
Services and promptly refund Client all fees under the applicable SOW as depreciated or amortized by an equal annual amount over
the lifetime of the Service, Deliverable, hardware, or software or seven (7) years, which ever period is greater. Notwithstanding
the above, Augmedix will have no liability under this Section 20(b) for infringement by the Google Glass device, or to the extent
such Claim: (i) involves infringement that is attributable to any components or elements of the solution supplied by Client; (ii)
is based on modification by Client of any deliverables provided by Augmedix or combination of deliverables with any non-Augmedix
hardware or software that is not supplied or recommended by Augmedix, in each case to the extent such Claim results from such
modification or combination; or (iii) to the extent it results from failure of the Indemnified Parties to use updated or modified
versions of any Items provided by Augmedix for avoiding such Claim, provided that such updates are provided at no charge and are
identified at the time of delivery as being provided to avoid such Claim.

 

    	SFO-154607	12

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

21. Non-Waiver of Rights.
The failure of any party to insist upon performance of the terms and conditions in this Agreement, or to exercise any rights or
remedies, shall not be construed as a waiver of their rights to assert any of the same or to rely on any such terms or conditions
at any time thereafter. The invalidity in whole or in part of any terms or conditions of this Agreement shall not affect the validity
of other parts hereof.

 

22. Applicable Law and Venue.
This Agreement shall be governed by and construed under the laws of the State of California without regard to those laws relating
to conflict of laws. The venue of any action hereunder or related hereto shall be in San Francisco, California. Augmedix shall
comply with all state and federal laws and regulations applicable to its performance of Services, including but not limited to
Augmedix’s employment or hiring of personnel to perform Services under this Agreement; confidentiality of information, data
security, and privacy laws protecting medical and personal information.

 

23. Assignment. Subject to
the provisions of Section 30, neither party may sell, assign, transfer any SOW executed by Client, or otherwise convey any of
its rights or delegate any of its duties under this Agreement to a third party without the prior written consent of the other,
except to a corporation which has succeeded to substantially all the business and assets of the assignor and assumed in writing
its obligations under this Agreement, or to a corporation surviving a merger or consolidation to which the party to this Agreement
is a party. Any attempted sale, assignment, transfer, conveyance, or delegation in violation of this paragraph shall be void and
shall relieve the party not making such attempt of any further obligation or liability hereunder. Notwithstanding the foregoing,
Augmedix may, without violation of this paragraph but subject to the limitations of Sections 6, 10, 11, 12, and Exhibit D, engage
the services of independent contractors to assist in the performance of its duties hereunder.

 

24. Conflicting Provisions.
This Agreement and any attachments, including each exhibit, SOW, schedule, and document attached hereto, are intended to be read
and construed in harmony with each other, but in the event any provisions in any of the foregoing attachments or an invoice conflict
with the provisions of this Agreement, the body of this Agreement and Exhibits B, C, D, and F shall be deemed to collectively
control, and such conflicting provision shall be deemed removed and replaced with the governing provision herein.

 

    	SFO-154607	13

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

25. Force Majeure. Neither
party shall be liable for any failure of or delay in the performance of its obligations under this Agreement (except labor strike
or transportation), including, without limitation, acts of God, acts of a public enemy, fires, floods, wars, civil disturbances,
sabotage, accidents, insurrections, embargoes, storms, explosions, acts of any governmental body (whether civil or military, foreign
or domestic), failure or delay of governmental bodies from whom a party is obtaining or must obtain approvals, franchises, or
permits, materials but only to the extent such failure or delay is due to circumstances beyond its control and .is unforeseeable,
(collectively referred to herein as “Force Majeure”). Each party shall use all reasonable efforts to minimize
the duration and consequences of any failure of or delay in performance resulting from a Force Majeure event.

 

26. Disputes. Client and Augmedix
agree to enter into negotiations to resolve any controversy, claim or dispute (“Dispute”) arising under or
relating to this Agreement. The parties agree to negotiate in good faith at a vice-president level or higher to reach a mutually
agreeable resolution of such Dispute within a reasonable period of time.

 

27. Multiple Copies or Counterparts
of Agreement; Acceptance of Facsimile and Scanned Signatures. This Agreement, including the SOW, may be executed in two or
more counterparts, each of which shall be deemed an original but all of which together shall constitute one and the same instrument.
When signed in pen ink, this Agreement may be delivered by facsimile transmission or by scanned email attachment, and said copies
shall be treated in all respects as original.

 

28. Notices. All notices given
under any of the provisions of this Agreement shall be deemed to have been given by the notifying party if mailed by first class
mail to the receiving party addressed to its or his mailing address set forth below, or such other address as the parties may
designate in writing. Additionally, notices sent by any other means (i.e. fax, overnight mail, etc.) may be acceptable subject
to written confirmation of both the transmission and receipt of the notice. If notice by a party is given by e-mail, such notice
shall be deemed to have been properly given if sent to at least three recipients of the other party who are, or should reasonably
expected to he, reasonably familiar with the parties’ relationship and the e-mail’s subject matter and the recipient’s
internet service provider confirms receipt thereof.

 

All notices shall be sent by either party
in writing to the other in matters dealing with this Agreement to the following addresses:

 

If to Client:

 

		(1)	Client’s Name (See SOW)

Client’s Address (See SOW)

Attention: Business Sponsor (See SOW)

 

    	SFO-154607	14

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

		(2)	Copy to:

Dignity Health

185 Berry Street, Suite 300

San Francisco, CA 94 107-1739

Attention:
General Counsel

 

If to Augmedix:

 

		(1)	Augmedix’s Name: Augmedix, Inc.

Address: 1161 Mission Street, Suite 210

San Francisco, CA 94103

Attention: CEO

 

		(2)	Copy to:

Fenwick & West LLP

Attention: Stefano Quintini

801 California Street

Mountain View, CA 94041

 

29. Severability. If any covenant,
condition, term, or provision contained in this Agreement shall be held or finally determined to be invalid, illegal. or unenforceable
in any respect, in whole or in part, by judgment, order, or decree of any court or other judicial tribunal of competent jurisdiction,
from which no further appeal or petition for review is available, such covenant, condition, term, or provision shall be severed
from this Agreement, and the validity of the remaining covenants, conditions, terms, and provisions contained in this Agreement,
shall in no way be affected, prejudiced, or disturbed thereby.

 

30. Third Party Beneficiaries.
This Agreement does not create, and shall not be construed as creating any right or providing any benefit enforceable by any person
not a party to this Agreement. The use of the term “third party” throughout this Agreement does not include Client’s
affiliates, parent company and its subsidiaries, or personnel supplied by either party pursuant to this Agreement.

 

31. Waiver or Modification.
This Agreement may be modified, or part or parts hereof waived, only by an instrument in writing specifically referencing this
Agreement and signed by an authorized representative of the party against whom enforcement of the purported modification or waiver
is sought.

 

32. Entire Agreement. This
Agreement, including all Exhibits attached hereto, constitutes the entire agreement between the parties relative to the subject
matter hereof and supersedes any prior or contemporaneous or any other kind of proposals, agreements, documents, commitments or
representations of any kind, whether written or oral, including any online “click-wrap” agreement or other online
terms, with respect to the Services and Deliverable between Augmedix and Client.

 

33. Acknowledgement of Client
Corporate Integrity Program. Notwithstanding Section 32 above, Augmedix acknowledges that Client operates under a compliance
program known as the Corporate Integrity Program of Dignity Health. Augmedix further acknowledges that notwithstanding anything
contained herein, Client shall not be required to engage in any conduct that may violate any policies, procedures, or directives
of the Corporate Integrity Program. Augmedix further represents that it has not been, nor currently is, excluded from participation
in government funded healthcare programs, including, but not limited to, Medicare, Medicaid, CHAMPUS, and FEHP.

 

    	SFO-154607	15

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

34. No
Conflict of Interest or Conflicting Obligation.

 

(a) Augmedix
shall not accept consulting assignments or otherwise contract, agree, or enter into any arrangement to provide expert testimony
or evaluation on behalf of a plaintiff in connection with any claim against Company or Client or its affiliates expected to be
named as a defendant. if Augmedix is a physician, Augmedix shall not accept similar consulting assignments if (a) the defendants
or anticipated defendants include a member of the Client’s medical staff, and (b) the matter relates to events that occurred
at Company or Client or any of its affiliates; provided, however, the provisions of this Section shall not apply to situations
in which Augmedix served as a treating physician.

 

(b) Augmedix
represents and warrants that it is not a party to any agreement that conflicts with, or would be materially breached by, with the
performance of its obligations under this Agreement.

 

35. Headings. The paragraph
headings in this Agreement are inserted for convenience only and are not intended to affect the meaning or interpretation of this
Agreement.

 

36. Time of the Essence. Time
is of the essence in each and every provision of this Agreement.

 

37. Interpretation. This Agreement
is drafted and reviewed by both parties and with full opportunity for assistance from their respective counsel and it shall not
be interpreted for or against any party.

 

[COUNTERPART SIGNATURE
PAGES FOLLOW]

 

    	SFO-154607	16

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

IN WITNESS WHEREOF, the authorized
parties hereto have caused this Agreement to be executed as of the date of the last signatory below.

 

	Dignity Health	 	Augmedix, Inc.
	 	 	 
	/s/ Michael Stern	 	/s/ Pelu Tran
	Signature	 	Signature
	 	 	 
	Michael Stern	 	Pelu Tran
	Print Name	 	Print Name
	 	 	 
	Director, IT Contracting	 	Cofounder, President, Chief Customer Officer 
	Title	 	Title
	 	 	 
	9/17/15	 	9/17/2015
	Date	 	Date

 

    	SFO-154607	17

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

SCHEDULE 1

 

Definitions

 

The following terms will have the meanings indicated below:

 

		(1)	“Augmedix
Solution” means the proprietary solution of Augmedix, comprising a combination of processes, the Software, and the Augmedix
Google Glass Device, that enables the Services.

 

		(2)	“Augmedix
                                         Google Glass Device(s)” means the Google Glass Device that has been materially
                                         modified by Augmedix (e.g., addition of proprietary software on the device) for secure
                                         use as part of the Augmedix Solution.

 

		(3)	“Authorized
                                         User(s)” are individual healthcare providers designated by Dignity Health and
                                         approved by Augmedix who will be wearing the Augmedix Google Glass Device and utilizing
                                         the Augmedix Solution.

 

		(4)	“Designated
                                         Augmedix Facility” means the following facilities: (1) Augmedix facility in
                                         San Francisco at 1161 Mission Street, Suite 210, San Francisco, CA 94103 and (2) designated
                                         Augmedix offshore partner as written in the Offshore Due Diligence Document for each
                                         Dignity Health approved offshore subcontractor, which document is incorporated herein
                                         by reference.

 

		(5)	“Dignity
                                         Health Facility(-ies)” means the Dignity Health facility or facilities identified
                                         by Dignity Health where Authorized Users will be wearing Google Glass and utilizing the
                                         Augmedix Solution front-end.

 

		(6)	“Documentation”
                                         means all materials and documentation provided by Augmedix to Dignity Health, whether
                                         in hard copy, magnetic media or machine-readable form, pertaining to the capabilities,
                                         operation, software and/or services of the Augmedix Solution, as amended and updated
                                         by Augmedix from time to time.

 

		(7)	“Embedded
                                         Software” means third party computer programs listed in the Documentation,
                                         which are licensed by Augmedix and incorporated in the Software, and which are subject
                                         to the terms specified in the SOW.

 

		(8)	“Hardware”
                                         means the minimum recommended hardware required to operate the Software, as described
                                         in the SOW.

 

		(9)	“Scribe(s)”
                                         means an individual who performs Scribing on behalf of a provider.

 

		(10)	“Scribing”
                                         means the acts of inputting EHR data and searching the subject patient’s EHR
                                         for pertinent information by the Scribe from the perspective of, and on behalf of, the
                                         Provider, during or in connection with a provider session/encounter and based on the
                                         interaction between a patient and provider, the EHR input of which will be reviewed,
                                         finalized and approved by Provider in accordance with the Dignity Health Scribe Policy
                                         and the applicable, mutually agreed upon Standard Operating Procedure document.

 

		(11)	“Software”
                                         means the proprietary Augmedix software required to operate the Augmedix Google Glass
                                         Device. Software includes Embedded Software.

 

		(12)	“SOP”
                                         means a written standard operating procedure agreed to by Dignity Health and Augmedix
                                         that sets forth the day-to-day expectations of the parties, including processes, protocols,
                                         training, patient interaction, patient notices, and specific means of carrying out each
                                         party’s obligations under the Agreement, the SOW and Dignity Health’s Scribe
                                         Policy. The SOP also includes the master list of current and to-be-initiated Authorized
                                         Users, to-be-initiated Authorized Dignity Health Facilities, and preferred initiation
                                         dates, as determined and maintained by the Dignity Health in collaboration with Augmedix.

 

    	SFO-154607	18

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

EXHIBIT A 

 

STATEMENT OF WORK (SOW)

 

[Attached]

 

    	SFO-154607	19

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

EXHIBIT A

 

STATEMENT OF WORK (SOW)

AUGMEDIX EXPANSION PROJECT

 

This Statement of Work (“SOW”),
entered into by and between Dignity Health Medical Foundation (a Dignity Health Affiliate) and Augmedix, Inc. (jointly
“Parties”), is effective as of September 1, 2015 (the “SOW Effective Date”) and is a supplement
to the Services Agreement dated September 1, 2015 (the “Agreement”) by and between Dignity Health with
a place of business at 185 Berry Street, Suite 300, San Francisco, California 94107 (“Client”), and Augmedix, Inc.,
a Delaware corporation with its principal offices at 1161 Mission St, Suite 210, San Francisco, CA 94103 (“Augmedix”),
and is hereby made a part of the Agreement. To the extent this SOW is inconsistent with the terms of the Agreement, the terms
of the Agreement will prevail. All capitalized terms used in this SOW and not defined herein shall have the meaning assigned to
such terms in the Agreement. Notwithstanding any prior agreements, the Parties hereby agree that as of the SOW Effective Date,
the Services Agreement dated November 7, 2013 between the Parties, including all amendments and statements of work thereunder,
are deemed terminated and superseded by the Agreement (described above) between Dignity Health and Augmedix. This SOW replaces
all prior SOWs by and between the Parties with an effective date prior to September 1, 2015.

 

Client’s Business Sponsor (name
of executive): Dr. Davin Lundquist, Vice President-Chief Medical Information Officer (Dignity Health Medical Foundation)

 

Primary Client Contact: [*] Program Manager - Telehealth 

 

1. Overview and Definitions

 

a. Augmedix Solution
Overview

 

With the introduction of Electronic
Health Record (“EHR”) systems, licensed physicians (“Provider(s)”) are increasingly required
to interact with technology during a patient session. Providers often spend hours completing documentation in their patients’
charts. Depending upon the Provider’s practice style, this might get accomplished during office hours, in between patient
sessions, or after hours.

 

Augmedix shall ensure that the Augmedix
Solution will enable: (a) Scribes to readily perform Scribing activities in accordance with Dignity Health’s Policy, this
SOW and the applicable SOP, and (b) Providers wearing the Augmedix Google Glass to readily and securely communicate electronically
live audio, video and/or data during a patient session/encounter with a Scribe.

 

Augmedix shall utilize the Google Glass
platform as a means to pass-through audio, video, and data to and from remote Scribes located at a Designated Augmedix Facility
(as defined below) or on-site at the Client facility, as applicable. Scribes will complete much of the documentation that Providers
do themselves today, in real-time, during a patient session and will input that data directly into the applicable Client EHR.

 

b. Project Overview

 

This project is a collaborative effort
between Augmedix and Client, to undertake deployment of the Augmedix Solution at authorized Client Facilities, with direct participation
of certain designated Providers of Client.

 

Client Facilities utilize EHRs which can be common
between facilities or unique to a specific facility.

 

When performing the Services,
Scribes will always be located at the Designated Augmedix Facility or on-site at the Client facility and will be scribing directly
into the respective El4R.

 

Scribes will work with Client’s
on-site staff to incorporate patient education into the registration process, as well as to capture post-appointment feedback
with respect to patient satisfaction and comfort with the interaction between patient and Provider during a patient session.

 

During each phase described below, Augmedix’s
team will conduct interviews with the participating Providers to measure their satisfaction, interaction and capture efficiencies
gained by introducing the Augmedix Solution.

 

    	SFO-[160980]	 

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

2. Services and Deliverables

 

		a.	Commencing on the Effective Date of this SOW, Augmedix
shall perform the following services and provide the following Services and Deliverables to Client:

 

		(1)	Implementation.
Augmedix shall perform implementation Services in accordance with Section 2(c) below.

 

		(2)	Scribing.
Scribing is to be performed by Augmedix Scribes. Augmedix shall facilitate coordination of Scribing integration into the EHR,
in pending status, awaiting the Provider’s review, finalization, and approval.

 

		(3)	Formatting.
Augmedix shall transfer Scribing results into the format requested by Client.

 

		b.	Certain Requirements

 

		(1)	Augmedix
shall provide the necessary Augmedix Google Glass Devices and Embedded Software for the Authorized Users.

 

		(2)	Any
and all Client Hardware (including servers) used to implement and operate the Augmedix Solution will remain on Facility premises
at all times. Audio, video, and data content will be generated and used only in real time during a patient session using the Augmedix
Google Glass Device which will be encrypted both at rest and during the session, and, in any event, at all times in accordance
with the RSAM documents and the SOP, which when finalized or updated by the parties are deemed incorporated herein by reference.
For purposes of this SOW, “real time” means streaming without caching, storage or retention of the content, except
for caching in encrypted form on the Augmedix Google Glass Device as permitted by this Agreement when the wifi connection to the
Designated Augmedix Facility is unavailable and other caching and storage specifically permitted under the SOP.

 

		(3)	The
SOP will comply with all of the requirements of the Agreement, this SOW and Client’s Scribe Policy. Any content in the SOP
that conflicts with a requirement in any of the foregoing shall only be valid when approved in writing by Augmedix and Client’s
Business Sponsor, legal counsel and if it pertains to a privacy matter, its Facility Privacy Official.

 

		(4)	Augmedix
will ensure that all Scribes complete all training on relevant Dignity Health policies and software applications, as requested
by Dignity Health, and comply with all Dignity Health policies applicable to the Services, including without limitation, Dignity
Health’s scribe policy, which is attached to this SOW as Attachment1  (Dignity Health Scribe Policy), which policy may be
updated from time to time by Dignity Health.

 

		c.	Certain Augmedix
                                         Responsibilities

 

		(1)	Augmedix shall install and configure the Software onto
the Hardware under the supervision and with the support of the appropriate Client-designated personnel. As part of the implementation
Services, Augmedix shall complete collection of physician and site preferences, technical site evaluation, IT infrastructure setup,
and deployment of on-site Augmedix Scribe trainers and Augmedix Scribes as needed, and onboarding of Authorized Users and Augmedix
personnel (including Scribes). Augmedix shall perform all other services necessary to implement the Software, Hardware, and Services
so that they can be used in full production.

 

		(2)	Augmedix shall notify Client when the implementation Services
described above are complete. Client will have the right to test the Software, Hardware and Services as implemented. Augmedix
shall promptly correct any errors or deficiencies. The Software. Hardware, and Services will not be deemed accepted unless and
until Client notifies Augmedix of its acceptance, provided however that for acceptance after the first implementation with respect
to each Facility EHR or new version thereof, the Software, Hardware and Services for each implementation will be deemed accepted
if Client does not reject them after five (5) business days of production use following notification by Augmedix that such implementation
Services are complete. Go-live date for each Authorized User will occur upon first productive use by that Authorized User following
notice from Augmedix that all implementation services are complete for that Authorized User, unless disputed by Client within
five (5) business days after such notice.

 

    	SFO-[160980]	Page 2

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

		(3)	Augmedix
shall provide the Augmedix Google Glass and all technical support for it.

 

		(4)	Augmedix
shall ensure that the Augmedix Designated Facility meets the requirements of the relevant security document (i.e. RSAM for Augmedix
Designated Facilities located in the United States and the Offshore Diligence Document for Augmedix Designated Facilities located
overseas) at all times.

 

		(5)	Augmedix
shall ensure that all data and content (including audio and video content) generated or collected by the Augmedix Google Glass
Devices will at all times be encrypted and streamed in encrypted form through the Facility Wi-Fi network and to the Designated
Augmedix Facility via the internet.

 

		(6)	Augmedix
shall ensure that EHR entries created by Scribes will at all times be transmitted in encrypted form from the Augmedix Designated
Facility to the Facility EHR.

 

		(7)	All
hardware used by the Scribes will remain at all times within the premises of the Augmedix Designated Facility. Augmedix and Scribes
will not remove any hardware from the Augmedix Designated Facility premises.

 

		(8)	Augmedix
shall provide appropriately configured Augmedix Google Glass devices, loaded with Software. Augmedix shall replace this hardware
as needed and to offset normal hardware wear and tear. If Client so chooses to utilize prescription lenses for a particular Authorized
User, Augmedix shall supply the appropriate frames for the Authorized User or the Client to pay for. The Authorized User or the
Client must then oversee the custom creation of lenses and installation. Augmedix shall make best efforts to assist with these
lens installation logistics. Augmedix shall also provide appropriate numbers of external batteries and USB cables.

 

		(9)	Augmedix
shall be responsible for ensuring the availability and functionality of sufficient Augmedix Google Glass Devices and other Hardware
to provide the Services under this Statement of Work. The Augmedix Google Glass Devices and other Hardware provided for the purpose
of the Agreement are owned by Augmedix and will be provided and supported entirely by Augmedix.

 

		(10) 	Augmedix
shall work together with Client to develop appropriate patient education materials and associated training.

 

		(11) 	Augmedix
shall provide Standard Operating Procedure (SOP) to configure Google Glass to the Augmedix specification utilizing Client Network.

 

		(12) 	Augmedix
shall provide invoices to Client in a timely matter. Augmedix shall also respond to billing inquiries promptly and thoroughly.

 

		(13) 	Augmedix
shall ensure each Scribe is properly trained on Client’s EHR and Client’s data entry standards and policies associated
with such data entry and EHR access.

 

		(14) 	Augmedix
shall obtain the name and contact information of the office manager and/or clinic director for each physician for which Services
are performed and shall include that information in each invoice.

 

    	SFO-[160980]	Page 3

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

		d.	Client Responsibilities

 

		(1)	Client will provide the remote login capabilities for the
Scribe to access the EHR and the patient schedule, subject to Augmedix’s and each Scribe’s compliance with all applicable
policies and procedures of Client. Client shall also
provide the necessary will infrastructure and bandwidth to access the internet from Client facilities, as agreed by the parties
in writing.

 

		(2)	Client-designated
personnel will provide Standard Operating Procedure (SOP) on Accessing EHR Remotely.

 

		(3)	Client-designated
personnel will assist Augmedix in installing and configuring the Software onto the Augmedix’s hardware.

 

		(4)	Client
will work together with Augmedix to develop patient education materials.

 

		(5)	Client
will provide training to Augmedix personnel pertaining to the use of EHR software.

 

		(6)	Client
will arrange for appropriate access and related credentials for Scribes and Scribe trainers to access the EHR and related software.

 

		(7)	(Intentionally
omitted)

 

		(8)	Client
will designate one or more person(s) at each Client Facility for administrative duties in SOP, Administrative Duties include:

 

		●	Nightly
collection of devices (Glass units, battery packs, etc.) for charging and secure storage.

 

		●	Daily
distribution of devices for utilization.

 

		●	Handover
of Google Glass units to visiting Augmedix personnel for the purposes of software upgrades, audits, or research.

 

		●	Participation
on Augmedix or Client initiated audits for the purposes of security or asset verification

 

		●	Point
of Contact for Incident Reporting and Client/Augmedix issue resolution.

 

		(9)	Client
will be responsible for providing patient education in accordance with applicable laws and regulations. Without limiting the foregoing,
Client will make available to patients the education materials, including FAQs, provided by Augmedix and approved in writing by
Client. The parties agree to cooperate in timely and jointly reviewing such materials. Client will designate one or more persons
at each authorized facility in SOP to administer patient education process for all patients to be seen by an Authorized User.
In the event that a patient wishes for the Augmedix Solution to be partially or completely disabled / removed, the Client is responsible
for adhering to stated patient preferences. Augmedix shall provide training and support to assist Client with these circumstances.

 

		(10) 	Client
will designate one or more persons at each authorized facility in SOP to provide Augmedix with long-term and short-term schedules
for Authorized Users listed in the SOP.

 

		(11) 	Client will provide full EHR audit-trail access to Augmedix.
This permits Augmedix to see the precise character-by-character changes made to the EHR (by providers, scribes. other staff, or
other systems), with time-stamps and user logs. This access should permit visibility into all EHR documentation associated with
the providers listed in the SOP, but subject, however, to the role-based access provided by Client.

 

		(12) 	Client
is responsible for securing and safeguarding Augmedix-provided Augmedix Google Glass Devices, batteries, and related accessories.
If these Google Glass units or related accessories are lost or damaged through usage beyond mere day-to-day use and such loss
or damage amounts to negligence by Client, the replacement costs will be billed to the Client.

 

		(13) 	Either
party may require Authorized Users to wear Augmedix Google Glass Devices while seeing patients for as much as two weeks prior
to scheduled initiation of service for that particular Authorized User, This requirement will he upon the request of either party,
as reasonably necessary, in an effort to efficiently train Scribes. Each party will ensure that its personnel will comply with
these requirements.

 

    	SFO-[160980]	Page 4

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

		e.	Software

 

		(1)	License.
                                         Subject to the terms and conditions of this Agreement, Augmedix hereby grants Client
                                         and its affiliates, and Client hereby accepts on behalf of itself and its affiliates,
                                         a non-exclusive, nontransferable license for Client and its Authorized Users to use the
                                         Augmedix Solution and Documentation for the term of this SOW. For the avoidance of doubt,
                                         the Software may be used on a concurrent user basis. In addition. Client may retain a
                                         copy of all Documentation for its records in perpetuity.

 

		(2)	Restrictions.
                                         Without the prior written consent of Augmedix, Client and its affiliates agree not
                                         to (nor assist or encourage third parties to): (a) sell, rent, lease, lend, license,
                                         sublicense, distribute or otherwise transfer the Software or Documentation to any third
                                         party; (b) decompile, disassemble or reverse engineer the Software, in whole or in part;
                                         (c) write or develop any derivative software or any other software program based upon
                                         the Software, the Documentation or any Augmedix Confidential Information: (d) use the
                                         Software to provide processing or other services to third parties, or otherwise use the
                                         Software on a “service bureau” basis; or (e) provide, disclose, divulge or
                                         make available to, or permit use of the Software or Documentation by any third party
                                         without Augmedix’s prior written consent. The Software contains Embedded Software
                                         and Client will comply with any applicable license terms and conditions as set forth
                                         in Section 2(e)(1) of this SOW.

 

		(3)	Embedded
Software Terms and Conditions.

 

		●	Prior
                                         to commencement of the Project, Augmedix shall notify Client in writing of all Embedded
                                         Software and provide for Client’s review their associated terms and conditions
                                         (“Embedded Software Licenses”). As Client proceeds with expansion,
                                         Client agrees to comply with all such Embedded Software Licenses that are reasonably
                                         acceptable to it, which are required to use the Software licensed by Augmedix hereunder.

 

		●	In
addition to the terms and conditions of the Embedded Software Licenses, Client acknowledges the following:

 

		●	EMBEDDED
SOFTWARE IS PROVIDED “AS IS” AND ANY EXPRESSED OR IMPLIED WARRANTIES, INCLUDING. BUT NOT LIMITED TO, THE IMPLIED WARRANTIES
OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE ARE DISCLAIMED. IN NO EVENT SHALL THE SUPPLIER OP ANY EMBEDDED SOFTWARE
OR ITS AUTHOR OR CONTRIBUTORS BE LIABLE FOR ANY DIRECT, INDIRECT, INCIDENTAL, SPECIAL, EXEMPLARY, OR CONSEQUENTIAL DAMAGES (INCLUDING,
BUT NOT LIMITED TO, PROCUREMENT OF SUBSTITUTE GOODS OR SERVICES; LOSS OF USE, DATA, OR PROFITS; OR BUSINESS INTERRUPTION) HOWEVER
CAUSED AND ON ANY THEORY OF LIABILITY, WHETHER IN CONTRACT, STRICT LIABILITY, OR TORT (INCLUDING NEGLIGENCE OR OTHERWISE) ARISING
IN ANY WAY OUT OF THE USE OF THIS SOFTWARE, EVEN IF ADVISED OF THE POSSIBILITY OF SUCH DAMAGE.

 

		●	Augmedix
relies on Embedded Software for proper operation of the Software. Augmedix hereby assigns all assignable warranties and services
provided by Embedded Software licensors to Client, if’ any.

 

		●	If
a problem with any Embedded Software affects the performance of the Software in accordance with Documentation. Augmedix shall
use commercially reasonable efforts to work with the Embedded Software licensor to resolve the problem.

 

		●	Augmedix
warrants that it has obtained all necessary rights for third party software required to operate the Augmedix Solution.

 

		●	Client further
                                                                                                                                               agrees to accept the applicable Google Terms of Use prior to its use of the Augmedix Google Glass Device. Furthermore, Client
                                                                                                                                               acknowledges that, to the extent permitted by applicable laws, Google shall have no liability for any damages, whether direct, indirect, incidental or consequential,
arising from the use of the Google Glass Device, and all warranties with respect to the Google Glass Device, including without
limitation, warranties for merchantability, fitness for a particular purpose, and non-infringement are hereby disclaimed.

 

    	SFO-[160980]	Page 5

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

3. Term
and Schedule of Work Milestones

 

		a.	Term.
                                         This SOW shall begin on its Effective Data and continue until terminated as provided
                                         in the Agreement. Such term shall be referred to as the “Term” of the SOW.

 

		b.	Milestones:

 

		i.	Services and Deliverables are fully implemented and Scribes
are ready to begin full performance under this SOW.

 

		ii.	Acceptance of the Services and Deliverables by each applicable
physician and the office manager for each such physician.

 

		iii.	Payment for each physician does not begin until acceptance
as described above and go-live have occurred.

 

4. Fees;
Schedule; Invoicing

 

		a.	Fees.

 

		i.	Fees
will be charged and assessed for Authorized User beginning on the go-live date, but not before such date unless otherwise agreed
by the parties.

 

		ii.	Augmedix
and Client shall by mutual agreement classify Authorized Users into the following billing categories, based on the expected number
of service hours used:

 

	Billing
    Category.	 	Monthly
    Charge*
	[*]	 	[*]
	[*]	 	[*]
	[*]	 	[*]
	[*]	 	[*]
	[*]	 	[*]
	[*]	 	[*]

 

		*	Augmedix shall bill the Client for each Authorized User
at the applicable rate set foal above.

 

		*	If Client has
Authorized Users using over 140 service hours per month. such extra service hours shall be billed to Client at a rate of [*] per
service hour used over the 140 hour allocation.

 

		*	These fees may not be changed in the event Augmedix is
unable to use Scribes outside the jurisdiction of the United States of America as a result of Security Incident.

 

		iii.	At 90 days
after the initial classification of Authorized Users into billing categories, and every 90 days thereafter, Augmedix reserves
the right to re-classify an Authorized User into a different billing category if such Authorized User uses, on average, more than
the upper limit or less than the lower limit of service hours based on his/her last billing category classification for each such
90 day period. By way of example, an Authorized User who was classified as “Up to 110 service hours per month” before
the go-live date but on average has used 120 Service hours per month in the 90 days since the go-live date can be re-classified
by Augmedix to the “Up to 140 service hours per month” billing category and will incur a monthly charge of [*] for
the next 90 day period (and 90 day periods thereafter, assuming a similar 120 service hour per month usage).

 

    	SFO-[160980]	Page 6

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

		iv.	Fees
and charges paid by Client under this SOW are non-refundable. All payments will be made in US dollars.

 

		v.	Augmedix reserves
                                                                                                                                                                  the right to raise the fees incurred under this SOW by up to [*] upon the yearly anniversary of the Effective Date and every
                                                                                                                                                                  yearly anniversary thereafter.

 

		vi.	Augmedix
shall continue to provide the Services. free of charge, to the current Authorized Users of the DHMF Ventura clinic (“Free
Pilot”) through October 31, 2015. Augmedix and DHMF Ventura clinic shall mutually agree in writing to extend the Free
Pilot past October 31, 2015. For clarity, due to the unique history of the Free Pilot, this arrangement is provided only to the
current Authorized Users of the DHMF Ventura clinic and to no other Dignity Health or Dignity Health Medical Foundation entity
or affiliate.

 

		b.	Scheduling

 

Prior to initiation for each new Authorized User and each month
thereafter, Client shall provide a generic daily schedule for each Authorized User for each day of the following month (“Daily
Schedule”).

 

14 day written notice is required for schedule
changes. If less than 14 day written notice is received, Augmedix will make good faith efforts to accommodate such requests but
does guarantee availability of such service.

 

		c.	Invoicing

 

All amounts due will be invoiced monthly
in arrears in accordance with the Agreement and the terms of this SOW. In the event that service for a particular Authorized User
is canceled, any remaining balance will be reimbursed to Client or credited towards payment for another Authorized User.

 

5. Other Miscellaneous Terms and Conditions

 

		a.	Sales and Use Tax. The parties acknowledge that,
as of the Effective Date of this SOW, no law, rule or regulation requires any sales or use taxes to be due or payable as they
relate to the Service and Deliverables under this SOW. Therefore no such tax shall be due or included in invoices.

 

		b.	Tax Withholding Requirements. In accordance with
Section 4(c) of the Agreement, payments for services under this SOW may be subject to state tax withholding requirements. If the
services under this SOW include services performed or payable in California, Augmedix warrants and represents that it has completed,
signed and submitted to Client one of the following: (Check applicable box below)

 

		☐	California Franchise Tax Board Form 587 (Nonresident Withholding
Allocation Worksheet)

 

		☐	California Franchise Tax Board Form 590 (Withholding Exemption
Certificate)

 

		d.	Background
                                         Screening Requirements. As required by Section 11(d) of the Agreement, Augmedix represents
                                         and warrants that: (Check applicable box below):

 

☐ Augmedix has successfully completed
a criminal background check for each of its personnel and subcontractors providing services under this SOW and has provided Client
with documentation of such, in accordance with Exhibit E.

 

    	SFO-[160980]	Page 7

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

		e.	Insurance
                                         Compliance. Augmedix has provided Client with proof of insurance as required under
                                         Exhibit C of the Agreement.

 

(check applicable box below):

☐ Yes

☐ No (If no, explain
why not):

 

 

 

 

 

 

		f.	Deliveries.
                                         Unless specified otherwise by Client, all tangible deliveries, including reports
                                         shall be delivered only to the Client’s Business Sponsor or designee at Client’s
                                         address shown above.

 

    	SFO-[160980]	Page 8

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

IN WITNESS WHEREOF, the parties hereto have caused this Statement
of Work to be executed by their respective authorized representatives.

 

	Accepted and Approved by:	 	Accepted and Approved by:
	 	 	 
	Dignity Health Medical Foundation	 	Augmedix, Inc
	 	 	 
	/s/ Michael Stern	 	/s/ Pelu Tran
	Signature	 	Signature
	 	 	 
	Michael Stern	 	Pelu Tran
	Print Name	 	Print Name
	 	 	 
	Director, IT Contracting	 	Cofounder, President, Chief Customer Officer 
	Title	 	Title
	 	 	 
	9/17/15	 	9/17/15
	Date	 	Date

 

    	SFO-[160980]	Page 9

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

ATTACHMENT 1

 

TO EXHIBIT A 

 

DIGNITY HEALTH SCRIBE POLICY

 

 

    	SFO-[160927]
 Dignity Health -- Augmedix. Inc. SOW	  

Page 10 of 10

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

Scribe Services

100.2.001

 

DIGNITY HEALTH

ADMINISTRATIVE POLICY AND PROCEDURE

 

	FROM:	Dignity Health Care Management
	 	 
	SUBJECT:	Scribe Services
	 	 
	EFFECTIVE DATE:	January 17, 2012
	 	 
	REVISED:	May 12, 2010
	 	 
	ORIGINAL EFFECTIVE DATE: 	May 12, 2010
	 	 
	REPLACES:	 
	 	 
	APPLIES TO:	System Offices:	☐	 
	 	Acute Care Entities:	☒	 
	 	Non-acute Care Entities:	☒	 

 

		I.	POLICY:

 

Physicians may be permitted to utilize the services of qualified,
trained and competent clerical staff referred to as scribes (“Scribes”) to improve medical record documentation speed
and accuracy. The supervising physician is ultimately responsible for all documentation in the medical record. including the entries
made by the Scribes. The supervising physician must ensure that all documentation in the medical record conforms with Hospital
policy, the requirements of the Joint Commission and applicable legal requirements. Under no circumstances may Scribes provide
clinical services.

 

		II.	PURPOSE:

 

The purpose of this policy is to establish Dignity Health requirements
for the use of Scribes in a clinical setting at Dignity Health facilities.

 

		III.	PROCEDURES:

 

		A.	Scribes are not licensed healthcare providers and do not
perform any clinical or medical tasks (no direct patient care). The supervising physician is responsible for all medical care
provided to the patient. It is the responsibility of the supervising physician to ensure that the Scribe does not perform any
clinical or medical task. To avoid confusion. Scribes shall not be given any title that includes the word “clinical.”

 

    	Page 1 of 4
Effective: January 17, 2012
	 

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

Scribe Services

100.2.001

 

		B.	Scribes
may accompany the physician or non-physician provider (NPP) during his/her duties, including patient care. The supervising physician
or NPP must introduce the Scribe to each patient upon initial presentation.

 

		C.	The
Scribe’s duties must be performed under direct supervision of the physician. He/she may not act independently of the supervising
physician.

 

		D.	Scribes
assist the physician and NPP staff by making entries into the medical record. Scribes will function as transcriptionists and transcribe
verbal or written information provided by the physician or NPP directly into the hospital medical record or any written documentation
forms used by the Hospital. The medical record may be electronic or paper. All entries must be legible.

 

		E.	All
medical records that contain documentation by a Scribe must be reviewed and approved by the supervising physician and contain
countersignature with date and time stamp in the form of an attestation statement indicating that the supervising physician has
reviewed the entries, agrees with the entries and approves the entries made by the Scribe as if the entries were directly written
by the supervising physician. The attestation must read, at a minimum: “I have read the [medical record] [Scribe entries).
I approve the care and treatment provided to this patient. as recorded by the Scribe(s).” Such review and approval must
be signed and dated by the physician before the patient is discharged or transferred from the Hospital department where the patient
is receiving care (e.g., the Emergency Department).

 

		F.	If
the Scribe is performing services for an NPP. the NPP must ensure that the entries made by the Scribe accurately reflect the NPP’s
services for the patient. In such cases. the Scribe entries related to the NPP’s activities must be signed, dated and timed
by the NPP before the patient is discharged or transferred from the Hospital department where the patient is receiving care.

 

		G.	The
Scribe’s job duties may include only the following, as requested by the physician or NPP:

 

		1.	The
Scribe may document the history of present illness (HPI) and physical examination (PE) performed by the physician or NPP, as dictated
by the physician/NPP.

 

		2.	The
Scribe may document procedures performed by the physician or NPP, as dictated by the physician/NPP.

 

    	Page 2 of 4
Effective: January 17, 2012
	 

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

Scribe Services

100.2.001

 

		3.	The
Scribe may record procedures performed by the physician or NPP, results, progress notes and information for the physician treatment
records, as dictated by the physician/NPP.

 

		4.	The
Scribe may transcribe proper diagnoses and discharge/follow-up instructions, as dictated by the physician/NPP.

 

		5.	The
Scribe may provide the patient with pre-printed questionnaire regarding the patient’s past medical, social and family history.

 

		6.	The
Scribe may check on progress of lab, x-ray or other test/evaluations in order to expedite physician/NPP decision making regarding
the patient.

 

		7.	The
Scribe may retrieve reports and other information and present them to the physician/NPP in printed or electronic format for physician/NPP
review.

 

		8.	The
Scribe may access medical records on behalf of the supervising physician/NPP for treatment purposes only.

 

		9.	The
Scribe may only sign-on to any electronic medical record using the Scribes individual log-on and password.

 

		10.	The
Scribe may fax treatment summaries to the patient’s private physician or next provider(s) of care and document such faxing
in the medical record.

 

		11.	The Scribe may provide simple kindnesses. without any clinical
impact, for patients (for example: obtaining a blanket for a patient).

 

		H.	The following activities are prohibited:

 

		1.	The
Scribe may not transcribe or write any orders into the medical record.

 

		2.	The
Scribe may not write prescription orders for the physician/NPP to sign.

 

		3.	The
Scribe may not ask the patient any questions about the patient’s medical condition, medical history, family history or anything
else that is related to the patient’s treatment or reason for visiting the hospital.

 

		4.	The
Scribe may not provide any services that are within the scope of practice of a licensed health practitioner.

 

		5.	The
Scribe may not access or view confidential laboratory results.

 

		I.	The Scribe must meet the Dignity Health Human Resources
requirements for contractors working in the Hospital, including HIPAA privacy training and criminal background checks. Meeting
these requirements is the responsibility of the Scribe’s employer. A Hospital should cross-reference its applicable Human
Resource policies regarding the health and background screenings required of third-party contractors working in the Hospital.

 

    	Page 3 of 4
Effective: January 17, 2012
	 

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

Scribe Services

100.2.001

 

		J.	A
hard copy verification of the qualification and requirement standards must be maintained on site at the Hospital and be readily
available, including acknowledgement of all trainings and a copy of the Hospital Network Usage Policy signed by the Scribe.

 

		K.	The
Scribe will be given appropriate access to the electronic or paper medical record. The Hospital Medical Staff office will provision
the Scribes for the electronic medical record entry. in accordance with this policy. The Scribe will not have access to any computerized
order entry and will only be able to chart in the electronic medical record or paper record. The Scribe role will be regularly
audited according to Dignity Health auditing policies.

 

		L.	All
relationships with Scribes and/or Scribe Programs must receive Legal Department review prior to becoming operational.

 

    	Page 4 of 4
Effective: January 17, 2012
	 

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

EXHIBIT B

PRICING

 

		a.	Fees will be charged and assessed for Authorized User beginning
on the go-live date, but not before such date unless otherwise agreed by the parties.

 

		b.	Augmedix and Client shall by mutual agreement classify
Authorized Users into the following billing categories, based on the expected number of service hours used:

 

	Billing
    Category	 	Monthly
    Charge*
	[*]	 	[*]
	[*]	 	[*]
	[*]	 	[*]
	[*]	 	[*]
	[*]	 	[*]
	[*]	 	[*]

 

		*	Augmedix shall bill the Client for each Authorized User
at the applicable rate set forth above.

 

		*	If Client has Authorized Users using over 140 service hours per month. such extra service
                                                                                 hours shall be billed to Client at a rate of [*] per service hour used over the 140 hour allocation.

 

		*	These fees may not be changed in the event Augmedix is
unable to use Scribes outside the jurisdiction of the United States of America as a result of Security Incident.

 

		c.	At 90 days after
                                                                                                                                                              the initial classification of Authorized Users into billing categories, and every 90 days thereafter, Augmedix reserves the
                                                                                                                                                              right to re-classify an Authorized User into a different billing category if such Authorized User uses, on average, more than
                                                                                                                                                              the upper limit or less than the lower limit of service hours based on his/her last billing category classification for each
                                                                                                                                                              such 90 day period. By way of example, an Authorized User who was classified as “Up to 110 service hours per
                                                                                                                                                              month” before the go-live date but on average has used 120 Service hours per month in the 90 days since the go-live
                                                                                                                                                              date can be re-classified by Augmedix to the “Up to 140 service hours per month” billing category and will incur
                                                                                                                                                              a monthly charge of [*] for the next 90 day period (and 90 day periods thereafter, assuming a similar 120 service hour per
                                                                                                                                                              month usage).

 

		d.	Fees
and charges paid by Client under this SOW are non-refundable. All payments will be made in US dollars.

 

		e.	Augmedix reserves
                                                                                                                                                              the right to raise the fees incurred under this SOW by up to [*] upon the yearly anniversary of the Effective Date and every
                                                                                                                                                              yearly anniversary thereafter.

 

    	SFO-154607	20

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

EXHIBIT C

INSURANCE

 

A. General Requirements.
Within ten days after the Effective Date or upon request, Augmedix shall provide to Dignity Health evidence of all insurance
required hereunder. All policies and certificates of insurance will be written as primary policies with Services performed
and deliverable items produced by Augmedix and its subcontractors and not written as policies contributing to, or to be used
in excess of Dignity Health’s insurance policies or any self-insurance program in which Dignity Health may participate
with respect to such Software and Services. The insurance requirements under this section are mandatory; failure of Dignity
Health to request certificates of insurance will not constitute a waiver of Augmedix’s obligations and requirements to
maintain the minimal coverage’s specified. In the event of any modification, termination, expiration, non-renewal or
cancellation of any of such insurance policies, Augmedix shall give written notice thereof to Dignity Health not more than
ten (10) days following Augmedix’s receipt of such notification. In the event Augmedix fails to procure. maintain or
pay for the insurance required under this section, Dignity Health will have the right, but not the obligation, to obtain such
insurance. In such event, Augmedix shall promptly reimburse Dignity Health for the cost thereof upon written request, and
failure to repay the same upon demand by Dignity Health will constitute a material breach of the Agreement.

 

B. Types and Amounts. During the
term of this Agreement, and at its own cost and expense, Augmedix shall obtain and maintain the following insurance coverages
or self-insurance:

 

		●	Commercial
General Liability insurance, including products/complete operations and advertising injury coverage, with a minimum combined single
limit of [*] per occurrence and minimum general annual aggregate limit of [*];

 

		●	Comprehensive
professional liability insurance covering the liability for financial loss due to error, omission or negligence of Augmedix, with
a minimum amount of [*] and not less than [*] in the annual aggregate;

 

		●	Workers’
compensation insurance and other insurance as required by statutes in the states in which the work will be performed. Coverage
will include Employers Liability with a limit not less than [*]  for each occurrence;

 

		●	Business
Automobile Liability Insurance covering owned, non-owned and hired vehicles with a combined single limit of not less than [*]
per accident for bodily injury and property damage; and

 

		●	Network
Security Liability and Privacy Liability including expenses associated with data breach, cyber-crime, cyber-security and related
thereto the investigation, remediation, notification costs, credit monitoring, call center expenses, public relations expenses
and legal costs in an amount not less than [*] per occurrence and [*] annual aggregate.

 

    	SFO-154607	21

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

If Augmedix purchases “claims made”
insurance, all acts and omissions of Augmedix and its representatives and agents, will be, during the term of this Agreement, “continually
covered” notwithstanding the termination of this Agreement or the provisions of this Agreement allowing Augmedix to purchase
“claims made” insurance coverage. In order for the acts and omissions of Augmedix and its representatives and agents
to be “continually covered” there must be insurance coverage for the entire period commencing on the Effective Date
of this Agreement and ending on the date that is at a minimum of three (3) years after the final date that this Agreement is effective,
including any extensions or renewals hereof, and such insurance must satisfy the liability coverage requirements provided for in
this Agreement. Augmedix acknowledges and agrees that the provisions of this Exhibit C may require Augmedix to purchase “tail
insurance” if its coverage lapses or “nose insurance” and/or “tail insurance” if Augmedix changes
insurance carriers, even after this Agreement is terminated.

 

Subcontractors. Augmedix agrees
to require any Subcontractor it uses to perform work at Client’s premises, if any, to carry, or Augmedix shall carry on
behalf of said Subcontractors, at a minimum, the following limits of insurance:

 

	 	●	Workers’ Compensation and other insurance in the amount required by statute in the state in which the work will be performed;

 

	 	●	Commercial
General Liability Insurance, including independent contractors coverage, written on a broad form basis in a combined single limit
of [*] per occurrence with an annual aggregate of not less than [*]; and

 

	 	●	Business
Automobile Liability Insurance, if applicable, covering any auto with a combined single limit of not less than [*].

 

Policy Requirements. Client will
be listed on all such insurance policies obtained by Augmedix (except Worker’s Compensation) as “Additional Insureds”
up to the amount required of Augmedix in this Exhibit C. Augmedix shall similarly require certain Subcontractors to list Client
as “Additional Insureds” if Augmedix does not carry on behalf of such Subcontractors the insurance required in this
Exhibit C. The provisions of this Exhibit C will not be deemed to limit the liability of Augmedix hereunder, or limit any rights
that Client or any Client affiliates may have, including, rights of indemnity or contribution. Notwithstanding any other provisions
of this Agreement, the provisions of this Exhibit C will survive termination of this Agreement.

 

    	SFO-154607	22

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

EXHIBIT D

BUSINESS ASSOCIATE EXHIBIT

 

The parties agree that, under this Exhibit, Augmedix (“Business
Associate”) shall have all the rights and obligations of a “Business Associate,” as defined in HIPAA (defined
below), and Dignity Health (“Dignity Health”) affiliated covered entity, which includes Client (“Covered
Entity”), shall have all the rights and obligations of a “Covered Entity,” as defined in HIPAA.

 

1. Definitions. All capitalized
terms not defined herein shall have the meaning ascribed to them by HIPAA (defined below), including Business Associate, Covered
Entity, Limited Data Set, Data Aggregation and Designated Record Set.

 

(a) “Breach”
shall mean the unlawful or unauthorized access to, viewing, acquisition, use or disclosure of PHI.

 

(b) “HIPAA”
shall mean the Health Insurance Portability and Accountability Act of 1996 (Public Law 104-191), Title XIII of the American
Recovery and Reinvestment Act of 2009 (Public Law 111-005) and the rules, guidance and regulations promulgated thereunder, as amended
from time to time, including 45 Code of Federal Regulations, Parts 160 and 164.

 

(c) “Patient”
shall have the same meaning as the term “individual” under HIPAA and shall include a person who qualifies as a
personal representative.

 

(d) “Protected
Health Information” (“PHI”) shall have the meaning given to such term under HIPAA and shall include any information,
whether oral or recorded in any form or medium, limited to the information created or received by Business Associate from or on
behalf of Covered Entity (i) that relates to the past, present or future physical or mental health condition of the patient, the
provision of health care to patient, or the past, present or future payment for the provision of health care to patient; and (ii)
that identifies the patient or with respect to which there is a reasonable basis to believe the information can be used to identify
the patient.

 

(e) “Secretary”
shall mean the Secretary of the U.S. Department of Health and Human Services or her/his designee.

 

(f) “Security
Incident” shall mean any accidental, malicious or natural act that: (i) Results in a Breach of any PHI or credit card
information; or (ii) Adversely impacts the functionality of the Dignity Health network; or (iii) Permits unauthorized access to
the Dignity Health network; or (iv) Involves the loss or loss of control of a Dignity Health owned or managed information technology
resource; or (v) Involves the use of Dignity Health technology resources for illegal purposes or to launch attacks against other
individuals or organizations; or (vi) Impacts the integrity of Dignity Health’s files or databases including, but not limited
to: (1) interface failures; (2) inadequate testing or change control procedures; or (3) other failures which result in the deletion
or unauthorized changes to an electronic database. A “Security Incident” shall not include any attempted access of
system operations in an information system by a Packer Internet Groper (PING) program.

 

    	SFO-154607	23

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

(g) “State” shall
mean the state in which the Covered Entity is located.

 

(h) “Subpart
E” shall mean 45 Code of Federal Regulations, Part 164. Subpart E, which consists of Sections 164.500 et seq., as amended
from time to time.

 

2. Permitted Uses and Disclosures by Business Associate

 

(a) For Covered
Entity. Except as otherwise limited in the Agreement and this Exhibit, Business Associate (i) shall create, maintain, transmit,
access, use or disclose PHI only for the benefit of Covered Entity and to Perform functions, activities, or services as specified
in the Agreement, and (ii) shall not use or disclose PHI in a manner that would violate HIPAA if done by Covered Entity. To the
extent Business Associate is to carry out one or more of Covered Entity’s obligations under Subpart E of 45 CFR Part 164,
Business Associate shall comply with the requirements of Subpart E that apply to Covered Entity in the performance of such obligations.

 

(b) Minimum
Necessary. Business Associate shall use only the minimum amount of PHI necessary to perform the specified functions, activities
or services, in accordance with Covered Entity’s minimum necessary policies and procedures. In the event of inadvertent
access by Business Associate to more than the minimum necessary amount of Covered Entity’s PHI, Business Associate will:
(i) treat all such PHI in accordance with the Agreement and this Exhibit; (ii) promptly notify Covered Entity, in accordance with
paragraph 3(d) below, of such access; (iii) erase, delete, and/or return such PHI as quickly as possible; and (iv) take all necessary
actions to prevent further unauthorized access to PHI beyond the minimum necessary amount.

 

(c) Management
of Business Associate. Except as otherwise limited in the Agreement or this Exhibit, Business Associate may use or disclose
PHI for its proper management and administration or to carry out its legal responsibilities, provided that (i) the disclosure
is required by law, or (ii) the Business Associate obtains reasonable assurances from the person to whom the information is disclosed
that such information shall remain confidential and be used or further disclosed solely as required by law or for the purpose
of assisting Business Associate to meet Business Associate’s obligations under the Agreement. Business Associate shall require
any person to whom PHI is disclosed under this subsection to notify Business Associate of any instance of which it is aware in
which the confidentiality or security of the PHI has been breached.

 

(d) Data
Aggregation. Except as otherwise permitted in the Agreement and this Exhibit, Business Associate may use PHI to provide Data
Aggregation services only for Covered Entity.

 

(e) Compliance
with State Laws. Business Associate may use, disclose and access PHI only as permitted by State law, unless such State law
is contrary to HIPAA and is preempted by HIPAA in accordance with 45 Code of Federal Regulations Sections 160.201 et seq.

 

    	SFO-154607	24

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

3. Obligations of Business Associate

 

(a) Use.
Business Associate shall not use or disclose PHI other than as permitted or required by the Agreement, this Exhibit or as
required by law.

 

(b) Safeguards.
Business Associate shall use appropriate safeguards to prevent use or disclosure of PHI other than as provided for by the
Agreement and this Exhibit. Business Associate shall implement administrative, physical and technical safeguards that reasonably
and appropriately protect the confidentiality, security, integrity and availability of PHI that it receives, maintains, transmits
or creates on behalf of Covered Entity and that comply with the requirements of HIPAA. In addition, if Business Associate conducts
credit card transactions (i) such safeguards shall consist of or include the recommendations of the Payment Card Industry Data
Security Standards, found at https://www.pcisecuritystandards.org and (ii) Business Associate shall not store security
code (i.e. CVC) information or credit card magnetic strip information in any form.

 

(c) Mitigation.
Business Associate shall promptly mitigate, to the extent practicable, any harmful effect of a use or disclosure of PHI by
Business Associate in violation of the Agreement and this Exhibit.

 

(d) Notify
Covered Entity. Business Associate shall promptly notify Covered Entity of any Security Incident or Breach in writing in
the most expedient time possible, and not to exceed forty-eight (48) hours in the event of a Breach, following Business
Associate’s initial awareness of such Security Incident or Breach. Notwithstanding any notice provisions in the
Agreement, such notice shall be made to the Dignity Health Chief Privacy Administrator or his/her designee by means of fax to
[*] or by email to [*]. Business Associate shall cooperate in good faith with Covered Entity in the investigation of any
Breach or Security Incident.

 

(e) Breach
Notification. Following notification to Covered Entity of a Breach, Business Associate shall promptly cooperate with Covered
Entity in determining which entity shall provide any required Breach notification. If the parties agree that Business Associate
shall provide any required Breach notification, Business Associate shall provide such notification timely and provide Covered
Entity with documentation of Business Associate’s actions, including documentation of the names and addresses of those to
whom the notifications were provided.

 

(f) Access. If Business Associate
holds PHI in Designated Record Sets as determined by Covered Entity, Business Associate shall provide prompt access to the PHI
to Covered Entity whenever so requested by Covered Entity, or, if directed by Covered Entity, to a Patient in order to meet the
requirements. of HIPAA and State Law, as applicable. If requested, such access shall be in electronic format. If Patient requests
directly from Business Associate (i) to inspect or copy his or her PHI, or (ii) requests its disclosure to a third party, the
Business Associate shall promptly notify Covered Entity’s facility privacy official of such request.

 

    	SFO-154607	25

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

(g) Amendments. Business Associate
shall promptly make amendment(s) to PHI requested by Covered Entity and shall do so in the time and manner requested by Covered
Entity to enable it to comply with HIPAA and State Law, as applicable. If Patient requests an amendment to his or her PHI, directly
from Business Associate, the Business Associate shall promptly notify Covered Entity’s facility privacy official of such
request and await such official’s denial or approval of the request.

 

(h) internal Records.
Business Associate shall promptly make its internal practices, books, records, including its policies and procedures, relating
to the use, disclosure, or security of PHI that the Business Associate received from, maintained or created for or on behalf of
Covered Entity, available to Covered Entity or the Secretary, in a time and manner designated by Covered Entity or the Secretary,
to enable the Secretary to determine compliance with HIPAA.

 

(i) Accountings.
Business Associate shall document all disclosures of PHI and information related to such disclosures as required under HIPAA
in order that it may provide an accounting of such disclosures as Covered Entity directs. Business Associate shall: (i) Provide
an accounting as required under HIPAA to those Patients who direct their requests to Business Associate; or (ii) Provide the accounting
information required under HIPAA to Covered Entity, if so requested by Covered Entity, in the time and manner specified by Covered
Entity.

 

(j)
Preservation. Business Associate shall cooperate with Covered Entity and its medical staff to preserve and protect the
confidentiality of PHI accessed or used pursuant to the Agreement and shall not disclose or testify about such information
during or after the termination of the Agreement, except as required by law.

 

(k) Destruction. If, during
the term of the Agreement, Business Associate wishes to destroy the PHI, it shall notify Covered Entity in writing about its intent
to destroy data at least ten (10) days before such date of destruction, and shall comply with the requirements for destruction
of PHI found in Section 5(a) of this Exhibit. If Covered Entity requests the return of any PHI, Business Associate shall comply
as requested.

 

(l) HIPAA Compliance. Business
Associate shall comply with 45 Code of Federal Regulations Part 164, Subpart C with respect to electronic PHI. The written policies
and procedures and documentation required to be maintained by Business Associate under the Agreement, this Exhibit and HIPAA shall
be made available to Covered Entity, upon Covered Entity’s request.

 

4. Effect of Breach of Obligations.
If Business Associate breaches any of its obligations. Covered Entity shall have the option to do the following:

 

(a) Cure. Provide
Business Associate an opportunity to cure the breach, to the extent curable, and end the violation within a reasonable time specified
by Covered Entity. If Business Associate does not cure the breach or end the violation as and within the time specified by Covered
Entity, or if the breach is not curable, Covered Entity may terminate the Agreement; or

 

(b) Termination.
Immediately terminate the Agreement, if Covered Entity reasonably determines that Business Associate (1) has acted with gross
negligence in performing its obligations; (2) has willfully violated or is violating the privacy and security provisions of this
Exhibit or HIPAA; or (3) is unable to provide, if requested, written assurances to Covered Entity of its ability to protect the
confidentiality and security of the PHI. Such termination of the Agreement shall be without prejudice to other legal remedies
available to Covered Entity.

 

    	SFO-154607	26

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

5.
Effect of Termination

 

(a)
Disposition of PHI.  Upon termination of the Agreement and subject to Section 5(b) below, Business Associate shall
promptly return to Covered Entity a copy of all PHI, including derivatives thereof, and shall take all reasonable steps to
promptly destroy all other PHI held by Business Associate by: (i) shredding; (ii) securely erasing, or (iii) otherwise
modifying the information in those records to make it unreadable or undecipherable through any means. This provision shall
apply to PHI in the possession of subcontractors or agents of Business Associate. At Covered Entity’s request, Business
Associate shall certify in writing that it has complied with the requirements of this Section.

 

(b)
Infeasible; Survival. If the return or destruction of PHI is infeasible. Business Associate shall promptly notify Covered
Entity of the conditions that make such return or destruction infeasible. Upon mutual determination by the parties that return
or destruction of PHI is infeasible, the obligations of the Business Associate under this Exhibit shall survive the termination
of this Agreement. Business Associate shall limit the further use or disclosure of all PHI to the purposes that make its return
or destruction infeasible. If Business Associate subsequently wishes to destroy PHI, Business Associate shall notify Covered Entity
in writing about its intent to destroy data at least ten (10) days before such date of destruction, and shall comply with Section
5(a) above. If Covered Entity requests the return of any PHI, Business Associate shall comply as requested.

 

6.
Credit Monitoring. In the event that either party is required by law to notify individuals whose PHI was inappropriately
accessed, used, or disclosed by Business Associate, its employees, subcontractor(s) or its agents, and the PHI contains: (i)
the individual’s first initial or first name, last name, and social security number; (ii) the individual’s first initial or
first name, last name, and driver’s license or state identification card; (iii) the individual’s first initial or first name,
last name, account number, credit or debit card number, in combination with any required security code, access code, or
password that would permit access to an individual’s financial account; and/or (iv) the individual’s first initial or first
name, last name, and PHI, then Business Associate and Covered Entity shall work together to structure a credit monitoring
offering commensurate to the risk posed by the breach and Business Associate shall, in any event, pay the costs of credit
monitoring for one (1) year for such individuals and the costs and fees related to timely notification in accordance with
law.

 

7.
Amendment. The parties agree to promptly modify or amend this Exhibit to permit parties to comply with any new laws,
rules or regulations that might modify the terms and conditions herein.

 

8.
General. The Agreement, including this Exhibit and attachments hereto are intended to be construed in harmony with each
other, but in the event that any provision in this Exhibit conflicts with the provisions of the Agreement, or its other
attachments, the provisions in this Exhibit shall be deemed to control and such conflicting provision or part thereof shall
be deemed removed and replaced with the governing provision herein to the extent necessary to reconcile the conflict, except
that the indemnity and insurance provisions of this Exhibit (if any) and the Agreement are to be read as separate, concurrent
obligations such that Business Associate shall comply with each obligation and one shall not replace the other.

 

    	SFO-154607	27

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

9.
Audits. Upon reasonable notice to Business Associate, Covered Entity shall have the right to inspect and audit Business Associate’s
privacy and security controls relating to Business Associate’s compliance with the terms of the Agreement, this Exhibit and HIPAA.
Business Associate may impose reasonable restrictions upon Covered Entity’s access to Business Associate’s premises information
systems, including but not limited to limiting access only to those information systems which contain Covered Entity’s PHI and
limiting access to ensure Business Associate’s compliance with existing confidentiality obligations to its other customers. Such
audits shall occur no more often than once per year or after any Breach or Security Incident and only upon a good faith belief
by Covered Entity that Business Associate is not in compliance with its obligations under the Agreement, this Exhibit or HIPAA
relating to Covered Entity’s PHI. All audits shall be conducted with the least interruption to Business Associate’s normal business
operations as feasible. Covered Entity shall be responsible for all costs incurred in order to perform the audit.

 

10.
No Third Party Beneficiary. The provisions and covenants set forth in this Exhibit are expressly entered into only by and
between Business Associate and Covered Entity, and are only for their benefit. Neither Business Associate nor Covered Entity intends
to create or establish any third party beneficiary status or right (or the equivalent thereof) in any other third party and no
such third party shall have any right to enforce or enjoy any benefit created or established by the provisions and covenants in
this Exhibit.

 

11.
Indemnity. Subject to Section 19 of the Agreement, Business Associate shall promptly and fully defend, indemnify and hold
harmless Covered Entity. its affiliates and respective officers, directors, agents and employees (“Indemnified Parties”)
against any claim, demand, liability, loss, fine, penalty, assessment, cost, judgment, award or attorney’s fees, related
to (i) the breach of this Exhibit by Business Associate, (ii) the negligent acts or omissions of Business Associate or any employee,
subcontractor, or agent of Business Associate, (iii) any related Breach, Security Incident or any cost of notification or remediation
relating to notifications required by law, (iv) any wrongful termination or any other claim or action against Covered Entity with
respect to the actual or constructive termination by Business Associate of any agent, business associate or personnel employed
or contracted by Business Associate, whether or not providing services under the Agreement and (v) any action to enforce this
Section (collectively, “Claims”). The Claims covered by this Section shall include Claims made or recovered
against the Indemnified Parties and Claims issued in favor of a third party. This Section shall survive the expiration or termination
of this Exhibit.

 

    	SFO-154607	28

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

EXHIBIT
E-1

DRUG
AND HEALTH SCREENING REQUIREMENTS

 

Augmedix
shall ensure that each of its Augmedix employees and contractors providing Services at any Client facility has met the following
requirements before providing the Services. Augmedix will perform all screening required by this Section at Augmedix’s own expense,
and Augmedix shall provide certification of completion of all screening upon request. The requirements are as follows:

 

i.
Drugs Screen. Negative result to a 10 panel drug screen (consistent with testing done on a Client facility’s employee, but no
less than 10 panel; provided, however, that the parties shall mutually agree on any testing required in excess of 10 panel). The
10 panel drug screen shall include screening for: Amphetamines, Barbituates, Benzodizepines, Cannabindoids (Marijuana), Cocaine
Metabolite. Methadone, Oxycodone, Opiates 2000, Phencyclidine and Propoxyphene.

 

ii.
Tuberculosis. A tuberculosis signs and symptoms questionnaire must be completed; and either (A), (B), or (C), as applicable: (A)
Two-step TB skin test (“TST”) for individuals with no history of a positive TST who have not been tested in
the last 12 months; (B) One-step TST for individuals with proof of a negative TST in the last 12 months; or (C) Chest radiograph
for individuals with proof of past positive TST.

 

iii.
Rubella: Documented receipt of one vaccination on or after 1st birthday, serology indicating immunity or documentation
of birth before 1957.

 

iv.
Rubeola: Documented receipt of two vaccinations on or after birthday, or serology indicating immunity.

 

v.
Chicken Pox: History, serology indicating immunity, or proof of vaccination.

 

vi.
Hepatitis B: Vaccines, or titer indicating immunity (positive HbsAb level at any point in time), or statement of refusal (consistent
with testing on Client facility employees).

 

vii.
Proof of flu vaccination within three (3) months prior to the First day of any individual providing Services at any Client facility
and annually thereafter, or written documentation of the individual declining such vaccination because of medical or religious
reasons. Notwithstanding any written documentation provided by an individual, if an individual declines to receive the vaccinations
set forth in this Section (vii), any Client facility where the individual provides Services may. in its sole discretion,
require the individual to wear protective clothing, masks, or take any other actions the Client facility deems necessary while
the individual is providing Services at such Client facility.

 

viii.
All other or different screens required by the applicable facility.

 

ix.
Documentation of completion of all immunizations and vaccinations.

 

    	SFO-154607	29

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

EXHIBIT
E-2

BACKGROUND
SCREENING GRID

 

	Scope / Applicable	Screening Type	General Description
	All Positions	Criminal History	Search of court records to identify past criminal conduct. Shows both misdemeanor and felony convictions.
	OIG/GSA Search	Identifies individuals listed by the government as excluded from participation in Medicare, Medicaid and other federal healthcare. Programs.
	Sex Offender Search	Identifies registered sex offenders (national database search)
	SSN Trace and Validation (or analogous validation in non-US jurisdictions)	Lists names and addresses associated with SSN and confirms validity of the SSN.
	Employment Verification	Verification directly from past employers including dates of employment, position & salary history.
	Reference Interview	Through personal interviews, obtains and reviews information regarding candidate’s capabilities and work history.
	Positions Director Level and Above	Professional License Verification	Verification with Licensing Board or Agency. Shows status, dates, to whom issued and whether adverse action has been taken against license.
	Education Verification	Verification of institution attended, dates of attendance, degrees and/or credential earned, and major area of study.
	Driving Positions	Motor Vehicle Records Examination	Shows motor vehicle driving violations, license suspensions, restrictions and revocations and driving related convictions. Varies by state.
	Vehicle Insurance Verification	Verification of vehicle insurance.
	Data Sensitive Positions (DSP) include:

            

1. Positions with access to credit card information and transactional systems from multiple transactions; 

2. Positions involving Payroll, Human Resources, Finance, Information & Technology, Security, and Compliance.	Civil History	Review of court records by name, county, or jurisdiction to detect law suits, restraining orders, and other civil court activity.
	Federal Civil Search	Search of court records to identify bankruptcies, tax liens and other adverse information.
	Credit History Examination	Identifies if an applicant has any accounts in collections, open loans, inquiries made by third parties, etc., by accessing credit bureau information.
	Federal Criminal History	Search of federal court records to identify past criminal conduct.
	Drug Testing / Health Screening	Tests for presence of some prescription and illegal substances as required by the Client facility where the Services are being provided. Confirm completion of those health screens required by the applicable Client facility.

 

    	SFO-154607	30

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

EXHIBIT F

BACKGROUND SCREENING SCORING GUIDELINES

 

Definitions

 

	 	●	Non-Conviction: Any disposition other than a plea of guilty, no contest or a finding of guilt. Non-Convictions can be one of three categories.

	 	o	Passing: Non-Conviction leading to charge being dismissed, Nolle Prosse, Nolle Prosequi, Expunged, Not Guilty verdict or acquittal of defendant.

	 	o	Failing: Any adjudication withheld/deferred where the charge was not dismissed, expunged, Nolle Prosse or Nolle Prosequi.

	 	o	Provisional: Any active or pending case.

	 	●	Passing Disposition: Any Non-Conviction disposition leading to the case being dismissed. None Prosse, Nolle Prosequi, Expunged, Not Guilty verdict or acquittal of defendant.

	 	●	Failing
    Disposition: Any disposition resulting in a Conviction or Non-Conviction (adjudication differed/withheld) that has not
    led to the case being dismissed or expunged.

 

Pass

Score all candidates as “Pass” for the following conditions:

	 	●	Any Misdemeanor or Felony crime with a Passing Disposition.

 

	 	●	Any misdemeanor (or lower) traffic violations (DUI is not considered a traffic violation).

 

	 	●	Any Misdemeanor with a disposition date older than 7 years, with the exception of any Misdemeanor violent crimes, nonconsensual sexual crimes, and crimes against children with a Failing Disposition.

 

	 	●	For Client facilities located in California:

 

	 	o	Any Misdemeanor Marijuana offense over 2 years old in the state of California.

 

Provisional (such
applicants may be approved for hire upon consultation with Client Human Resources and legal counsel) Score all candidates as
“Provisional” for the following conditions:

 

	 	●	Any Misdemeanor or Felony case that is currently active or pending.

	 	●	Any SSN Trace where SSN was reported used in Death Benefits Claim.

	 	●	Any outstanding warrants.

	 	●	Any Felony with a failing disposition that is greater than 7 years old.

	 	●	Any Misdemeanor crime with a Failing Disposition greater than 2 years*.

	 	●	Any Bankruptcy within the last ten years or tax liens, accounts past due or accounts in collections within the last seven years.

	 	●	Any other finding determined to be significant enough for further review.

 

Fail

Score all candidates as “Fail” for the following conditions:

 

	 	●	Any case with a Failing Disposition for Misdemeanor or Felony violent crimes, nonconsensual sexual crimes, and crimes against children regardless of elapsed time from disposition date.

	 	●	Any other Felony crime with a Failing Disposition within the last 7 years.

	 	●	Any Misdemeanor crime with a Failing Disposition within the last 2 years*.

	 	●	Any Controlled Substance Offense (misdemeanor or felony) with a Failing Disposition within the last 7 years*.

 

Client facilities in California:
Exclude misdemeanor marijuana convictions more than 2 years old.

 

Note: The above guidelines
shall be applied only upon individual review of each screening record and in any event in compliance with all applicable laws and
regulations.

 

    	SFO-154607	31

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

	Storage
    SOP	Effective
    DECEMBER 18, 2015.

 

Augmedix & Dignity Health.

Storage SOP.

 

This document serves as the SOP1 only
in regards to Content (as defined below) and Storage (as defined below) for Dignity Health and its Affiliates (as defined in the
Services Agreement) (all entities herein referred to as “Dignity”) and Augmedix as to services provided under
the Services Agreement dated July 15, 2015 (the “Services Agreement”) and any relevant SOWs entered into under
the Services Agreement between Augmedix and Dignity Health or Dignity Health Medical Foundation (the “SOWs”).

 

For clarity, this document fulfills the requirements
and serves as the master control document for Sections 6(f) and 18(c) of the Services Agreement, and as it relates to data retention
and Storage for Sections 1(a), 2(b)(2) and 2(b)(3) of the SOWs.

 

Previous History

 

When Augmedix first began providing services for Dignity, its
solution operated on a streaming-only basis – audio/video that was transmitted by the wearable device (in this case, Google
Glass) would be sent to its final destination without any caching or storing of the content. The same principle applied to any
content sent by Augmedix to a provider over the Google Glass unit. For the purposes of this SOP, “Content” refers
to the audio/video feed or images transmitted by the Augmedix-supplied device worn by the medical provider (“Google Glass”),
and information sent by a scribe to a medical provider on Google Glass, including Cards (as defined below). For purposes of
this SOP, Content explicitly excludes any metadata created by such transmissions.

 

Current Status in 2015

 

Augmedix uses Storage to improve and enhance the
services it is able to provide customers such as Dignity. “Storage” or “Stored” refers to
the caching/storage of Content in an encrypted format for up to 72 hours; such caching/storage may occur on the Google Glass
device or on a U.S.-based server owned by Augmedix or an appropriate third-party provider, as retained by Augmedix (at the time
of this SOP, such providers are Amazon Web Services and TrueVault).

 

Storage enables the following features, which would otherwise
not be available:

 

		●	WiFi
Continuity. Allows authorized Augmedix personnel (including personnel of authorized third party contractors) to view Content
in non-real time of its creation (for up to 72 hours) in order to fill in documentation
gaps or conduct QA that would otherwise not be possible due to network connectivity issues.

 

 

		1	As defined in Schedule 1, Item 12 of the Services Agreement.

 

     

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

	Storage
    SOP	Effective
    DECEMBER 18, 2015.

 

	 	●	Card Persistence. “Cards” are the manner by which scribes communicate with medical providers using Google Glass – text and/or images appear on the heads-up display of Google Glass. There are many instances where Cards need to be loaded and prepared either ahead of a patient visit or viewed by a provider after a patient visit. Card persistence allows these Cards to be Stored such that they can be accessed by a provider or authorized Augmedix personnel in non-real time from the creation of the cards. Cards may not be Stored for more than 72 hours.

 

	 	●	QA and Training. In order to assure excellent documentation for Dignity and scale the Augmedix solution for Dignity in a reliable way, authorized Augmedix personnel may view Content that has been Stored and produce draft workproduct that is Stored in order to facilitate such activities.

 

Data Retention 

 

Content, Cards, and draft workproduct (i.e. the text that is
written by a scribe to be entered into the EHR) is held only for up to 72 hours and may be deleted sooner than 72 hours. After
72 hours, settings are in place to automatically delete any such Content, Cards or draft workproduct that has been Stored.

 

Except as authorized, permitted or otherwise obligated
by the Services Agreement, SOW or Business Associate Agreement, such aforementioned Storage in its limited capacity is the only
data retained by Augmedix. The patient record is ultimately retained by Dignity in the EHR.

 

Limitations; Future Offerings

 

Currently, Augmedix does not have the technical capacity to
send digital copies of Content to Dignity – all Content can only be accessed through the Augmedix Scribe Portal by
authorized Augmedix personnel, and such Content is retained for only up to 72 hours. Both parties understand and acknowledge that,
except as required by law, requests for Content in a manner and form accessible by Dignity are by extraordinary exception outside
the scope of usual business or other understandings.

 

Augmedix understands that Dignity
may want to request and receive copies of Content in certain situations. Once such a capability is reached (a rough estimate suggests
Q4 2016), Augmedix will create a Content access protocol by which such Content can be requested, archived and securely delivered
to appropriate Dignity personnel.

 

Content access protocol is envisioned
to be as follows: in emergency situations, an authorized Dignity representative contacts Augmedix through the appropriate
channel as soon as possible, with the understanding that Content will be erased by the 72 hour mark. If such contact occurs
and Content is still available, Augmedix will take commercially reasonable efforts to set up a system in which requested
Content can be flagged, archived and securely delivered to appropriate Dignity personnel.

 

Disclaimer 

Notwithstanding anything to the contrary in this SOP, if any
party hereunder is obligated by applicable law to preserve the Content or otherwise notifies the other party of such obligation,
the parties shall cooperate to ensure the preservation of the Content for as long as necessary as required by applicable law.

 

REVIEWED AND APPROVED BY LEGAL COUNSEL OF BOTH AUGMEDIX
AND DIGNITY AS OF DECEMBER 18, 2015.

 

     

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

EXHIBIT A 

 

STATEMENT OF
WORK (SOW)

AUGMEDIX EXPANSION PROJECT

 

This Statement of Work (“SOW”),
entered into by and between Dignity Health Medical Foundation (a Dignity Health Affiliate) and Augmedix, Inc. (jointly “Parties”),
is effective as of July 15, 2015 (the “SOW Effective Date”) and is a supplement to the Services Agreement dated
July 15, 2015 (the “Agreement”) by and between Dignity Health with a place of business at 185 Berry Street,
Suite 300, San Francisco, California 94107 (“Client”), and Augmedix, Inc., a Delaware corporation with its
principal offices at 1161 Mission St, Suite 210, San Francisco, CA 94103 (“Augmedix”), and is hereby made a
part of the Agreement. To the extent this SOW is inconsistent with the terms of the Agreement, the terms of the Agreement will
prevail. All capitalized terms used in this SOW and not defined herein shall have the meaning assigned to such terms in the Agreement.
Notwithstanding any prior agreements, the Parties hereby agree that as of the SOW Effective Date, the Services Agreement dated
November 7, 2013 between the Parties, including all amendments and statements of work thereunder, are deemed terminated and superseded
by the Agreement (described above) between Dignity Health and Augmedix. This SOW replaces all prior SOWs by and between the Parties
with an effective date prior to July 15, 2015.

 

Client’s Business Sponsor (name of executive): Robert Folden,
Executive Director, DHMF North State

 

Primary Client Contact: [*], Director of Clinic Operations

 

1. Overview and Definitions

 

		a.	Augmedix Solution Overview

 

With the introduction of Electronic Health Record
(“EHR”) systems, licensed physicians (“Provider(s)”) are increasingly required to interact with
technology during a patient session. Providers often spend hours completing documentation in their patients’ charts. Depending
upon the Provider’s practice style, this might get accomplished during office hours, in between patient sessions, or after hours.

 

Augmedix shall ensure that the
Augmedix Solution will enable: (a) Scribes to readily perform Scribing activities in accordance with Dignity Health’s Policy, this
SOW and the applicable SOP, and (b) Providers wearing the Augmedix Google Glass to readily and securely communicate electronically
live audio, video and/or data during a patient session/encounter with a Scribe.

 

Augmedix shall utilize the Google
Glass platform as a means to pass-through audio, video, and data to and from remote Scribes located at a Designated Augmedix Facility
(as defined below) or on-site at the Client facility, as applicable. Scribes will complete much of the documentation that Providers
do themselves today, in real-time, during a patient session and will input that data directly into the applicable Client EHR.

 

		b.	Project Overview

 

This project is a collaborative
effort between Augmedix and Client, to undertake deployment of the Augmedix Solution at authorized Client Facilities, with direct
participation of certain designated Providers of Client.

 

Client Facilities utilize EHRs which can be common between facilities
or unique to a specific facility.

 

When performing the Services,
Scribes will always be located at the Designated Augmedix Facility or on-site at the Client facility and will be scribing directly
into the respective EHR.

 

Scribes will work with Client’s
on-site staff to incorporate patient education into the registration process, as well as to capture post-appointment feedback with
respect to patient satisfaction and comfort with the interaction between patient and Provider during a patient session.

 

    	SFO-[160980]	 

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

During each phase described
below, Augmedix’s team will conduct interviews with the participating Providers to measure their satisfaction, interaction
and capture efficiencies gained by introducing the Augmedix Solution.

 

2. Services and Deliverables

 

		a.	Commencing on the Effective Date of this SOW, Augmedix
shall perform the following services and provide the following Services and Deliverables to Client:

 

		(I)	Implementation. Augmedix shall perform implementation
Services in accordance with Section 2(c) below.

 

		(2)	Scribing.
Scribing is to be performed by Augmedix Scribes. Augmedix shall facilitate coordination of Scribing integration into the EHR, in pending
status, awaiting the Provider’s review, finalization, and approval.

 

		(3)	Formatting.
Augmedix shall transfer Scribing results into the format requested by Client.

 

		b.	Certain Requirements

 

		(1)	Augmedix shall provide the necessary Augmedix Google
Glass Devices and Embedded Software for the Authorized Users.

 

	 	(2)	Any and all Client Hardware (including servers) used to implement and operate the Augmedix Solution will remain on Facility premises at all times. Audio, video, and data content will be generated and used only in real time during a patient session using the Augmedix Google Glass Device which will be encrypted both at rest and during the session, and, in any event, at all times in accordance with the RSAM documents and the SOP, which when finalized or updated by the parties are deemed incorporated herein by reference. For purposes of this SOW, “real time” means streaming without caching, storage or retention of the content, except for caching in encrypted form on the Augmedix Google Glass Device as permitted by this Agreement when the wife connection to the Designated Augmedix Facility is unavailable and other caching and storage specifically permitted under the SOP.

 

	 	(3)	The SOP will comply with all of the requirements of the Agreement, this SOW and Client’s Scribe Policy. Any content in the SOP that conflicts with a requirement in any of the foregoing shall only be valid when approved in writing by Augmedix and Client’s Business Sponsor, legal counsel and if it pertains to a privacy matter, its Facility Privacy Official.

 

	 	(4)	Augmedix will ensure that all Scribes complete all training on relevant Dignity Health policies and software applications, as requested by Dignity Health, and comply with all Dignity Health policies applicable to the Services, including without limitation, Dignity Health’s scribe policy, which is attached to this SOW as Attachment I (Dignity Health Scribe Policy), which poll.cy may be updated from time to time by Dignity Health.

 

c. Certain Augmedix Responsibilities

 

		(1)	Augmedix shall install and configure the Software onto
the Hardware under the supervision and with the support of the appropriate Client-designated personnel. As part of the implementation
Services, Augmedix shall complete collection of physician and site preferences. technical site evaluation, IT infrastructure setup,
and deployment of on-site Augmedix Scribe trainers and Augmedix Scribes as needed, and onboarding of Authorized Users and Augmedix
personnel (including Scribes). Augmedix shall perform all other services necessary to implement the Software, Hardware, and Services
so that they can be used in full production.

 

		(2)	Augmedix shall notify Client when the implementation
Services described above are complete. Client will have the right to test the Software, Hardware and Services as implemented.
Augmedix shall promptly correct any errors or deficiencies. The Software, Hardware, and Services will not be deemed accepted unless
and until Client notifies Augmedix of its acceptance, provided however that for acceptance after the first implementation
with respect to each Facility EHR or new version thereof, the Software, Hardware and Services for each implementation will be deemed
accepted if Client does not reject them after five (5) business days of production use following notification by Augmedix that
such implementation Services are complete. Go-live date for each Authorized User will occur upon first productive use by that Authorized
User following notice from Augmedix that all implementation services are complete for that Authorized User, unless disputed by
Client within five (5) business days after such notice.

 

    	SFO-[160980]	Page 2

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

	 	(3)	Augmedix shall provide the Augmedix Google Glass and all technical support for it.

 

	 	(4)	Augmedix shall ensure that the Augmedix Designated Facility meets the requirements of the relevant security document (i.e. RSAM for Augmedix Designated Facilities located in the United States and the Offshore Diligence Document for Augmedix Designated Facilities located overseas) at all times.

 

	 	(5)	Augmedix shall ensure that all data and content (including audio and video content) generated or collected by the Augmedix Google Glass Devices will at all times be encrypted and streamed in encrypted form through the Facility Wi-Fi network and to the Designated Augmedix Facility via the internet.

 

	 	(6)	Augmedix shall ensure that EHR entries created by Scribes will at all times be transmitted in encrypted form from the Augmedix Designated Facility to the Facility EHR.

 

	 	(7)	All hardware used by the Scribes will remain at all times within the premises of the Augmedix Designated Facility. Augmedix and Scribes will not remove any hardware from the Augmedix Designated Facility premises.

 

	 	(8)	Augmedix shall provide appropriately configured Augmedix Google Glass devices, loaded with Software. Augmedix shall replace this hardware as needed and to offset normal hardware wear and tear. If Client so chooses to utilize prescription lenses for a particular Authorized User, Augmedix shall supply the appropriate frames for the Authorized User or the Client to pay for. The Authorized User or the Client must then oversee the custom creation of lenses and installation. Augmedix shall make best efforts to assist with these lens installation logistics. Augmedix shall also provide appropriate numbers of external batteries and USB cables.

 

	 	(9)	
        Augmedix shall be responsible for ensuring the
        availability and functionality of sufficient Augmedix Google Glass Devices and other Hardware to provide the Services under
        this Statement of Work. The Augmedix Google Glass Devices and other Hardware provided for the purpose of the Agreement are
        owned by Augmedix and will be provided and supported entirely by Augmedix.

 

	 	(10)	Augmedix shall work together with Client to develop appropriate patient education materials and associated training.

 

	 	(11)	Augmedix shall provide Standard Operating Procedure (SOP) to configure Google Glass to the Augmedix specification utilizing Client Network.

 

	 	(12)	Augmedix shall provide invoices to Client in a timely matter. Augmedix shall also respond to billing inquiries promptly and thoroughly.

 

	 	(13)	Augmedix shall ensure each Scribe is properly trained on Client’s EHR and Client’s data entry standards and policies associated with such data entry and EHR access.

 

	 	(14)	Augmedix shall obtain the name and contact information of the office manager and/or clinic director for each physician for which Services are performed and shall include that information in each invoice.

 

d. Client Responsibilities

 

		(1)	schedule, subject to Augmedix’s and each Scribe’s compliance with all applicable policies and
                                                                                  Client will provide the remote login capabilities for the Scribe to access the EHR and the patient procedures of Client. Client shall also provide the
necessary wife infrastructure and bandwidth to access the internet from Client facilities, as agreed by the parties in writing.

 

    	SFO-[160980]	Page 3

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

	 	(2)	Client-designated personnel will provide Standard Operating Procedure (SOP) on Accessing CUR Remotely.

 

	 	(3)	Client-designated personnel will assist Augmedix in installing and configuring the Software onto the Augmedix’s hardware.

 

	 	(4)	Client will work together with Augmedix to develop patient education materials.

 

	 	(5)	Client will provide training to Augmedix personnel pertaining to the use of EHR software.

 

	 	(6)	Client will arrange for appropriate access and related credentials for Scribes and Scribe trainers to access the EHR and related software.

 

	 	(7)	(Intentionally omitted)

 

	 	(8)	Client will designate one or more person(s) at each Client Facility for administrative duties in SOP. Administrative Duties include:

 

		●	Nightly
collection of devices (Glass units, battery packs, etc.) for charging and secure storage.

 

		●	Daily
distribution of devices for utilization.

 

		●	Handover
of Google Glass units to visiting Augmedix personnel for the purposes of software upgrades, audits, or research.

 

		●	Participation
on Augmedix or Client initiated audits for the purposes of security or asset verification

 

		●	Point
of Contact for Incident Reporting and Client/Augmedix issue resolution.

 

		(9)	Client will be responsible for providing patient education
in accordance with applicable laws and regulations. Without limiting the foregoing, Client will make available to patients the
education materials, including FAQs, provided by Augmedix and approved in writing by Client. The parties agree to cooperate in
timely and jointly reviewing such materials. Client will designate one or more persons at each authorized facility in SOP to administer
patient education process for all patients to be seen by an Authorized User. In the event that a patient wishes for the Augmedix
Solution to be partially or completely disabled / removed, the Client is responsible for adhering to stated patient preferences. Augmedix shall
provide training and support to assist Client with these circumstances.

 

	 	(10)	Client will designate one or more persons at each authorized facility in SOP to provide Augmedix with long-term and short-term schedules for Authorized Users listed in the SOP.

 

	 	(11)	Client will provide full EHR audit-trail access to Augmedix. This permits Augmedix to see the precise character-by-character changes made to the EHR (by providers, scribes, other staff, or other systems), with time-stamps and user logs. This access should permit visibility into all EHR documentation associated with the providers listed in the SOP, but subject, however, to the role-based access provided by Client.

 

	 	(12)	Client is responsible for securing and safeguarding Augmedix-provided Augmedix Google Glass Devices, batteries, and related accessories. If these Google Glass units or related accessories are lost or damaged through usage beyond mere day-to-day use and such loss or damage amounts to negligence by Client, the replacement costs will be billed to the Client.

 

	 	(13)	Either party may require Authorized Users to wear Augmedix Google Glass Devices while seeing patients for as much as two weeks prior to scheduled initiation of service for that particular Authorized User. This requirement will be upon the request of either party, as reasonably necessary, in an effort to efficiently train Scribes. Each party will ensure that its personnel will comply with these requirements.

 

    	SFO-[160980]	Page 4

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

e. Software

 

		(1)	License. Subject to the terms and conditions
of this Agreement, Augmedix hereby grants Client and its affiliates, and Client hereby accepts on behalf of itself and its affiliates,
a non-exclusive, nontransferable license for Client and its Authorized Users to use the Augmedix Solution and Documentation for
the term of this SOW. For the avoidance of doubt, the Software may be used on a concurrent user basis. In addition, Client may
retain a copy of all Documentation for its records in perpetuity.

 

	 	(2)	Restrictions. Without the prior written consent of Augmedix, Client and its affiliates agree not to (nor assist or encourage third parties to): (a) sell, rent, lease, lend, license, sublicense, distribute or otherwise transfer the Software or Documentation to any third party; (b) decompile, disassemble or reverse engineer the Software, in whole or in part; (c) write or develop any derivative software or any other software program based upon the Software, the Documentation or any Augmedix Confidential Information; (d) use the Software to provide processing or other services to third parties, or otherwise use the Software on a “service bureau” basis; or (e) provide, disclose, divulge or make available to, or permit use of the Software or Documentation by any third party without Augmedix’s prior written consent. The Software contains Embedded Software and Client will comply with any applicable license terms and conditions as set forth in Section 2(e)(1) of this SOW.

 

	 	(3)	Embedded Software Terms and Conditions.

 

		●	Prior
to commencement of the Project, Augmedix shall notify Client in writing of all Embedded Software and provide for Client’s review
their associated terms and conditions (“Embedded Software Licenses”). As Client proceeds with expansion, Client
agrees to comply with all such Embedded Software Licenses that are reasonably acceptable to it, which are required to use the
Software licensed by Augmedix hereunder.

 

		●	In
addition to the terms and conditions of the Embedded Software Licenses, Client acknowledges the following:

 

		■	EMBEDDED
SOFTWARE IS PROVIDED “AS 1S” AND ANY EXPRESSED OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, THE IMPLIED WARRANTIES
OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE ARE DISCLAIMED. IN NO EVENT SHALL THE SUPPLIER OF ANY EMBEDDED SOFTWARE
OR ITS AUTHOR OR CONTRIBUTORS BE LIABLE FOR ANY DIRECT, INDIRECT, INCIDENTAL, SPECIAL, EXEMPLARY, OR CONSEQUENTIAL DAMAGES (INCLUDING,
BUT NOT LIMITED TO, PROCUREMENT OF SUBSTITUTE GOODS OR SERVICES; LOSS OF USE, DATA, OR PROFITS; OR BUSINESS INTERRUPTION) HOWEVER
CAUSED AND ON ANY THEORY OF LIABILITY, WHETHER IN CONTRACT, STRICT LIABILITY, OR TORT (INCLUDING NEGLIGENCE OR OTHERWISE) ARISING
IN ANY WAY OUT OF THE USE OF THIS SOFTWARE, EVEN IF ADVISED OF THE POSSIBILITY OF SUCH DAMAGE.

 

		■	Augmedix
relies on Embedded Software for proper operation of the Software. Augmedix hereby assigns all assignable warranties and services
provided by Embedded Software licensors to Client, if any.

 

		■	If
a problem with any Embedded Software affects the performance of the Software in accordance with Documentation, Augmedix shall
use commercially reasonable efforts to work with the Embedded Software licensor to resolve the problem.

 

		■	Augmedix
warrants that it has obtained all necessary rights for third party software required to operate the Augmedix Solution.

 

		■	Client further
                                                                                                                                                                     agrees to accept the applicable Google Terms of Use prior to its use of the Augmedix Google Glass Device. Furthermore, Client
                                                                                                                                                                     acknowledges that, to the extent permitted by applicable laws, Google shall have no liability for any damages, whether direct, indirect, incidental
or consequential, arising from the use of the Google Glass Device, and all warranties with respect to the Google Glass Device,
including without limitation, warranties for merchantability, fitness for a particular purpose, and non-infringement are hereby
disclaimed.

 

    	SFO-[160980]	Page 5

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

3. Term and Schedule of Work Milestones

 

		a.	Term.
This SOW shall begin on its Effective Data and continue until terminated as provided in the Agreement. Such term shall be
referred to as the “Term” of the SOW.

 

		b.	Milestones:

 

		i.	Services and Deliverables are fully implemented and
Scribes are ready to begin full performance under this SOW.

		ii.	Acceptance of the Services and Deliverables by each
applicable physician and the office manager for each such physician.

		iii.	Payment for each physician does not begin until acceptance
as described above and go-live have occurred.

 

4. Fees; Schedule; Invoicing

 

		a.	Fees.

 

		i.	Fees
                                         will be charged and assessed for Authorized User beginning on the go-live date, but not
                                         before such date unless otherwise agreed by the parties.

 

		ii.	Augmedix
                                         and Client shall by mutual agreement classify Authorized Users into the following billing
                                         categories, based on the expected number of service hours used:

 

	Billing
    Category	 	Monthly
    Charge*
	[*]	 	[*]
	[*]	 	[*]
	[*]	 	[*]
	[*]	 	[*]
	[*]	 	[*]
	[*]	 	[*]

 

		*	Augmedix shall
                                         bill the Client for each Authorized User at the applicable rate set forth above.

 

		*	If Client has
Authorized Users using over 140 service hours per month, such extra service hours shall be billed to Client at a rate of [*] per
service hour used over the 140 hour allocation.

 

		*	These fees may not be changed in the event Augmedix is
unable to use Scribes outside the jurisdiction of the United States of America as a result of Security Incident.

 

	 	iii.	At
90 days after the initial classification of Authorized Users into billing categories. and every 90 days thereafter, Augmedix reserves
the right to re-classify an Authorized User into a different billing category if such Authorized User uses, on average, more than
the upper limit or less than the lower limit of service hours based on his/her last billing category classification for each such
90 day period. By way of example, an Authorized User who was classified as “Up to 110 service hours per month” before
the go-live date but on average has used 120 Service hours per month in the 90 days since the go-live date can be re-classified
by Augmedix to the “Up to 140 service hours per month” billing category and will incur a monthly charge of [*]
for the next 90 day period (and 90 day periods thereafter, assuming a similar 120 service hour per month usage).

 

    	SFO-[160980]	Page 6

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

  

	 	iv.	Fees and charges paid by Client under this SOW are non-refundable. All payments will be made in US dollars.

 

	 	v.	Augmedix
reserves the right to raise the fees incurred under this SOW by up to [*] upon the yearly anniversary of the Effective Date and
every yearly anniversary thereafter.

 

		b.	Scheduling

 

Prior to initiation for each new Authorized User
and each month thereafter, Client shall provide a generic daily schedule for each Authorized User for each day of the following
month (“Daily Schedule”).

 

14
day written notice is required for schedule changes. If less than 14 day written notice is received, Augmedix will make good faith
efforts to accommodate such requests but does guarantee availability of such service.

 

		c.	Invoicing

 

All
amounts due will be invoiced monthly in arrears in accordance with the Agreement and the terms of this SOW. In the event that
service for a particular Authorized User is canceled, any remaining balance will be reimbursed to Client or credited towards payment
for another Authorized User.

 

5. Other Miscellaneous Terms and Conditions

 

	 	a.	Sales and Use Tax. The parties acknowledge that, as of the Effective Date of this SOW, no law, rule or regulation requires any sales or use taxes to be due or payable as they relate to the Service and Deliverables under this SOW. Therefore no such tax shall be due or included in invoices.

 

	 	b.	Tax Withholding Requirements. In accordance with Section 4(c) of the Agreement, payments for services under this SOW may be subject to state tax withholding requirements. If the services under this SOW include services performed or payable in California, Augmedix warrants and represents that it has completed, signed and submitted to Client one of the following: (Check applicable box below)

 

		☐	California
Franchise Tax Board Form 587 (Nonresident Withholding Allocation Worksheet)

 

		☐	California Franchise Tax Board Form 590 (Withholding
Exemption Certificate)

 

		d.	Background
                                         Screening Requirements. As required by Section 11(d) of the Agreement, Augmedix represents
                                         and warrants that: (Check applicable box below):

 

		☐	Augmedix has successfully completed a criminal
background check for each of its personnel and subcontractors providing services under this SOW and
has provided Client with documentation of such, in accordance with Exhibit E.

 

		e.	Insurance Compliance. Augmedix has provided Client
with proof of insurance as required under Exhibit of the Agreement.

 

(Check applicable box below):

		☐	Yes

		☐	No (if no, explain why not):

 

 

 

 

 

		f.	Deliveries. Unless specified otherwise by Client,
all tangible deliveries, including reports shall be delivered only to the Client’s Business Sponsor or designee at Client’s address
shown above.

 

    	SFO-[160980]	Page 7

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

IN WITNESS
WHEREOF, the parties hereto have caused this Statement of Work to be executed by their respective authorized representatives.

 

	Accepted and Approved by:	 	Accepted and Approved by:
	 	 	 
	Dignity Health Medical Foundation	 	Augmedix, Inc.
	 	 	 
	/s/ Robust Folden	 	/s/ Ian Shakil
	Signature	 	Signature
	 	 	 
	Robust Folden	 	Ian Shakil
	Print Name	 	Print Name
	 	 	 
	Executive Director	 	CEO & Co-Founder
	Title	 	Title
	 	 	 
	6/14/16	 	7/3/2016
	Date	 	Date

 

    	SFO-[160980]	Page 8

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

ATTACHMENT 1

 

TO EXHIBIT A 

 

DIGNITY HEALTH SCRIBE POLICY

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    	SFO-[160927]
 Dignity Health – Augmedix, Inc. SOW	

Page 9 of 9

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

AMENDMENT TO THE STATEMENT
OF WORK

BY AND BETWEEN

DIGNITY HEALTH MEDICAL FOUNDATION AND
AUGMEDIX, INC.

 

This Amendment,
made this July 21, 2017 (“Effective Date”), hereby amends the Statement of Work dated July 15, 2016 (“DHMF
SOW”) by and between Dignity Health Medical Foundation (“DHMF” or “Client”), a
California non-profit, public benefit corporation, for itself and its affiliate facilities, and Augmedix, Inc., a
Delaware corporation, (“Augmedix”).

 

In consideration
of the mutual benefits and promises between the parties, the sufficiency of which each party hereby acknowledges, the DHMF SOW
is hereby amended as follows:

 

1. Services Agreement
Date.

 

The opening
paragraph of the DHMF SOW makes reference to a Services Agreement by and between Dignity Health and Augmedix (“Agreement”)
but: with an incorrect date of July 15, 2015. The correct date of the Agreement is September 1, 2015 and the erroneous date
in the SOW is hereby amended to state the correct date of September 1, 2015. DHMF acknowledges that it is an affiliate of Dignity
Health and the parties hereby confirm that the DHMF SOW is subject to the terms and conditions of said Agreement.

 

2. Effective Date of DHMF SOW.
The DHMF SOW was fully executed on July 3, 2016 as shown by the date below the last signature on the SOW, and hence, the DHMF
SOW is hereby amended to state its correct effective date which is July 3, 2016.

 

3. Client Business Sponsor. The Client Business
Sponsor for the DHMF SOW shall be: Dr. Davin Lundquist, Vice President-Chief Medical Information Officer, Dignity Health Medical
Foundation.

 

4. Section 4.a.ii, Fees. Section 4.a.ii of
the DHMF SOW is hereby deleted and replaced with the following provision, as follows:

 

ii. Order Form. Client may designate any number of Authorized Users, provided that the applicable Client’s facility site
lead completes, and Client signs and submits to Augmedix for countersignature, an Order Form in the format of the template attached
hereto as Attachment A, which is incorporated herein by reference. Such Client facility site shall be responsible for the
fees and charges billed by Augmedix according to the applicable Authorized User’s billing category and service hours of actual
usage of each designated Authorized User under such Order Form. The Order Form shall state the estimated number of service hours
used per month by each Authorized User. The billing rates per Authorized User shall be in accordance with the Pricing rates in
Exhibit B of the Agreement.

 

5. Scheduling and Removal of Authorized
Users. Section 4.b of the DHMF SOW is hereby deleted and replaced with the following provisions:

 

i.
Daily Schedule. Prior to initiation of each new Authorized User and each month thereafter, Client shall provide Augmedix
with online access to a generic daily schedule for each Authorized User for each day of the following month (the “Daily
Schedule”).

 

Fourteen (14) days or more written
notice is required for material schedule changes by Client. If less than 14-day written notice is received, Augmedix will make
good faith efforts to accommodate such requests but does not guarantee availability of such service.

 

    	SF0-175066	Page 1

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

ii.
Vacations/Leave of Absence. Client shall continue to pay an Authorized User’s monthly fee in the event of a vacation
and/or leave of absence of two (2) consecutive weeks or less. In the event Client desires to suspend Services for an Authorized
User for more than two (2) consecutive weeks but less than (8) consecutive weeks, and provided that Client provides at least two
(2) weeks’ notice of any such vacation and/or leave of absence, Augmedix will continue to hold the Scribe assigned to such
Authorized User during his/her absence. Augmedix shall make reasonable efforts to re-assign the Scribe to another Authorized User
within DHMF or other Dignity Health Client, and if despite reasonable efforts, no Authorized User is found within Augmedix will
not release the assigned Scribe so long as Client continues to pay a minimum monthly fee of [*], prorated for the applicable absence
period (“Suspension Fee”). In the event Client desires to suspend Services for an Authorized User for a period of
more than eight (8) consecutive calendar weeks or elects not to or fails to pay the Suspension Fee, Augmedix reserves the right
to reallocate the Scribe assigned to such Authorized User, and upon resuming the Services, Client shall pay such Authorized Users’
monthly fee during the training and implementation of a new Scribe (for clarity, Client does not pay Authorized Users’ monthly
fee during the initial implementation of a Scribe),

 

iii.
Authorized User Swap, At any time after an Authorized. User’s acceptance/go-live date, Client may swap one Authorized
User for another upon thirty (30) days’ prior written notice to Augmedix, provided, however, that Client pays (a) the applicable
fees for the Services performed through the effective date of termination, and (b) a swap fee of [*].

 

iv.
Removal of Authorized Users. At any time after an Authorized User’s acceptance/go-live date, Client may remove such Authorized
User from the Services upon ninety (90) days’ prior written notice to Augmedix, provided, however, that Client continues to pay
the applicable fees for the Services performed through the effective date of termination. Notwithstanding the foregoing, if Client
desires to remove an. Authorized User due to termination of the relationship between Client and such Authorized User, Client may
remove such Authorized User from the Services upon thirty (30) days’ prior written notice, provided that Client notifies Augmedix
of the termination and Client pays the applicable fees for Services performed through the effective date of termination.

 

6. Generic DHMF SOW. As of the
Effective Date of this Amendment, the DHMF SOW, as hereby amended, shall apply to all DHMF affiliates and DHMF Authorized Users
that participate and avail of the Services and Deliverables under the referenced Service Agreement and each shall execute the
required Order Form to avail of Augmedix’s Services.

 

7. General. This
Amendment is hereby incorporated into the DHMF SOW by reference. Except as expressly amended herein, all other terms of the
DHMF SOW are hereby confirmed and remain in full force and effect. To the extent that there is any conflict between the terms
of this Amendment and those of the Agreement or the DHMF SOW, the terms of this Amendment shall control. This Amendment may
be executed in several counterparts, all of which taken together shall constitute one single agreement between the parties
and any full and complete copy thereof shall constitute an original. When signed in pen ink, such documents may be delivered
by facsimile transmission or by scanned email attachment, and said copies shall be treated in all respects as original.

 

(Signature page follows.)

 

    	SF0-175066	Page 2

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

AGREED AND ACCEPTED

 

	DIGNITY HEALTH MEDICAL FOUNDATION	 	AUGMEDIX, INC.
	 	 	 
	By	/s/ Michael Stern	 	By	/s/ Ian Shakil 
	Name 	Michael Stern	 	Name 	Ian Shakil
	Title	Director, IT Contracting	 	Title	CEO
	Date	7/26/17	 	Date	7-20-2017

 

    	SF0-175066	Page 3

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

Attachment A

 

ORDER
FORM

 

This
Order Form, effective as of the date of the last signature below, is made pursuant to the Statement of Work, including amendments
thereto, by and between Dignity Health Medical Foundation (“DHMF” or “Client”) and
Augmedix, Inc. for the benefit of Client’s service facility site below. Capitalized terms used but not otherwise
defined herein shall have the same meaning as in the DHMF SOW.

 

Client’s
Service Facility: _______________________________________________________________

 

Service
Address: ___________________________________________________________________

 

Client’s
Facility Site Lead: ______________________________________________________

 

	Phone: _______________________________	 	Email: _____________________________________

 

 

	Name
    of Clinician/Authorized Users	 	Projected
    Billing Category*	 	Estimated
    Monthly Charge**
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 

 

		*	See
                                         Exhibit B, Pricing exhibit, of Services Agreement dated September 1, 2015 for Billing:
                                         Categories.

 

		**	implementation
                                         and training included.

 

Send
this Order Form and related correspondence to:

[*] Enterprise Account Manager

[*]

[*]

 

	DIGNITY HEALTH MEDICAL FOUNDATION	 	AUGMEDIX, INC.
	 	 	 
	By	 	 	By	 
	 	 	 	 	 
	Print Name	 	 	Print Name	 
	 	 	 	 	 
	Title	 	 	Title	 
	 	 	 	 	 
	Date	 	 	Date	 

 

    	SF0-175066	Page 4

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

SECOND AMENDMENT TO THE STATEMENT OF WORK

BY AND BETWEEN

DIGNITY HEALTH MEDICAL FOUNDATION AND AUGMEDIX, INC.

 

This Second Amendment,
made this August 1, 2018 (“Effective Date”), hereby amends the Statement of Work dated July 3, 2016, as amended
(“DHMF SOW”), entered into pursuant to the Services Agreement dated September 1, 2015 (“Agreement”),
by and between Dignity Health Medical Foundation (“DHMF” or “Client”), a California
non-profit, public benefit corporation, for itself and its affiliate facilities, and Augmedix, Inc., a Delaware corporation,
(“Augmedix”).

 

In consideration of
the mutual benefits and promises between the parties, the sufficiency of which each party hereby acknowledges, the DHMF SOW is
hereby amended as follows:

 

1. Invoicing. Section 4.c of the DHMF SOW is
hereby deleted in its entirety and replaced with the following provisions.

 

		i.	Subject to subsection ii immediately below, the billing
period for Authorized Users shall be July 1 of each year through June 30 of the following year, and pro-rated for first time Authorized
Users for part of a year.

 

		ii.	Notwithstanding
                                         the foregoing or anything to the contrary in the Master Agreement or the SOW, if (a)
                                         the aggregate annual fees payable under the Master Agreement exceeds or is likely to
                                         exceed [*] but is less than [*] Augmedix shall invoice the total amount under the SOW
                                         as divided into [*], the [*] and the [*]; or (b) the aggregate annual fees payable under
                                         the Master Agreement exceeds or is likely to exceed [*], Augmedix shall invoice the total
                                         amount under the SOW as divided into [*], each invoiced on [*]. To the extent that billing
                                         category or billing periods change result in an overpayment or underpayment of Fees for
                                         the applicable invoice period, the parties will reconcile any credits owed to, or additional
                                         amounts owed by, Client against any prepaid amounts on a quarterly basis.

 

		iii.	In the event that Service for a particular Authorized
User is cancelled in accordance with section 4.b.iv of the SOW, any remaining prepayment balance will be credited towards payment
for another Authorized User or refunded to Client within ninety (90) days of the effective date of termination. Upon termination
of the Agreement, Augmedix will promptly refund Client any prepaid Fees for Services not rendered.”

 

2. Scribes. The following sentence shall be added
at the end of Section 2.c.(13) as follows:

 

“Upon mutual agreement of DHMF and
Augmedix on an Authorized User-by-Authorized User basis, the supporting Scribe shall, upon the express request or direction of
the Authorized User, promptly propose an order in the EHR for the Authorized User physician’s review and, if appropriate,
his or her signature.”

 

3. Section 4.a.ii Fees, Restored. A previous
Amendment dated July 21, 2017 (“First Amendment”) inadvertently deleted Section 4.a.ii under the section on
Fees of the DHMF SOW. The deletion was unintended and Section 4.a.ii, as originally stated in DHMF SOW, is hereby restored in
full. The “Order Form” provision that was numbered Section 4.a.ii in the First Amendment is hereby renumbered
as Section 4.a.vi of DHMF SOW.

 

    	Second Amendment to Statement of Work 
 Augmedix – Dignity Health Medical Foundation
 SFO 203072	 
  
 Page 1

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

4. General. This Second
Amendment is hereby incorporated into the DHMF SOW by reference. Except as expressly amended herein, all other terms of the
DHMF SOW are hereby confirmed and remain in full force and effect. To the extent that there is any conflict between the terms
of this Second Amendment and those of the Agreement or the DHMF SOW, the terms of this Second Amendment shall control. This
Second Amendment may be executed in several counterparts, all of which taken together shall constitute one single agreement
between the parties and any full and complete copy thereof shall constitute an original. When signed in pen ink, such
documents may be delivered by facsimile transmission or by scanned email attachment, and said copies shall be treated in all
respects as original.

 

AGREED AND ACCEPTED

 

	DIGNITY HEALTH MEDICAL FOUNDATION	 	AUGMEDIX, INC.
	 	 	 
	By	/s/ Michael Stern	 	By	/s/ Ian Shakil 
	Name	Michael Stern	 	Name	Ian Shakil
	Title	Director, SSRM Contracting	 	Title	CEO
	Date	Aug 3, 2018	 	Date	Aug 3, 2018

 

    	Second Amendment to Statement of Work 
 Augmedix – Dignity Health Medical Foundation
 SFO 203072	 
  
 Page 2

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

AMENDED AND RESTATED STATEMENT OF WORK (SOW)

 

This Amended and Rested Statement of Work
(“SOW”), effective as of the date of the last signature below (the “SOW Effective Date”),
is made pursuant to the Services Agreement dated September 1, 2015 (the “Agreement”) by and between Dignity
Health with principal place of business at 185 Berry Street, Suite 300, San Francisco, California 94107 (“Client”),
and Augmedix, Inc., a Delaware corporation with its principal offices at 1161 Mission St, Suite 210, San Francisco, CA 94103
(“Augmedix”), and hereby replaces, restates and amends the SOW dated July 15, 2015 between the parties (“DH-SOW-1”).
As of this SOW’s Effective Date, DH-SOW-1 is hereby deemed terminated. This SOW is subject to the terms of the Agreement
and to the extent this SOW is inconsistent with the terms of the Agreement, the terms of the Agreement will prevail. All capitalized
terms used in this SOW and not defined herein shall have the meaning assigned to such terms in the Agreement.

 

	Client’s Business Sponsor (name of executive):	[*] – Mercy Hospital Bakersfield
	 	 
	Primary Client Contact:	[*] – Mercy Hospital Bakersfield

 

1. Overview and Definitions

 

		a.	Augmedix Solution Overview

 

With the introduction of Electronic Health
Record (“EHR”) systems, licensed physicians (“Provider(s)”) are increasingly required to
interact with technology during a patient session. Providers often spend hours completing documentation in their patients’
charts. Depending upon the Provider’s practice style, this might get accomplished during office hours, in between patient sessions,
or after hours.

 

Augmedix shall ensure that the Augmedix
Solution will enable: (a) Scribes to readily perform Scribing activities in accordance with Dignity Health’s Policy, this
SOW and the applicable SOP, and (b) Providers wearing the Augmedix Google Glass to readily and securely communicate electronically
live audio, video and/or data during a patient session/encounter with a Scribe.

 

Augmedix shall utilize the Google Glass
platform as a means to pass-through audio, video, and data to and from remote Scribes located at a Designated Augmedix Facility
(as defined below) or on-site at the Client facility, as applicable. Scribes will complete much of the documentation that Providers
do themselves today, in real-time, during a patient session and will input that data directly into the applicable Client EHR.

 

		b.	Project Overview

 

This project is a collaborative effort
between Augmedix and Client, to undertake deployment of the Augmedix Solution at authorized Client Facilities, with direct participation
of certain designated Providers of Client.

 

Client Facilities utilize EHRs which can be common between facilities
or unique to a specific facility.

 

When performing the Services, Scribes will
always be located at the Designated Augmedix Facility or on-site at the Client facility and will be scribing directly into the
respective EHR.

 

Scribes will work with Client’s on-site
staff to incorporate patient education into the registration process, as well as to capture post-appointment feedback with respect
to patient satisfaction and comfort with the interaction between patient and Provider during a patient session.

 

During each phase described below, Augmedix’s
team will conduct interviews with the participating Providers to measure their satisfaction, interaction and capture efficiencies
gained by introducing the Augmedix Solution.

 

    	SFO - 205079	 

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

2. Services and Deliverables

 

		a.	Commencing on the Effective Date of this SOW, Augmedix
shall perform the following services and provide the following Services and Deliverables to Client:

 

		(1)	Implementation.
Augmedix shall perform implementation Services in accordance with Section 2(c) below.

 

	 	(2)	Scribing. Scribing is to be performed by Augmedix Scribes. Augmedix shall facilitate coordination of Scribing integration into the EHR, in pending status, awaiting the Provider’s review, finalization, and approval.

 

	 	(3)	Formatting. Augmedix shall transfer Scribing results into the format requested by Client.

 

		b.	Certain Requirements

 

	 	(1)	Augmedix
    shall provide one Augmedix Google Glass Device Kit or SmartPhone Kit (a Kit includes a primary and back-up device) per
    Authorized User and the Embedded Software for the Authorized Users. In the event an Authorized User deploys the Augmedix
    Solution at multiple locations, Client shall pay a per-location monthly fee of [*] per Augmedix Google Glass Device Kit or
    [*] per SmartPhone Kit for any additional devices necessary to Service such additional locations.

 

	 	(2)	Any and all Client Hardware (including servers) used to implement and operate the Augmedix Solution will remain on Facility premises at all times. Audio, video, and data content will be generated and used only in real time during a patient session using the Augmedix Google Glass Device which will be encrypted both at rest and during the session, and, in any event, at all times in accordance with the RSAM documents and the SOP, which when finalized or updated by the parties are deemed incorporated herein by reference. For purposes of this SOW, “real time” means streaming without caching, storage or retention of the content, except for caching in encrypted form on the Augmedix Google Glass Device as permitted by this Agreement when the wifi connection to the Designated Augmedix Facility is unavailable and other caching and storage specifically permitted under the SOP.

 

	 	(3)	The SOP will comply with all of the requirements of the Agreement, this SOW and Client’s Scribe Policy. Any content in the SOP that conflicts with a requirement in any of the foregoing shall only be valid when approved in writing by Augmedix and Client’s Business Sponsor, legal counsel and if it pertains to a privacy matter, its Facility Privacy Official.

 

	 	(4)	Augmedix will ensure that all Scribes complete all training on relevant Dignity Health policies and software applications, as requested by Dignity Health, and comply with all Dignity Health policies applicable to the Services, including without limitation, Dignity Health’s scribe policy, which is attached to this SOW as Attachment 1 (Dignity Health Scribe Policy), which policy may be updated from time to time by Dignity Health.

 

		c.	Certain Augmedix Responsibilities

 

	 	(1)	Augmedix shall install and configure the Software onto the Hardware under the supervision and with the support of the appropriate Client-designated personnel. As part of the implementation Services, Augmedix shall complete collection of physician and site preferences, technical site evaluation, IT infrastructure setup, and deployment of on-site Augmedix Scribe trainers and Augmedix Scribes as needed, and onboarding of Authorized Users and Augmedix personnel (including Scribes). Augmedix shall perform all other services necessary to implement the Software, Hardware, and Services so that they can be used in full production.

 

	 	(2)	Augmedix
    shall notify Client when the implementation Services described above are complete. Client will have the right to test the
    Software, Hardware and Services as implemented. Augmedix shall promptly correct any errors or deficiencies. The Software,
    Hardware, and Services will not be deemed accepted unless and until Client notifies Augmedix of its acceptance, provided
    however that for acceptance after the first implementation with respect to each Facility EHR or new version thereof, the Software, Hardware and Services for each implementation
will be deemed accepted if Client does not reject them after five (5) business days of production use following notification by
Augmedix that such implementation Services are complete. Go-live date for each Authorized User will occur upon first productive
use by that Authorized User following notice from Augmedix that all implementation services are complete for that Authorized User,
unless disputed by Client within five (5) business days after such notice.

 

    	SFO – 205079
 Augmedix – Dignity Health - Amended and Restated SOW
	
 Page 2 of 12

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

	 	(3)	Augmedix shall provide the Augmedix Google Glass and all technical support for it.

 

	 	(4)	Augmedix shall ensure that the Augmedix Designated Facility meets the requirements of the relevant security document (i.e. RSAM for Augmedix Designated Facilities located in the United States and the Offshore Diligence Document for Augmedix Designated Facilities located overseas) at all times.

 

	 	(5)	Augmedix shall ensure that all data and content (including audio and video content) generated or collected by the Augmedix Google Glass Devices will at all times be encrypted and streamed in encrypted form through the Facility Wi-Fi network and to the Designated Augmedix Facility via the internet.

 

	 	(6)	Augmedix shall ensure that EHR entries created by Scribes will at all times be transmitted in encrypted form from the Augmedix Designated Facility to the Facility EHR.

 

	 	(7)	All hardware used by the Scribes will remain at all times within the premises of the Augmedix Designated Facility. Augmedix and Scribes will not remove any hardware from the Augmedix Designated Facility premises.

 

	 	(8)	Augmedix shall provide appropriately configured Augmedix Google Glass devices, loaded with Software. Augmedix shall replace this hardware as needed and to offset normal hardware wear and tear. If Client so chooses to utilize prescription lenses for a particular Authorized User, Augmedix shall supply the appropriate frames for the Authorized User or the Client to pay for. The Authorized User or the Client must then oversee the custom creation of lenses and installation. Augmedix shall make best efforts to assist with these lens installation logistics. Augmedix shall also provide appropriate numbers of external batteries and USB cables.

 

	 	(9)	Augmedix shall be responsible for ensuring the availability and functionality of sufficient Augmedix Google Glass Devices and other Hardware to provide the Services under this Statement of Work. The Augmedix Google Glass Devices and other Hardware provided for the purpose of the Agreement are owned by Augmedix and will be provided and supported entirely by Augmedix.

 

	 	(10)	Augmedix shall work together with Client to develop appropriate patient education materials and associated training.

 

	 	(11)	Augmedix shall provide Standard Operating Procedure (SOP) to configure Google Glass to the Augmedix specification utilizing Client Network.

 

	 	(12)	Augmedix shall provide invoices to Client in a timely matter. Augmedix shall also respond to billing inquiries promptly and thoroughly.

 

	 	(13)	Augmedix shall ensure each Scribe is properly trained on Client’s EHR and Client’s data entry standards and policies associated with such data entry and EHR access. Upon mutual agreement of Client and Augmedix on an Authorized User-by-Authorized User basis, the supporting Scribe shall, upon the express request or direction of the Authorized User, promptly propose an order in the EHR for the Authorized User physician’s review and, if appropriate, his or her signature.

 

	 	(14)	Augmedix shall obtain the name and contact information of the office manager and/or clinic director for each physician for which Services are performed and shall include that information in each invoice.

 

		d.	Client Responsibilities

 

		(1)	Client will provide the remote login capabilities for
the Scribe to access the EHR and the patient schedule, subject to Augmedix’s and each Scribe’s compliance with all
applicable policies and procedures of Client. Client shall also
provide the necessary wifi infrastructure and bandwidth to access the internet from Client facilities, as agreed by the parties
in writing.

 

    	SFO – 205079
 Augmedix – Dignity Health - Amended and Restated SOW
	
 Page 3 of 12

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

	 	(2)	Client-designated personnel will provide Standard Operating Procedure (SOP) on Accessing EHR Remotely.

 

	 	(3)	Client-designated personnel will assist Augmedix in installing and configuring the Software onto the Augmedix’s hardware.

 

	 	(4)	Client will work together with Augmedix to develop patient education materials.

 

	 	(5)	Client will provide training to Augmedix personnel pertaining to the use of EHR software.

 

	 	(6)	Client will arrange for appropriate access and related credentials for Scribes and Scribe trainers to access the EHR and related software.

 

	 	(7)	(Intentionally omitted)

 

	 	(8)	Client will designate one or more person(s) at each Client Facility for administrative duties in SOP. 

 

Administrative Duties include:

 

		●	Nightly
collection of devices (Glass units, battery packs, etc.) for charging and secure storage.

 

	 	●	Daily distribution of devices for utilization.

 

	 	●	Handover of Google Glass units to visiting Augmedix personnel for the purposes of software upgrades, audits, or research.

 

	 	●	Participation on Augmedix or Client initiated audits for the purposes of security or asset verification

 

	 	●	Point of Contact for Incident Reporting and Client/Augmedix issue resolution.

 

	 	(9)	Client will be responsible for providing patient education in accordance with applicable laws and regulations. Without limiting the foregoing, Client will make available to patients the education materials, including FAQs, provided by Augmedix and approved in writing by Client. The parties agree to cooperate in timely and jointly reviewing such materials. Client will designate one or more persons at each authorized facility in SOP to administer patient education process for all patients to be seen by an Authorized User. In the event that a patient wishes for the Augmedix Solution to be partially or completely disabled / removed, the Client is responsible for adhering to stated patient preferences. Augmedix shall provide training and support to assist Client with these circumstances.

 

	 	(10)	Client will designate one or more persons at each authorized facility in SOP to provide Augmedix with long-term and short-term schedules for Authorized Users listed in the SOP.

 

	 	(11)	Client will provide full EHR audit-trail access to Augmedix. This permits Augmedix to see the precise character-by-character changes made to the EHR (by providers, scribes, other staff, or other systems), with time-stamps and user logs. This access should permit visibility into all EHR documentation associated with the providers listed in the SOP, but subject, however, to the role-based access provided by Client.

 

	 	(12)	Client is responsible for securing and safeguarding Augmedix-provided Augmedix Google Glass Devices, batteries, and related accessories. If these Google Glass units or related accessories are lost or damaged through usage beyond mere day-to-day use and such loss or damage amounts to negligence by Client, the replacement costs will be billed to the Client.

 

	 	(13)	Either party may require Authorized Users to wear Augmedix Google Glass Devices while seeing patients for as much as two weeks prior to scheduled initiation of service for that particular Authorized User. This requirement will be upon the request of either party, as reasonably necessary, in an effort to efficiently train Scribes. Each party will ensure that its personnel will comply with these requirements.

  

    	SFO – 205079
 Augmedix – Dignity Health - Amended and Restated SOW
	
 Page 4 of 12

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

		e.	Software

 

	 	(1)	License. Subject to the terms and conditions of this Agreement, Augmedix hereby grants Client and its affiliates, and Client hereby accepts on behalf of itself and its affiliates, a non-exclusive, nontransferable license for Client and its Authorized Users to use the Augmedix Solution and Documentation for the term of this SOW. For the avoidance of doubt, the Software may be used on a concurrent user basis. In addition, Client may retain a copy of all Documentation for its records in perpetuity.

 

	 	(2)	Restrictions. Without the prior written consent of Augmedix, Client and its affiliates agree not to (nor assist or encourage third parties to): (a) sell, rent, lease, lend, license, sublicense, distribute or otherwise transfer the Software or Documentation to any third party; (b) decompile, disassemble or reverse engineer the Software, in whole or in part; (c) write or develop any derivative software or any other software program based upon the Software, the Documentation or any Augmedix Confidential Information; (d) use the Software to provide processing or other services to third parties, or otherwise use the Software on a “service bureau” basis; or (e) provide, disclose, divulge or make available to, or permit use of the Software or Documentation by any third party without Augmedix’s prior written consent. The Software contains Embedded Software and Client will comply with any applicable license terms and conditions as set forth in Section 2(e)(1) of this SOW.

 

	 	(3)	Embedded Software Terms and Conditions.

 

		●	Prior
                                         to commencement of the Project, Augmedix shall notify Client in writing of all Embedded
                                         Software and provide for Client’s review their associated terms and conditions
                                         (“Embedded Software Licenses”). As Client proceeds with expansion,
                                         Client agrees to comply with all such Embedded Software Licenses that are reasonably
                                         acceptable to it, which are required to use the Software licensed by Augmedix hereunder.

 

	 	●	In addition to the terms and conditions of the Embedded Software Licenses, Client acknowledges the following:

 

	 	●	EMBEDDED SOFTWARE IS PROVIDED “AS IS” AND ANY EXPRESSED OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, THE IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE ARE DISCLAIMED. IN NO EVENT SHALL THE SUPPLIER OF ANY EMBEDDED SOFTWARE OR ITS AUTHOR OR CONTRIBUTORS BE LIABLE FOR ANY DIRECT, INDIRECT, INCIDENTAL, SPECIAL, EXEMPLARY, OR CONSEQUENTIAL DAMAGES (INCLUDING, BUT NOT LIMITED TO, PROCUREMENT OF SUBSTITUTE GOODS OR SERVICES; LOSS OF USE, DATA, OR PROFITS; OR BUSINESS INTERRUPTION) HOWEVER CAUSED AND ON ANY THEORY OF LIABILITY, WHETHER IN CONTRACT, STRICT LIABILITY, OR TORT (INCLUDING NEGLIGENCE OR OTHERWISE) ARISING IN ANY WAY OUT OF THE USE OF THIS SOFTWARE, EVEN IF ADVISED OF THE POSSIBILITY OF SUCH DAMAGE.

 

	 	●	Augmedix relies on Embedded Software for proper operation of the Software. Augmedix hereby assigns all assignable warranties and services provided by Embedded Software licensors to Client, if any.

 

	 	●	If a problem with any Embedded Software affects the performance of the Software in accordance with Documentation, Augmedix shall use commercially reasonable efforts to work with the Embedded Software licensor to resolve the problem.

 

	 	●	Augmedix warrants that it has obtained all necessary rights for third party software required to operate the Augmedix Solution.

  

    	SFO – 205079
 Augmedix – Dignity Health - Amended and Restated SOW
	
 Page 5 of 12

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

		●	Client further agrees to accept the applicable Google
Terms of Use prior to its use of the Augmedix Google Glass Device. Furthermore, Client acknowledges that, to the extent permitted
by applicable laws, Google shall have no liability for any damages, whether direct, indirect, incidental or consequential, arising
from the use of the Google Glass Device, and all warranties with respect to the Google Glass Device, including without limitation,
warranties for merchantability, fitness for a particular purpose, and non-infringement are hereby disclaimed.

 

3. Term and Schedule of Work Milestones

 

		a.	Term.
This SOW shall begin on its Effective Date and continue until terminated as provided in the Agreement. Such term shall be
referred to as the “Term” of the SOW.

 

		b.	Milestones:

 

a. Services and Deliverables are fully
implemented, and Scribes are ready to begin full performance under this SOW.

 

b. Acceptance of the Services and Deliverables
by each applicable physician and the office manager for each such physician.

 

c. Payment for each physician does not
begin until acceptance as described above and go-live have occurred.

 

4. Fees; Schedule; Invoicing

 

		a.	Fees.

 

		i.	Fees
will be charged and assessed for Authorized User beginning on the go-live date, but not before such date unless otherwise agreed
by the parties.

 

	 	ii.	Augmedix and Client shall by mutual agreement classify Authorized Users into the following billing categories, based on the expected number of Scribe service hours used:

 

	Billing
    Category	 	Monthly
    Charge*
	[*]	 	[*]
	[*]	 	[*]
	[*]	 	[*]
	[*]	 	[*]
	[*]	 	[*]
	[*]	 	[*]

 

		*	Augmedix shall bill the Client for each Authorized User
at the applicable rate set forth above.

		*	If Client has Authorized Users using over [*]
Scribe service hours per month, such extra Scribe service hours shall be billed to Client at a rate of [*] per Scribe service
hour used over the [*]-hour allocation.

		*	These fees may not be changed in the event Augmedix is
unable to use Scribes outside the jurisdiction of the United States of America as a result of Security Incident.

 

    	SFO – 205079
 Augmedix – Dignity Health - Amended and Restated SOW
	
 Page 6 of 12

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

  

	 	iii.	At
90 days after the initial classification of Authorized Users into billing categories under the Order Form, and every 90 days thereafter,
Augmedix reserves the right to re-classify an Authorized User into a different billing category if such Authorized User uses,
on average, more than the upper limit or less than the lower limit of Scribe service hours based on his/her last billing category
classification for each such 90-day period. By way of example, an Authorized User who was classified as “Up to 100 Scribe
service hours per month” before the go-live date but on average has used 115 Scribe Service hours per month in the 90 days
since the go-live date can be re-classified by Augmedix to the “Up to 120 Scribe service hours per month” billing
category and will incur a monthly charge of $[*] for the next 90 day period (and 90 day periods thereafter, assuming a similar
115 Scribe service hour per month usage).

 

	 	iv.	Fees and charges paid by Client under this SOW are non-refundable. All payments will be made in US dollars.

 

	 	v.	Augmedix
reserves the right to raise the fees incurred under this SOW by up to [*] upon the yearly anniversary of the Effective Date and
every yearly anniversary thereafter.

 

	 	vi.	Order Form. Client may designate any number of Authorized Users provided that the applicable Client’s facility site lead completes, and Client signs and submits to Augmedix for countersignature, an Order Form in the format of the template attached hereto as Attachment 2. Such Client’s facility site shall be responsible for the fees and charges billed by Augmedix according to the Scribe service hours of actual usage of each designated Authorized User under such Order Form. The Order Form shall state the number of devices and Scribe service hours expected to be used per month by each Authorized User. The billing rates per Authorized User shall be in accordance with the Pricing rates in Exhibit B of the Agreement.

 

b. Scheduling and Removal of Authorized Users

 

	 	i.	Daily Schedule. Prior to initiation for each new Authorized User and each month thereafter, Client shall provide Augmedix with online access to a generic daily schedule for each Authorized User for each day of the following month (“Daily Schedule”).

 

Fourteen (14) days or more written notice
is required for schedule changes by Client. If less than fourteen (14) day written notice is received, Augmedix will make good
faith efforts to accommodate such requests but does guarantee availability of such service.

 

	 	ii.	Vacations/Leave
    of Absence. Client shall continue to pay an Authorized User’s monthly fee in the event of a vacation and/or leave
    of absence of two (2) consecutive weeks or less. In the event Client desires to suspend Services for an Authorized User for
    more than two (2) consecutive weeks but less than (8) consecutive weeks, and provided that Client provides at least two (2)
    weeks’ notice of any such vacation and/or leave of absence, Augmedix will continue to hold the Scribe assigned to such
    Authorized User during his/her absence. Augmedix shall make reasonable efforts to re-assign the Scribe to another Authorized
    User within DHMF or other Dignity Health Client, and if despite reasonable efforts, no Authorized User is found within DHMF,
    Augmedix will not release the assigned Scribe so long as Client continues to pay a minimum monthly fee of [*], prorated for
    the applicable absence period (“Suspension Fee”). In the event Client desires to suspend Services for an
    Authorized User for a period of more than eight (8) consecutive calendar weeks or elects not to or fails to pay the Suspension
    Fee, Augmedix reserves the right to reallocate the Scribe assigned to such Authorized User, and upon resuming the Services,
    Client shall pay such Authorized Users’ monthly fee during the training and implementation of a new Scribe (for clarity,
    Client does not pay Authorized Users’ monthly fee during the initial implementation of a Scribe).

 

	 	iii.	Authorized
    User Swap. At any time after an Authorized User’s acceptance/go-live date, Client may swap one Authorized User for
    another upon thirty (30) days’ prior written notice to Augmedix, provided, however, that Client pays (a) the applicable
    fees for the Services performed through the effective date of termination, and (b) a swap fee of [*].

 

    	SFO – 205079
 Augmedix – Dignity Health - Amended and Restated SOW
	
 Page 7 of 12

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

		iv.	Removal of Authorized Users. At any time after
an Authorized User’s acceptance/go-live date, Client may remove such Authorized User from the Services upon ninety (90)
days’ prior written notice to Augmedix, provided, however, that Client continues to pay the applicable fees for the Services
performed through the effective date of termination. Notwithstanding the foregoing, if Client desires to remove an Authorized
User due to termination of the relationship between Client and such Authorized User, Client may remove such Authorized User from
the Services upon thirty (30) days’ prior written notice, provided that Client notifies Augmedix of the termination and
Client pays the applicable fees for Services performed through the effective date of termination.

 

		c.	Invoicing

 

i. Subject to subsection ii immediately below, the billing
period for Authorized Users shall be July 1 of each year through June 30 of the following year and pro-rated for first-time
Authorized Users for part of a year.

 

ii. Notwithstanding the foregoing
or anything to the contrary in the Master Agreement or the SOW, if (a) the aggregate annual fees payable under the Master Agreement
exceeds or is likely to exceed [*], Augmedix shall invoice the total amount under the SOW as divided into [*]; the [*] and the
[*]; or (b) the aggregate annual fees payable under the Master Agreement exceeds or is likely to exceed [*], Augmedix shall invoice
the total amount under the SOW as [*], each invoiced on [*]. To the extent that billing category or billing periods change result
in an overpayment or underpayment of Fees for the applicable invoice period, the parties will reconcile any credits owed to, or
additional amounts owed by, Client against any prepaid amounts on a quarterly basis.

 

iii. In the event that Service for a
particular Authorized User is cancelled in accordance with section 4.b.iv of the SOW, any remaining prepayment balance will
be credited towards payment for another Authorized User or refunded to Client within ninety (90) days of the effective date
of termination. Upon termination of the Agreement, Augmedix will promptly refund Client any prepaid Fees for Services not
rendered.

 

5. Other Miscellaneous Terms and Conditions

 

		a.	Sales
and Use Tax. The parties acknowledge that, as of the Effective Date of this SOW, no law, rule or regulation requires any sales
or use taxes to be due or payable as they relate to the Service and Deliverables under this SOW. Therefore no such tax shall be
due or included in invoices.

 

	 	b.	Tax Withholding Requirements. In accordance with Section 4(c) of the Agreement, payments for services under this SOW may be subject to state tax withholding requirements. If the services under this SOW include services performed or payable in California, Augmedix warrants and represents that it has completed, signed and submitted to Client one of the following: (Check applicable box below.)

 

		☐	California
Franchise Tax Board Form 587 (Nonresident Withholding Allocation Worksheet)

 

	 	☐	California Franchise Tax Board Form 590 (Withholding Exemption Certificate)

 

		d.	Background Screening Requirements. As required
by Section 11(d) of the Agreement, Augmedix represents and warrants that: (Check applicable box below)

 

		☐	Augmedix has successfully completed a criminal
background check for each of its personnel and subcontractors providing services under this SOW and has provided Client with documentation
of such, in accordance with Exhibit E.

  

    	SFO – 205079
 Augmedix – Dignity Health - Amended and Restated SOW
	
 Page 8 of 12

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

		e.	Insurance Compliance. Augmedix has provided Client
with proof of insurance as required under Exhibit C of the Agreement. (Check applicable box below)

 

		☐	Yes

		☐	No (If no, explain why not):

 

 

 

 

  

		f.	Deliveries. Unless specified otherwise by Client,
all tangible deliveries, including reports shall be delivered only to the Client’s Business Sponsor or designee at Client’s
address shown above.

 

(Signature page follows)

 

    	SFO – 205079
 Augmedix – Dignity Health - Amended and Restated SOW
	
 Page 9 of 12

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

IN WITNESS WHEREOF,
the parties hereto have caused this Statement of Work to be executed by their respective authorized representatives.

 

	Accepted and Approved by:	 	Accepted and Approved by:
	 	 	 
	Dignity
Health	 	Augmedix, Inc.
	 	 	 
	/s/
    Kelley Moore 	 	/s/
    Manny Krakaris
	Signature	 	Signature
	 	 	 
	Kelley
    Moore 	 	Manny Krakaris
	Print
    Name	 	Print
    Name
	 	 	 
	VP,
    Sourcing	 	CEO
	Title	 	Title
	 	 	 
	Jan 24, 2019	 	Jan 24, 2019
	Date	 	Date

 

    	SFO – 205079
 Augmedix – Dignity Health - Amended and Restated SOW
	
 Page 10 of 12

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

 

ATTACHMENT 1 

 

TO EXHIBIT A

 

DIGNITY HEALTH SCRIBE POLICY

 

(To follow.)

 

 

    	SFO – 205079
Augmedix, Inc. – Dignity Health SOW
	
 Page 11 of 12

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

ATTACHMENT 2

 

ORDER FORM

 

This Order Form, effective
as of the date of the last signature below, is made pursuant to the Statement of Work by and between Dignity Health (“Client”)
for the benefit of Client’s facility site named below, and Augmedix, Inc. Capitalized terms used but not otherwise
defined herein shall have the same meaning as in the Dignity Health SOW.

 

	Client’s Facility:	 

 

	Service Address:	 

 

	Client’s Facility Site Lead:	 

 

	Phone:	                 	 	Email:	                   

 

	
        Name of
Clinician /Authorized User
	 	Projected Billing Category*	 	Estimated Monthly charge**
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 

 

		*	See Section 4.a.ii
of the Amended and Restated Statement of Work, dated [*] for Billing Categories.

		**	Implementation and training included.

		***	The parties acknowledge that no law, rule or regulation
requires any sales or use taxes to be due or payable as they relate to the Services and Deliverables under this Order Form. Therefore,
no such tax shall be due or included in invoices.

 

Send this Order form and related correspondence to:

[*]

[*]

[*]

 

	DIGNITY
HEALTH	 	AUGMEDIX, INC.
	 	 	 	 	 
	By	                     	 	By	            
	 	 	 	 	 

	Print Name 	                     	 	Print Name 	             
	 	 	 	 	 

	Title	                     	 	Title	                           
	 	 	 	 	 
	Date	                     	 	Date	                     

 

    	SFO – 205079
Augmedix, Inc. – Dignity Health SOW
	
 Page 12 of 12

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

DH-IT-1186

 

OMNIBUS AMENDMENT

 

This Omnibus Amendment
(“Omnibus Amendment”) is made and entered into as of July 1, 2020, by and between, on the one hand, Augmedix,
Inc. (“Augmedix”) and, on the other hand, Dignity Health (“DH”), Dignity Health Medical Foundation
(“DHMF”), and Pacific Central Coast Health Centers (“PHC”), and amends:

 

		(1)	That
certain Amended and Restated Statement of Work, dated January 24, 2019, by and between DH and Augmedix (the “DH-SOW
No. 1”); and

 

	 	(2)	That certain Statement of Work No. 2, dated March 2, 2020, by and between DH and Augmedix (the “DH-SOW No. 2”); and

 

	 	(3)	That certain Statement of Work, dated July 3, 2016, as amended, by and between DHMF and Augmedix (the “DHMF-SOW”); and

 

	 	(4)	That certain Statement of Work, dated January 26, 2016, as amended, by and between PHC and Augmedix (the “PHC-SOW” and, together with the DH-SOW No. 1, DH-SOW No. 2, and DHMF-SOW, the “Dignity SOW(s)”).

 

WHEREAS, Dignity Health
(for itself and on behalf of its affiliates) and Augmedix entered into the Services Agreement dated September 1, 2015, as amended,
(the “Agreement”).

 

NOW, THEREFORE, in
consideration of the mutual benefits and promises between the parties, the sufficiency of which each party hereby acknowledges,
the Dignity SOWs are hereby amended as follows:

 

1. Term. Notwithstanding
anything to the contrary in the Dignity SOWs, this Omnibus Amendment extends the Term of the Dignity SOWs through and including
June 30, 2021, unless earlier terminated in accordance with the Agreement. By notice to Augmedix, the Dignity SOWs shall renew
on the same terms and conditions for up to three (3) successive one (1) year terms thereafter (each a “Renewal Term”).

 

2. Fees. Notwithstanding
anything to the contrary in the Dignity SOWs, Augmedix hereby agrees to not increase Fees prior to July 1, 2021. Commencing on
July 1, 2021, Augmedix may apply Fees increases as set forth in the Dignity SOWs on a go-forward basis.

 

3. Invoicing. Notwithstanding
anything to the contrary in the Dignity SOWs the following shall apply:

 

A. Augmedix will invoice Client on a quarterly
basis (or pro-rata portions thereof) for Service Fees of Authorized User(s) in advance of each quarter, and the first three (3)
months of Service for first-time Authorized Users in advance of go-live. The first quarter is defined as July 1 through September
30, the second quarter as October 1 through December 31, the third quarter as January 1 through March 31, and the fourth quarter
as April 1 through June 30. To the extent that a billing category change results in an overpayment or underpayment of Fees for
the applicable invoice period, the parties will reconcile any credits owed to, or additional amounts owed by, Client against any
prepaid amounts on a quarterly basis.

 

B. In the event that Service for a particular
Authorized User is cancelled in accordance with the above, any remaining prepayment balance will be credited towards payment for
another Authorized User or refunded to Client within ninety (90) days of the effective date of termination. Upon termination of
the Agreement, Augmedix will promptly refund Client any prepaid Fees for Services not rendered.

 

    	Omnibus Amendment
 Augmedix – Dignity Health	     
 Page 1

    CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

    

 

DH-IT-1186

 

4. General. Capitalized
terms used but not otherwise defined herein shall have the same meaning as in the Dignity SOWs and the Agreement. This Omnibus
Amendment is hereby incorporated into the Dignity SOWs by reference. Except as expressly amended herein, all other terms of the
Dignity SOWs are hereby confirmed and remain in full force and effect. To the extent that there is any conflict between the terms
of this Omnibus Amendment and those of the Agreement or the Dignity SOWs, the terms of this Omnibus Amendment shall control. This
Omnibus Amendment may be executed in several counterparts, all of which taken together shall constitute one single agreement between
the parties and any full and complete copy thereof shall constitute an original. When signed in pen ink, such documents may be
delivered by facsimile transmission or by scanned email attachment, and said copies shall be treated in all respects as original.

 

AGREED AND ACCEPTED

  

	DIGNITY HEALTH	 	AUGMEDIX, INC.
	 	 	 	 	 
	By	/s/ Kelley Moore	 	By	/s/ Manny Krakaris
	 	 	 	 	 
	Name 	Kelley Moore	 	Name 	Manny Krakaris
	 	 	 	 	 
	Title	System VP, Vendor Mgmt & Contracting	 	Title	CEO
	 	 	 	 	 
	Date	Jul 17, 2020	 	Date	Jul 17, 2020

 

	DIGNITY HEALTH MEDICAL FOUNDATION	 	 
	 	 	 	 	 
	By	/s/ Kelley Moore	 	 	 
	 	 	 	 	 
	Name 	Kelley Moore	 	 	 
	 	 	 	 	 
	Title	System VP, Vendor Mgmt & Contracting	 	 	 
	 	 	 	 	 
	Date	Jul 17, 2020	 	 	 

 

	PACIFIC CENTRAL COAST HEALTH CENTERS	 	 
	 	 	 	 	 
	By	/s/ Kelley Moore	 	 	 
	 	 	 	 	 
	Name 	Kelley Moore	 	 	 
	 	 	 	 	 
	Title	System VP, Vendor Mgmt & Contracting	 	 	 
	 	 	 	 	 
	Date	Jul 17, 2020	 	 	 

 

	Omnibus Amendment

Augmedix – Dignity Health	     

Page 2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00315-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00315-of-00352.parquet"}]]